reference_id,authors,title,journal,year,volume,citation_footer,citation_type,citation,urls,pubmed_id,doi,header,reference_type,study_id,exclusion_reason
CD009069-bib-0001,"Sow PS, Watson‐Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J. ",Safety and immunogenicity of human papillomavirus‐16/18 AS04‐adjuvanted vaccine: a randomized trial in 10‐25‐year‐old HIV‐Seronegative African girls and young women, Journal of Infectious Diseases ,2013,207,    ,['citation-journal']," Sow PS, Watson‐Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J. Safety and immunogenicity of human papillomavirus‐16/18 AS04‐adjuvanted vaccine: a randomized trial in 10‐25‐year‐old HIV‐Seronegative African girls and young women.  Journal of Infectious Diseases 2013;207(11):1753‐63. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1093/infdis/jis619', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+human+papillomavirus‐16/18+AS04‐adjuvanted+vaccine:+a+randomized+trial+in+10‐25‐year‐old+HIV‐Seronegative+African+girls+and+young+women+&author=PS+Sow&author=D+Watson‐Jones&author=N+Kiviat&author=J+Changalucha&author=KD+Mbaye&author=J+Brown&publication_year=2013&hl=en']",,https://doi.org/10.1093/infdis/jis619," African_2 country trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0001,
CD009069-bib-0002,"Mugo N, Ansah NA, Marino D, Saah A, Garner E I. ",Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub‐Saharan Africa, Human Vaccines & Immunotherapeutics ,2015,11,    ,['citation-journal']," Mugo N, Ansah NA, Marino D, Saah A, Garner E I. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub‐Saharan Africa.  Human Vaccines & Immunotherapeutics 2015;11(6):1323‐30. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1080/21645515.2015.1008877', 'https://www.ncbi.nlm.nih.gov/pubmed/25912475', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+safety+and+immunogenicity+of+a+quadrivalent+human+papillomavirus+vaccine+in+healthy+females+between+9+and+26+years+of+age+in+Sub‐Saharan+Africa+&author=N+Mugo&author=NA+Ansah&author=D+Marino&author=A+Saah&author=EI+Garner&publication_year=2015&hl=en']",25912475,https://doi.org/10.1080/21645515.2015.1008877," African_3 country trial (ph3,4v) {published data only}  ",included,CD009069-bbs2-0002,
CD009069-bib-0003,"Zhu F, Li J, Hu Y, Zhang X, Yang X, Zhao H, et al. ",Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years, Human Vaccines & Immunotherapeutics ,2014,10,    ,['citation-journal']," Zhu F, Li J, Hu Y, Zhang X, Yang X, Zhao H, et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.  Human Vaccines & Immunotherapeutics 2014;10(7):1795‐806. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4161/hv.28702', 'https://www.ncbi.nlm.nih.gov/pubmed/25424785', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+in+healthy+Chinese+girls+and+women+aged+9+to+45+years+&author=F+Zhu&author=J+Li&author=Y+Hu&author=X+Zhang&author=X+Yang&author=H+Zhao&publication_year=2014&hl=en']",25424785,https://doi.org/10.4161/hv.28702," Chinese trial (ph3,2v)_ adolescent {published data only}  ",included,CD009069-bbs2-0003,
CD009069-bib-0004,"Zhu F, Li J, Hu Y, Zhang X, Yang X, Zhao H, et al. ",Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years, Human Vaccines & Immunotherapeutics ,2014,10,    ,['citation-journal']," Zhu F, Li J, Hu Y, Zhang X, Yang X, Zhao H, et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.  Human Vaccines & Immunotherapeutics 2014;10(7):1795‐806. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4161/hv.28702', 'https://www.ncbi.nlm.nih.gov/pubmed/25424785', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+in+healthy+Chinese+girls+and+women+aged+9+to+45+years+&author=F+Zhu&author=J+Li&author=Y+Hu&author=X+Zhang&author=X+Yang&author=H+Zhao&publication_year=2014&hl=en']",25424785,https://doi.org/10.4161/hv.28702," Chinese trial (ph3,2v)_mid‐adult {published data only}  ",included,CD009069-bbs2-0004,
CD009069-bib-0005,"Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X, et al. ","Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial", International Journal of Cancer ,2014,135,    ,['citation-journal']," Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X, et al. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial.  International Journal of Cancer 2014;135(11):2612‐22. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1002/ijc.28897', 'https://www.ncbi.nlm.nih.gov/pubmed/24740596', 'https://scholar.google.com/scholar_lookup?title=Efficacy,+immunogenicity+and+safety+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+in+healthy+Chinese+women+aged+18‐25+years:+results+from+a+randomized+controlled+trial+&author=FC+Zhu&author=W+Chen&author=YM+Hu&author=Y+Hong&author=J+Li&author=X+Zhang&publication_year=2014&hl=en']",24740596,https://doi.org/10.1002/ijc.28897," Chinese trial (ph3,2v)_young {published data only}  ",included,CD009069-bbs2-0005,
CD009069-bib-0006,"Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, et al. ","Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial", Cancer Medicine ,2017,6,    ,['citation-journal']," Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, et al. Efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in Chinese women aged 18‐25 years: event‐triggered analysis of a randomized controlled trial.  Cancer Medicine 2017;6(2045‐7634 (Electronic), 2045‐7634 (Linking), 1):12‐25. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1002/cam4.869', 'https://www.ncbi.nlm.nih.gov/pubmed/27998015', 'https://scholar.google.com/scholar_lookup?title=Efficacy,+immunogenicity,+and+safety+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+in+Chinese+women+aged+18‐25+years:+event‐triggered+analysis+of+a+randomized+controlled+trial+&author=FC+Zhu&author=SY+Hu&author=Y+Hong&author=YM+Hu&author=X+Zhang&author=YJ+Zhang&publication_year=2017&hl=en']",27998015,https://doi.org/10.1002/cam4.869," Chinese trial (ph3,2v)_young {published data only}  ",included,CD009069-bbs2-0005,
CD009069-bib-0007,"Garcia‐Sicilia J, Schwarz TF, Carmona A, Peters K, Malkin JE, Tran PM. ",Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine coadministered with combined diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine to girls and young women, Journal of Adolescent Health ,2010,46,    ,['citation-journal']," Garcia‐Sicilia J, Schwarz TF, Carmona A, Peters K, Malkin JE, Tran PM. Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine coadministered with combined diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine to girls and young women.  Journal of Adolescent Health 2010;46(2):142‐51. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jadohealth.2009.11.205', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+human+papillomavirus‐16/18+AS04‐adjuvanted+cervical+cancer+vaccine+coadministered+with+combined+diphtheria‐tetanus‐acellular+pertussis‐inactivated+poliovirus+vaccine+to+girls+and+young+women+&author=J+Garcia‐Sicilia&author=TF+Schwarz&author=A+Carmona&author=K+Peters&author=JE+Malkin&author=PM+Tran&publication_year=2010&hl=en']",,https://doi.org/10.1016/j.jadohealth.2009.11.205," Co‐vaccination_dTpa_IPV trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0006,
CD009069-bib-0008,"Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlan G, Silfverdal SA. ",Randomized trial: immunogenicity and safety of coadministered human papillomavirus‐16/18AS04‐adjuvanted vaccine and combined hepatitis A and B vaccine in girls, Journal of Adolescent Health ,2012,50,    ,['citation-journal']," Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlan G, Silfverdal SA. Randomized trial: immunogenicity and safety of coadministered human papillomavirus‐16/18AS04‐adjuvanted vaccine and combined hepatitis A and B vaccine in girls.  Journal of Adolescent Health 2012;50(1):38‐46. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jadohealth.2011.10.009', 'https://scholar.google.com/scholar_lookup?title=Randomized+trial:+immunogenicity+and+safety+of+coadministered+human+papillomavirus‐16/18AS04‐adjuvanted+vaccine+and+combined+hepatitis+A+and+B+vaccine+in+girls+&author=C+Pedersen&author=M+Breindahl&author=N+Aggarwal&author=J+Berglund&author=G+Oroszlan&author=SA+Silfverdal&publication_year=2012&hl=en']",,https://doi.org/10.1016/j.jadohealth.2011.10.009," Co‐vaccination_HAB trial (Ph3, 2v) {published data only}  ",included,CD009069-bbs2-0007,
CD009069-bib-0009,"Schmeink CE, Bekkers RL, Josefsson A, Richardus JH, Berndtsson Blom K, et al. ",Co‐administration of human papillomavirus‐16/18 AS04‐adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls, Vaccine ,2011,29,    ,['citation-journal']," Schmeink CE, Bekkers RL, Josefsson A, Richardus JH, Berndtsson Blom K, et al. Co‐administration of human papillomavirus‐16/18 AS04‐adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.  Vaccine 2011;29(49):9276‐83. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2011.08.037', 'https://www.ncbi.nlm.nih.gov/pubmed/21856349', 'https://scholar.google.com/scholar_lookup?title=Co‐administration+of+human+papillomavirus‐16/18+AS04‐adjuvanted+vaccine+with+hepatitis+B+vaccine:+randomized+study+in+healthy+girls+&author=CE+Schmeink&author=RL+Bekkers&author=A+Josefsson&author=JH+Richardus&author=K+BerndtssonBlom&publication_year=2011&hl=en']",21856349,https://doi.org/10.1016/j.vaccine.2011.08.037," Co‐vaccination_HepB trial (ph3, 2v) {published data only}  ",included,CD009069-bbs2-0008,
CD009069-bib-0010,"Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P, Kreimer AR, et al. ","Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica", Cancer Discovery ,2011,1,    ,['citation-journal']," Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P, Kreimer AR, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in Guanacaste, Costa Rica.  Cancer Discovery 2011;1(5):408‐19. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1158/2159-8290.CD-11-0131', 'https://www.ncbi.nlm.nih.gov/pubmed/22586631', 'https://scholar.google.com/scholar_lookup?title=Prevention+of+persistent+human+papillomavirus+infection+by+an+HPV16/18+vaccine:+A+community‐based+randomized+clinical+trial+in+Guanacaste,+Costa+Rica+&author=R+Herrero&author=S+Wacholder&author=AC+Rodriguez&author=D+Solomon&author=P+Gonzalez&author=AR+Kreimer&publication_year=2011&hl=en']",22586631,https://doi.org/10.1158/2159-8290.CD-11-0131," CVT (ph3,2v) {published data only}  ",included,CD009069-bbs2-0009,
CD009069-bib-0011,"Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R. ",Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial, Vaccine ,2014,32,    ,['citation-journal']," Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R. Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial.  Vaccine 2014;32(39):5087‐97. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2014.06.038', 'https://www.ncbi.nlm.nih.gov/pubmed/25018097', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+the+HPV‐16/18+vaccine:+Final+according+to+protocol+results+from+the+blinded+phase+of+the+randomized+Costa+Rica+HPV‐16/18+vaccine+trial+&author=A+Hildesheim&author=S+Wacholder&author=G+Catteau&author=F+Struyf&author=G+Dubin&author=R+Herrero&publication_year=2014&hl=en']",25018097,https://doi.org/10.1016/j.vaccine.2014.06.038," CVT (ph3,2v) {published data only}  ",included,CD009069-bbs2-0009,
CD009069-bib-0012,"Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC. ",Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial, Lancet Oncology ,2011,12,    ,['citation-journal']," Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial.  Lancet Oncology 2011;12(9):862‐70. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S1470-2045(11)70213-3', 'https://www.ncbi.nlm.nih.gov/pubmed/21865087', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+a+bivalent+HPV+16/18+vaccine+against+anal+HPV+16/18+infection+among+young+women:+a+nested+analysis+within+the+Costa+Rica+Vaccine+Trial+&author=AR+Kreimer&author=P+Gonzalez&author=HA+Katki&author=C+Porras&author=M+Schiffman&author=AC+Rodriguez&publication_year=2011&hl=en']",21865087,https://doi.org/10.1016/S1470-2045(11)70213-3," CVT (ph3,2v) {published data only}  ",included,CD009069-bbs2-0009,
CD009069-bib-0013,"Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. ",Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine, Journal of the National Cancer Institute ,2011,103,    ,['citation-journal']," Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.  Journal of the National Cancer Institute 2011;103(19):1444‐51. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/jnci/djr319', 'https://www.ncbi.nlm.nih.gov/pubmed/21908768', 'https://scholar.google.com/scholar_lookup?title=Proof‐of‐principle+evaluation+of+the+efficacy+of+fewer+than+three+doses+of+a+bivalent+HPV16/18+vaccine+&author=AR+Kreimer&author=AC+Rodriguez&author=A+Hildesheim&author=R+Herrero&author=C+Porras&author=M+Schiffman&publication_year=2011&hl=en']",21908768,https://doi.org/10.1093/jnci/djr319," CVT (ph3,2v) {published data only}  ",included,CD009069-bbs2-0009,
CD009069-bib-0014,"Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P. ",Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates, American Journal of Epidemiology ,2014,180,    ,['citation-journal']," Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P. Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.  American Journal of Epidemiology 2014;180(6):599‐607. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/aje/kwu168', 'https://www.ncbi.nlm.nih.gov/pubmed/25139208', 'https://scholar.google.com/scholar_lookup?title=Effect+of+different+human+papillomavirus+serological+and+DNA+criteria+on+vaccine+efficacy+estimates+&author=KA+LangKuhs&author=C+Porras&author=JT+Schiller&author=AC+Rodriguez&author=M+Schiffman&author=P+Gonzalez&publication_year=2014&hl=en']",25139208,https://doi.org/10.1093/aje/kwu168," CVT (ph3,2v) {published data only}  ",included,CD009069-bbs2-0009,
CD009069-bib-0015,"Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM. ","The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV‐naive women aged 16 to 26 years", Journal of Infectious Diseases ,2009,199,    ,['citation-journal']," Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV‐naive women aged 16 to 26 years.  Journal of Infectious Diseases 2009;199(7):926‐35. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1086/597307', 'https://scholar.google.com/scholar_lookup?title=The+impact+of+quadrivalent+human+papillomavirus+(HPV;+types+6,+11,+16,+and+18)+L1+virus‐like+particle+vaccine+on+infection+and+disease+due+to+oncogenic+nonvaccine+HPV+types+in+generally+HPV‐naive+women+aged+16+to+26+years+&author=DR+Brown&author=SK+Kjaer&author=K+Sigurdsson&author=OE+Iversen&author=M+Hernandez‐Avila&author=CM+Wheeler&publication_year=2009&hl=en']",,https://doi.org/10.1086/597307," FUT I/II trials (ph3,4v) {published data only}  ",included,CD009069-bbs2-0010,
CD009069-bib-0016,"Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez‐Avila M. ","Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial", BMJ ,2010,341,    ,['citation-journal']," Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez‐Avila M. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.  BMJ 2010;341:c3493. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/20647284', 'https://scholar.google.com/scholar_lookup?title=Four+year+efficacy+of+prophylactic+human+papillomavirus+quadrivalent+vaccine+against+low+grade+cervical,+vulvar,+and+vaginal+intraepithelial+neoplasia+and+anogenital+warts:+randomised+controlled+trial+&author=J+Dillner&author=SK+Kjaer&author=CM+Wheeler&author=K+Sigurdsson&author=OE+Iversen&author=M+Hernandez‐Avila&publication_year=2010&hl=en']",20647284,," FUT I/II trials (ph3,4v) {published data only}  ",included,CD009069-bbs2-0010,
CD009069-bib-0017,"Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM, Perez G. ",A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high‐grade cervical and external genital lesions, Cancer Prevention Research ,2009,2,    ,['citation-journal']," Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM, Perez G. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high‐grade cervical and external genital lesions.  Cancer Prevention Research 2009;2(10):868‐78. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1158/1940-6207.CAPR-09-0031', 'https://www.ncbi.nlm.nih.gov/pubmed/19789295', 'https://scholar.google.com/scholar_lookup?title=A+pooled+analysis+of+continued+prophylactic+efficacy+of+quadrivalent+human+papillomavirus+(Types+6/11/16/18)+vaccine+against+high‐grade+cervical+and+external+genital+lesions+&author=SK+Kjaer&author=K+Sigurdsson&author=OE+Iversen&author=M+Hernandez‐Avila&author=CM+Wheeler&author=G+Perez&publication_year=2009&hl=en']",19789295,https://doi.org/10.1158/1940-6207.CAPR-09-0031," FUT I/II trials (ph3,4v) {published data only}  ",included,CD009069-bbs2-0010,
CD009069-bib-0018,"Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM. ",Impact of human papillomavirus (HPV)‐6/11/16/18 vaccine on all HPV‐associated genital diseases in young women, Journal of the National Cancer Institute ,2010,102,    ,['citation-journal']," Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM. Impact of human papillomavirus (HPV)‐6/11/16/18 vaccine on all HPV‐associated genital diseases in young women.  Journal of the National Cancer Institute 2010;102(5):325‐39. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/jnci/djp534', 'https://www.ncbi.nlm.nih.gov/pubmed/20139221', 'https://scholar.google.com/scholar_lookup?title=Impact+of+human+papillomavirus+(HPV)‐6/11/16/18+vaccine+on+all+HPV‐associated+genital+diseases+in+young+women+&author=N+Munoz&author=SK+Kjaer&author=K+Sigurdsson&author=OE+Iversen&author=M+Hernandez‐Avila&author=CM+Wheeler&publication_year=2010&hl=en']",20139221,https://doi.org/10.1093/jnci/djp534," FUT I/II trials (ph3,4v) {published data only}  ",included,CD009069-bbs2-0010,
CD009069-bib-0019,"Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM. ",Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection, Human Vaccines ,2009,5,    ,['citation-journal']," Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.  Human Vaccines 2009;5(10):696‐704. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4161/hv.5.10.9515', 'https://www.ncbi.nlm.nih.gov/pubmed/19855170', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+quadrivalent+HPV+6/11/16/18+vaccine+efficacy+against+cervical+and+anogenital+disease+in+subjects+with+serological+evidence+of+prior+vaccine+type+HPV+infection+&author=SE+Olsson&author=SK+Kjaer&author=K+Sigurdsson&author=OE+Iversen&author=M+Hernandez‐Avila&author=CM+Wheeler&publication_year=2009&hl=en']",19855170,https://doi.org/10.4161/hv.5.10.9515," FUT I/II trials (ph3,4v) {published data only}  ",included,CD009069-bbs2-0010,
CD009069-bib-0020,The FUTURE II study group. ,Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection, Journal of Infectious Diseases ,2007,196,    ,['citation-journal'], The FUTURE II study group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.  Journal of Infectious Diseases 2007;196(10):1438‐46. CENTRAL    Link to article     ,"['', 'https://doi.org/10.1086/522864']",,https://doi.org/10.1086/522864," FUT I/II trials (ph3,4v) {published data only}  ",included,CD009069-bbs2-0010,
CD009069-bib-0021,"Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Perez G. ","The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16 to 26 years", Journal of Infectious Diseases ,2009,199,    ,['citation-journal']," Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Perez G. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus‐like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16 to 26 years.  Journal of Infectious Diseases 2009;199(7):936‐44. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1086/597309', 'https://scholar.google.com/scholar_lookup?title=The+impact+of+quadrivalent+human+papillomavirus+(HPV;+types+6,+11,+16,+and+18)+L1+virus‐like+particle+vaccine+on+infection+and+disease+due+to+oncogenic+nonvaccine+HPV+types+in+sexually+active+women+aged+16+to+26+years+&author=CM+Wheeler&author=SK+Kjaer&author=K+Sigurdsson&author=OE+Iversen&author=M+Hernandez‐Avila&author=G+Perez&publication_year=2009&hl=en']",,https://doi.org/10.1086/597309," FUT I/II trials (ph3,4v) {published data only}  ",included,CD009069-bbs2-0010,
CD009069-bib-0022,"Castellsagué X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K. ","End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age", British Journal of Cancer ,2011,105,    ,['citation-journal']," Castellsagué X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K. End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24 to 45 years of age.  British Journal of Cancer 2011;105(1):28‐37. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1038/bjc.2011.185', 'https://www.ncbi.nlm.nih.gov/pubmed/21629249', 'https://scholar.google.com/scholar_lookup?title=End‐of‐study+safety,+immunogenicity,+and+efficacy+of+quadrivalent+HPV+(types+6,+11,+16,+18)+recombinant+vaccine+in+adult+women+24+to+45+years+of+age+&author=X+Castellsagué&author=N+Munoz&author=P+Pitisuttithum&author=D+Ferris&author=J+Monsonego&author=K+Ault&publication_year=2011&hl=en']",21629249,https://doi.org/10.1038/bjc.2011.185," FUTURE III trial (ph3,4v) {published data only}  ",included,CD009069-bbs2-0011,
CD009069-bib-0023,"Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. ",Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials, Obstetrics and Gynecology ,2009,114,    ,['citation-journal']," Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials.  Obstetrics and Gynecology 2009;114(6):1179‐88. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/AOG.0b013e3181c2ca21', 'https://www.ncbi.nlm.nih.gov/pubmed/19935017', 'https://scholar.google.com/scholar_lookup?title=Pregnancy+and+infant+outcomes+in+the+clinical+trials+of+a+human+papillomavirus+type+6/11/16/18vaccine:+a+combined+analysis+of+five+randomized+controlled+trials+&author=SM+Garland&author=KA+Ault&author=SA+Gall&author=J+Paavonen&author=HL+Sings&author=KL+Ciprero&publication_year=2009&hl=en']",19935017,https://doi.org/10.1097/AOG.0b013e3181c2ca21," FUTURE III trial (ph3,4v) {published data only}  ",included,CD009069-bbs2-0011,
CD009069-bib-0024,"Munoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K. ","Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial", Lancet ,2009,373,    ,['citation-journal']," Munoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial.  Lancet 2009;373(9679):1949‐57. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0140-6736(09)60691-7', 'https://www.ncbi.nlm.nih.gov/pubmed/19493565', 'https://scholar.google.com/scholar_lookup?title=Safety,+immunogenicity,+and+efficacy+of+quadrivalent+human+papillomavirus+(types+6,+11,+16,+18)+recombinant+vaccine+in+women+aged+24‐45+years:+a+randomised,+double‐blind+trial+&author=N+Munoz&author=R+Manalastas&author=P+Pitisuttithum&author=D+Tresukosol&author=J+Monsonego&author=K+Ault&publication_year=2009&hl=en']",19493565,https://doi.org/10.1016/S0140-6736(09)60691-7," FUTURE III trial (ph3,4v) {published data only}  ",included,CD009069-bbs2-0011,
CD009069-bib-0025,"Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. ",Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials, Obstetrics and Gynecology ,2009,114,    ,['citation-journal']," Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials.  Obstetrics and Gynecology 2009;114(6):1179‐88. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/AOG.0b013e3181c2ca21', 'https://www.ncbi.nlm.nih.gov/pubmed/19935017', 'https://scholar.google.com/scholar_lookup?title=Pregnancy+and+infant+outcomes+in+the+clinical+trials+of+a+human+papillomavirus+type+6/11/16/18vaccine:+a+combined+analysis+of+five+randomized+controlled+trials+&author=SM+Garland&author=KA+Ault&author=SA+Gall&author=J+Paavonen&author=HL+Sings&author=KL+Ciprero&publication_year=2009&hl=en']",19935017,https://doi.org/10.1097/AOG.0b013e3181c2ca21," FUTURE II trial (ph3,4v) {published data only}  ",included,CD009069-bbs2-0012,
CD009069-bib-0026,The FUTURE II study group. ,Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions, New England Journal of Medicine ,2007,356,    ,['citation-journal'], The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions.  New England Journal of Medicine 2007;356(19):1915‐27. CENTRAL    Link to article     ,"['', 'https://doi.org/10.1056/NEJMoa061741']",,https://doi.org/10.1056/NEJMoa061741," FUTURE II trial (ph3,4v) {published data only}  ",included,CD009069-bbs2-0012,
CD009069-bib-0027,"Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. ",Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials, Obstetrics and Gynecology ,2009,114,    ,['citation-journal']," Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine: a combined analysis of five randomized controlled trials.  Obstetrics and Gynecology 2009;114(6):1179‐88. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/AOG.0b013e3181c2ca21', 'https://www.ncbi.nlm.nih.gov/pubmed/19935017', 'https://scholar.google.com/scholar_lookup?title=Pregnancy+and+infant+outcomes+in+the+clinical+trials+of+a+human+papillomavirus+type+6/11/16/18vaccine:+a+combined+analysis+of+five+randomized+controlled+trials+&author=SM+Garland&author=KA+Ault&author=SA+Gall&author=J+Paavonen&author=HL+Sings&author=KL+Ciprero&publication_year=2009&hl=en']",19935017,https://doi.org/10.1097/AOG.0b013e3181c2ca21," FUTURE I trial (ph3,4v) {published data only}  ",included,CD009069-bbs2-0013,
CD009069-bib-0028,"Garland SM, Hernandez‐Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S. ",Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases, New England Journal of Medicine ,2007,356,    ,['citation-journal']," Garland SM, Hernandez‐Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.  New England Journal of Medicine 2007;356(19):1928‐43. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1056/NEJMoa061760', 'https://scholar.google.com/scholar_lookup?title=Quadrivalent+vaccine+against+human+papillomavirus+to+prevent+anogenital+diseases&author=SM+Garland&author=M+Hernandez‐Avila&author=CM+Wheeler&author=G+Perez&author=DM+Harper&author=S+Leodolter&publication_year=2007&hl=en']",,https://doi.org/10.1056/NEJMoa061760," FUTURE I trial (ph3,4v) {published data only}  ",included,CD009069-bbs2-0013,
CD009069-bib-0029,"Ngan HY, Cheung AN, Tam KF, Chan KK, Tang HW, Bi D, et al. ",Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong, Hong Kong Medical Journal ,2010,16,    ,['citation-journal']," Ngan HY, Cheung AN, Tam KF, Chan KK, Tang HW, Bi D, et al. Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong.  Hong Kong Medical Journal 2010;16(1024‐2708 (Print), 1024‐2708 (Linking), 3):171‐9. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/20519752', 'https://scholar.google.com/scholar_lookup?title=Human+papillomavirus‐16/18+AS04‐adjuvanted+cervical+cancer+vaccine:+immunogenicity+and+safety+in+healthy+Chinese+women+from+Hong+Kong+&author=HY+Ngan&author=AN+Cheung&author=KF+Tam&author=KK+Chan&author=HW+Tang&author=D+Bi&publication_year=2010&hl=en']",20519752,," Hong Kong trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0014,
CD009069-bib-0030,"Medina DM, Valencia A, de Velasquez A, Huang LM, Prymula R, Garcia‐Sicilia J. ","Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine: a randomized, controlled trial in adolescent girls", Journal of Adolescent Health ,2010,46,    ,['citation-journal']," Medina DM, Valencia A, de Velasquez A, Huang LM, Prymula R, Garcia‐Sicilia J. Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine: a randomized, controlled trial in adolescent girls.  Journal of Adolescent Health 2010;46(5):414‐21. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jadohealth.2010.02.006', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine:+a+randomized,+controlled+trial+in+adolescent+girls+&author=DM+Medina&author=A+Valencia&author=A+Velasquez&author=LM+Huang&author=R+Prymula&author=J+Garcia‐Sicilia&publication_year=2010&hl=en']",,https://doi.org/10.1016/j.jadohealth.2010.02.006," Immunobridging(ph3,2v) {published data only}  ",included,CD009069-bbs2-0015,
CD009069-bib-0031,"Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, et al. ",Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine in healthy Indian women, Journal of Obstetrics and Gynaecology Research ,2010,36,    ,['citation-journal']," Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, et al. Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine in healthy Indian women.  Journal of Obstetrics and Gynaecology Research 2010;36(1):123‐32. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1111/j.1447-0756.2009.01167.x', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+human+papillomavirus‐16/18+AS04‐adjuvanted+cervical+cancer+vaccine+in+healthy+Indian+women+&author=N+Bhatla&author=V+Suri&author=P+Basu&author=S+Shastri&author=SK+Datta&author=D+Bi&publication_year=2010&hl=en']",,https://doi.org/10.1111/j.1447-0756.2009.01167.x," Indian trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0016,
CD009069-bib-0032,"Konno R, Tamura S, Dobbelaere K, Yoshikawa H. ","Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial", International Journal of Gynecological Cancer ,2010,20,    ,['citation-journal']," Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial.  International Journal of Gynecological Cancer 2010;20(3):404‐10. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/IGC.0b013e3181d373a5', 'https://www.ncbi.nlm.nih.gov/pubmed/20375805', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+human+papillomavirus+16/18+AS04‐adjuvanted+vaccine+in+Japanese+women+aged+20+to+25+years:+interim+analysis+of+a+phase+2+double‐blind,+randomized,+controlled+trial+&author=R+Konno&author=S+Tamura&author=K+Dobbelaere&author=H+Yoshikawa&publication_year=2010&hl=en']",20375805,https://doi.org/10.1111/IGC.0b013e3181d373a5," Japanese trial (ph2,2v) {published data only}  ",included,CD009069-bbs2-0017,
CD009069-bib-0033,"Konno R, Tamura S, Dobbelaere K, Yoshikawa H. ","Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial", International Journal of Gynecological Cancer ,2010,20,    ,['citation-journal']," Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial.  International Journal of Gynecological Cancer 2010;20(5):847‐55. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/IGC.0b013e3181da2128', 'https://www.ncbi.nlm.nih.gov/pubmed/20606533', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+human+papillomavirus+type+16/18+AS04‐adjuvanted+vaccine+in+Japanese+women+aged+20+to+25+years:+final+analysis+of+a+phase+2+double‐blind,+randomized+controlled+trial+&author=R+Konno&author=S+Tamura&author=K+Dobbelaere&author=H+Yoshikawa&publication_year=2010&hl=en']",20606533,https://doi.org/10.1111/IGC.0b013e3181da2128," Japanese trial (ph2,2v) {published data only}  ",included,CD009069-bbs2-0017,
CD009069-bib-0034,"Konno R, Yoshikawa H, Okutani M, Quint W, Suryakiran V, Lin L, et al. ",Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women, Human Vaccines & Immunotherapeutics ,2014,10,    ,['citation-journal']," Konno R, Yoshikawa H, Okutani M, Quint W, Suryakiran V, Lin L, et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.  Human Vaccines & Immunotherapeutics 2014;10(7):1781‐94. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4161/hv.28712', 'https://www.ncbi.nlm.nih.gov/pubmed/25424783', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+the+human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+vaccine+against+cervical+intraepithelial+neoplasia+and+cervical+infection+in+young+Japanese+women+&author=R+Konno&author=H+Yoshikawa&author=M+Okutani&author=W+Quint&author=V+Suryakiran&author=L+Lin&publication_year=2014&hl=en']",25424783,https://doi.org/10.4161/hv.28712," Japanese trial (ph2,2v) {published data only}  ",included,CD009069-bbs2-0017,
CD009069-bib-0035,"Yoshikawa H, Ebihara K, Tanaka Y, Noda K. ","Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18 to 26 years", Cancer Science ,2013,104,    ,['citation-journal']," Yoshikawa H, Ebihara K, Tanaka Y, Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18 to 26 years.  Cancer Science 2013;104(4):465‐72. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/cas.12106', 'https://www.ncbi.nlm.nih.gov/pubmed/23331518', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+quadrivalent+human+papillomavirus+(types+6,+11,+16+and+18)+vaccine+(GARDASIL)+in+Japanese+women+aged+18+to+26+years+&author=H+Yoshikawa&author=K+Ebihara&author=Y+Tanaka&author=K+Noda&publication_year=2013&hl=en']",23331518,https://doi.org/10.1111/cas.12106," Japanese trial (ph2,4v) {published data only}  ",included,CD009069-bbs2-0018,
CD009069-bib-0036,"Kang S, Kim KH, Kim YT, Kim YT, Kim JH, Song YS. ","Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo‐controlled trial in 176 Korean subjects", International Journal of Gynecological Cancer ,2008,18,    ,['citation-journal']," Kang S, Kim KH, Kim YT, Kim YT, Kim JH, Song YS. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo‐controlled trial in 176 Korean subjects.  International Journal of Gynecological Cancer 2008;18(5):1013‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1111/j.1525-1438.2007.01123.x', 'https://www.ncbi.nlm.nih.gov/pubmed/17986242', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+a+vaccine+targeting+human+papillomavirus+types+6,+11,+16+and+18:+a+randomized,+placebo‐controlled+trial+in+176+Korean+subjects+&author=S+Kang&author=KH+Kim&author=YT+Kim&author=YT+Kim&author=JH+Kim&author=YS+Song&publication_year=2008&hl=en']",17986242,https://doi.org/10.1111/j.1525-1438.2007.01123.x," Korean trial (ph2,4v) {published data only}  ",included,CD009069-bbs2-0019,
CD009069-bib-0037,"Kim YJ, Kim KT, Kim JH, Cha SD, Kim JW, Bae DS, et al. ",Vaccination with a human papillomavirus (HPV)‐16/18 AS04‐adjuvanted cervical cancer vaccine in Korean girls aged 10‐14 years, Journal of Korean Medical Science ,2010,25,    ,['citation-journal']," Kim YJ, Kim KT, Kim JH, Cha SD, Kim JW, Bae DS, et al. Vaccination with a human papillomavirus (HPV)‐16/18 AS04‐adjuvanted cervical cancer vaccine in Korean girls aged 10‐14 years.  Journal of Korean Medical Science 2010;25(8):1197‐204. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.3346/jkms.2010.25.8.1197', 'https://www.ncbi.nlm.nih.gov/pubmed/20676333', 'https://scholar.google.com/scholar_lookup?title=Vaccination+with+a+human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+cervical+cancer+vaccine+in+Korean+girls+aged+10‐14+years+&author=YJ+Kim&author=KT+Kim&author=JH+Kim&author=SD+Cha&author=JW+Kim&author=DS+Bae&publication_year=2010&hl=en']",20676333,https://doi.org/10.3346/jkms.2010.25.8.1197," Korean trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0020,
CD009069-bib-0038,"Kim SC, Song YS, Kim YT, Kim YT, Ryu KS, Gunapalaiah B. ",Human papillomavirus 16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in 15 to 25 years old healthy Korean women, Journal of Gynecologic Oncology ,2011,22,    ,['citation-journal']," Kim SC, Song YS, Kim YT, Kim YT, Ryu KS, Gunapalaiah B. Human papillomavirus 16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in 15 to 25 years old healthy Korean women.  Journal of Gynecologic Oncology 2011;22(2):67‐75. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.3802/jgo.2011.22.2.67', 'https://www.ncbi.nlm.nih.gov/pubmed/21860731', 'https://scholar.google.com/scholar_lookup?title=Human+papillomavirus+16/18+AS04‐adjuvanted+cervical+cancer+vaccine:+immunogenicity+and+safety+in+15+to+25+years+old+healthy+Korean+women+&author=SC+Kim&author=YS+Song&author=YT+Kim&author=YT+Kim&author=KS+Ryu&author=B+Gunapalaiah&publication_year=2011&hl=en']",21860731,https://doi.org/10.3802/jgo.2011.22.2.67," Korean trial (ph3b,2v) {published data only}  ",included,CD009069-bbs2-0021,
CD009069-bib-0039,"Lim BK, Ng KY, Omar J, Omar SZ, Gunapalaiah B, Teoh YL, et al. ",Immunogenicity and safety of the AS04‐adjuvanted human papillomavirus‐16/18 cervical cancer vaccine in Malaysian women aged 18 to 35 years: a randomized controlled trial, Medical Journal of Malaysia ,2014,69,    ,['citation-journal']," Lim BK, Ng KY, Omar J, Omar SZ, Gunapalaiah B, Teoh YL, et al. Immunogenicity and safety of the AS04‐adjuvanted human papillomavirus‐16/18 cervical cancer vaccine in Malaysian women aged 18 to 35 years: a randomized controlled trial.  Medical Journal of Malaysia 2014;69(0300‐5283 (Print), 0300‐5283 (Linking), 1):2‐8. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+the+AS04‐adjuvanted+human+papillomavirus‐16/18+cervical+cancer+vaccine+in+Malaysian+women+aged+18+to+35+years:+a+randomized+controlled+trial+&author=BK+Lim&author=KY+Ng&author=J+Omar&author=SZ+Omar&author=B+Gunapalaiah&author=YL+Teoh&publication_year=2014&hl=en']",,," Malaysian trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0022,
CD009069-bib-0040,"Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B. ",Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials, BMJ ,2010,340,    ,['citation-journal']," Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials.  BMJ 2010;340:c712. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1136/bmj.c712', 'https://www.ncbi.nlm.nih.gov/pubmed/20197322', 'https://scholar.google.com/scholar_lookup?title=Risk+of+miscarriage+with+bivalent+vaccine+against+human+papillomavirus+(HPV)+types+16+and+18:+pooled+analysis+of+two+randomised+controlled+trials+&author=S+Wacholder&author=BE+Chen&author=A+Wilcox&author=G+Macones&author=P+Gonzalez&author=B+Befano&publication_year=2010&hl=en']",20197322,https://doi.org/10.1136/bmj.c712," PATRICIA & CVT (ph3,2v) {published data only}  ",included,CD009069-bbs2-0023,
CD009069-bib-0041,"Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland S, Castellsagué X. ","Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial", Lancet Oncology ,2012,13,    ,['citation-journal']," Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland S, Castellsagué X. Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial.  Lancet Oncology 2012;13(1):89‐99. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S1470-2045(11)70286-8', 'https://www.ncbi.nlm.nih.gov/pubmed/22075171', 'https://scholar.google.com/scholar_lookup?title=Overall+efficacy+of+HPV‐16/18+ASO4‐adjuvanted+vaccine+against+grade+3+or+greater+cervical+intraepithelial+neoplasia:+4‐year+end‐of‐study+analysis+of+the+randomised,+double‐blind+PATRICIA+trial+&author=M+Lehtinen&author=J+Paavonen&author=CM+Wheeler&author=U+Jaisamrarn&author=S+Garland&author=X+Castellsagué&publication_year=2012&hl=en']",22075171,https://doi.org/10.1016/S1470-2045(11)70286-8," PATRICIA trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0024,
CD009069-bib-0042,"Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM. ","Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial", Lancet ,2007,369,    ,['citation-journal']," Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM. Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial.  Lancet 2007;369(9580):2161‐70. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0140-6736(07)60946-5', 'https://www.ncbi.nlm.nih.gov/pubmed/17602732', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+a+prophylactic+adjuvanted+bivalent+L1+virus‐like‐particle+vaccine+against+infection+with+human+papillomavirus+types+16+and+18+in+young+women:+an+interim+analysis+of+a+phase+III+double‐blind,+randomised+controlled+trial+&author=J+Paavonen&author=D+Jenkins&author=FX+Bosch&author=P+Naud&author=J+Salmeron&author=CM+Wheeler&publication_year=2007&hl=en']",17602732,https://doi.org/10.1016/S0140-6736(07)60946-5," PATRICIA trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0024,
CD009069-bib-0043,"Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S‐N, Apter D. ","Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women", Lancet ,2009,374,    ,['citation-journal']," Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S‐N, Apter D. Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women.  Lancet 2009;374:301‐14. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0140-6736(09)61248-4', 'https://www.ncbi.nlm.nih.gov/pubmed/19586656', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+human+papillomavirus+(HPV)‐16/18+ASO4‐adjuvanted+vaccine+against+cervical+infection+and+precancer+caused+by+oncogenic+HPV+types+(PATRICIA):+final+analysis+of+a+double‐blind,+randomised+study+in+young+women+&author=J+Paavonen&author=P+Naud&author=J+Salmeron&author=CM+Wheeler&author=S‐N+Chow&author=D+Apter&publication_year=2009&hl=en']",19586656,https://doi.org/10.1016/S0140-6736(09)61248-4," PATRICIA trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0024,
CD009069-bib-0044,"Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P. ",Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18, International Journal of Cancer ,2011,131,    ,['citation-journal']," Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15 to 25 years with and without serological evidence of previous exposure to HPV‐16/18.  International Journal of Cancer 2011;131(1):106‐16. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1002/ijc.26362', 'https://www.ncbi.nlm.nih.gov/pubmed/21858807', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+the+human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+vaccine+in+women+aged+15+to+25+years+with+and+without+serological+evidence+of+previous+exposure+to+HPV‐16/18+&author=A+Szarewski&author=WA+Poppe&author=SR+Skinner&author=CM+Wheeler&author=J+Paavonen&author=P+Naud&publication_year=2011&hl=en']",21858807,https://doi.org/10.1002/ijc.26362," PATRICIA trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0024,
CD009069-bib-0045,"Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P. ","Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial", Lancet Oncology ,2011,13,    ,['citation-journal']," Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P. Cross‐protective efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by non‐vaccine oncogenic HPV‐types: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial.  Lancet Oncology 2011;13(1):100‐10. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S1470-2045(11)70287-X', 'https://www.ncbi.nlm.nih.gov/pubmed/22075170', 'https://scholar.google.com/scholar_lookup?title=Cross‐protective+efficacy+of+HPV‐16/18+ASO4‐adjuvanted+vaccine+against+cervical+infection+and+precancer+caused+by+non‐vaccine+oncogenic+HPV‐types:+4‐year+end‐of‐study+analysis+of+the+randomised,+double‐blind+PATRICIA+trial+&author=CM+Wheeler&author=X+Castellsagué&author=SM+Garland&author=A+Szarewski&author=J+Paavonen&author=P+Naud&publication_year=2011&hl=en']",22075170,https://doi.org/10.1016/S1470-2045(11)70287-X," PATRICIA trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0024,
CD009069-bib-0046,"Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB. ",A controlled trial of a human papillomavirus type 16 vaccine, New England Journal of Medicine ,2002,347,    ,['citation-journal']," Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB. A controlled trial of a human papillomavirus type 16 vaccine.  New England Journal of Medicine 2002;347(21):1645‐51. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1056/NEJMoa020586', 'https://scholar.google.com/scholar_lookup?title=A+controlled+trial+of+a+human+papillomavirus+type+16+vaccine&author=LA+Koutsky&author=KA+Ault&author=CM+Wheeler&author=DR+Brown&author=E+Barr&author=FB+Alvarez&publication_year=2002&hl=en']",,https://doi.org/10.1056/NEJMoa020586," Phase2 trial (ph2,1v) {published data only}  ",included,CD009069-bbs2-0025,
CD009069-bib-0047,"Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ. ",Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial, Obstetrics and Gynecology ,2006,107,    ,['citation-journal']," Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ. Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.  Obstetrics and Gynecology 2006;107(1):18‐27. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1097/01.AOG.0000192397.41191.fb', 'https://www.ncbi.nlm.nih.gov/pubmed/16394035', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+human+papillomavirus‐16+vaccine+to+prevent+cervical+intraepithelial+neoplasia:+a+randomized+controlled+trial+&author=C+Mao&author=LA+Koutsky&author=KA+Ault&author=CM+Wheeler&author=DR+Brown&author=DJ+Wiley&publication_year=2006&hl=en']",16394035,https://doi.org/10.1097/01.AOG.0000192397.41191.fb," Phase2 trial (ph2,1v) {published data only}  ",included,CD009069-bbs2-0025,
CD009069-bib-0048,"Rowhani‐Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE. ",Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine, Vaccine ,2009,27,    ,['citation-journal']," Rowhani‐Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine.  Vaccine 2009;27(41):5612‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2009.07.027', 'https://www.ncbi.nlm.nih.gov/pubmed/19647066', 'https://scholar.google.com/scholar_lookup?title=Longer+term+efficacy+of+a+prophylactic+monovalent+human+papillomavirus+type+16+vaccine&author=A+Rowhani‐Rahbar&author=C+Mao&author=JP+Hughes&author=FB+Alvarez&author=JT+Bryan&author=SE+Hawes&publication_year=2009&hl=en']",19647066,https://doi.org/10.1016/j.vaccine.2009.07.027," Phase2 trial (ph2,1v) {published data only}  ",included,CD009069-bbs2-0025,
CD009069-bib-0049,"De Carvalho N, Teixeira J, Roteli‐Martins CM, Naud P, De Borba P, Zahaf T. ",Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women, Vaccine ,2010,28,    ,['citation-journal']," De Carvalho N, Teixeira J, Roteli‐Martins CM, Naud P, De Borba P, Zahaf T. Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women.  Vaccine 2010;28(38):6247‐55. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2010.07.007', 'https://www.ncbi.nlm.nih.gov/pubmed/20643092', 'https://scholar.google.com/scholar_lookup?title=Sustained+efficacy+and+immunogenicity+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+up+to+7.3+years+in+young+adult+women+&author=N+Carvalho&author=J+Teixeira&author=CM+Roteli‐Martins&author=P+Naud&author=P+Borba&author=T+Zahaf&publication_year=2010&hl=en']",20643092,https://doi.org/10.1016/j.vaccine.2010.07.007," Phase2 trial (ph2,2v) {published data only}  ",included,CD009069-bbs2-0026,
CD009069-bib-0050,"Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A. ",Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, Lancet ,2004,364,    ,['citation-journal']," Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A. Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.  Lancet 2004;364(9447):1757‐65. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0140-6736(04)17398-4', 'https://www.ncbi.nlm.nih.gov/pubmed/15541448', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+a+bivalent+L1+virus‐like+particle+vaccine+in+prevention+of+infection+with+human+papillomavirus+types+16+and+18+in+young+women:+a+randomised+controlled+trial+&author=DM+Harper&author=EL+Franco&author=C+Wheeler&author=DG+Ferris&author=D+Jenkins&author=A+Schuind&publication_year=2004&hl=en']",15541448,https://doi.org/10.1016/S0140-6736(04)17398-4," Phase2 trial (ph2,2v) {published data only}  ",included,CD009069-bbs2-0026,
CD009069-bib-0051,"Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli‐Martins CM. ",Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial, Lancet ,2006,367,    ,['citation-journal']," Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli‐Martins CM. Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial.  Lancet 2006;367(9518):1247‐55. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0140-6736(06)68439-0', 'https://www.ncbi.nlm.nih.gov/pubmed/16631880', 'https://scholar.google.com/scholar_lookup?title=Sustained+efficacy+up+to+4.5+years+of+a+bivalent+L1+virus‐like+particle+vaccine+against+human+papillomavirus+types+16+and+18:+follow‐up+from+a+randomised+control+trial+&author=DM+Harper&author=EL+Franco&author=CM+Wheeler&author=AB+Moscicki&author=B+Romanowski&author=CM+Roteli‐Martins&publication_year=2006&hl=en']",16631880,https://doi.org/10.1016/S0140-6736(06)68439-0," Phase2 trial (ph2,2v) {published data only}  ",included,CD009069-bbs2-0026,
CD009069-bib-0052,"Naud PS, Roteli‐Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. ","Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination", Human Vaccines & Immunotherapeutics ,2014,10,    ,['citation-journal']," Naud PS, Roteli‐Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination.  Human Vaccines & Immunotherapeutics 2014;10(8):2147‐62. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4161/hv.29532', 'https://www.ncbi.nlm.nih.gov/pubmed/25424918', 'https://scholar.google.com/scholar_lookup?title=Sustained+efficacy,+immunogenicity,+and+safety+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine:+Final+analysis+of+a+long‐term+follow‐up+study+up+to+9.4+years+post‐vaccination+&author=PS+Naud&author=CM+Roteli‐Martins&author=NS+Carvalho&author=JC+Teixeira&author=PC+Borba&author=N+Sanchez&publication_year=2014&hl=en']",25424918,https://doi.org/10.4161/hv.29532," Phase2 trial (ph2,2v) {published data only}  ",included,CD009069-bbs2-0026,
CD009069-bib-0053,The GlaxoSmithKline Vaccine HPV‐007 Study Group. ,Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years, Lancet ,2009,374,    ,['citation-journal'], The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years.  Lancet 2009;374:1975‐85. CENTRAL    Link to article     PubMed     ,"['', 'https://doi.org/10.1016/S0140-6736(09)61567-1', 'https://www.ncbi.nlm.nih.gov/pubmed/19962185']",19962185,https://doi.org/10.1016/S0140-6736(09)61567-1," Phase2 trial (ph2,2v) {published data only}  ",included,CD009069-bbs2-0026,
CD009069-bib-0054,"Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE. ",Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection, Human Vaccines ,2009,5,    ,['citation-journal']," Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.  Human Vaccines 2009;5(10):696‐704. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4161/hv.5.10.9515', 'https://www.ncbi.nlm.nih.gov/pubmed/19855170', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+quadrivalent+HPV+6/11/16/18+vaccine+efficacy+against+cervical+and+anogenital+disease+in+subjects+with+serological+evidence+of+prior+vaccine+type+HPV+infection+&author=SE+Olsson&author=SK+Kjaer&author=K+Sigurdsson&author=OE+Iversen&publication_year=2009&hl=en']",19855170,https://doi.org/10.4161/hv.5.10.9515," Phase2 trial (ph2,4v) {published data only}  ",included,CD009069-bbs2-0027,
CD009069-bib-0055,"Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP. ","Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18", Vaccine ,2006,24,    ,['citation-journal']," Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.  Vaccine 2006;24(27):5571‐83. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2006.04.068', 'https://www.ncbi.nlm.nih.gov/pubmed/16753240', 'https://scholar.google.com/scholar_lookup?title=Immunologic+responses+following+administration+of+a+vaccine+targeting+human+papillomavirus+Types+6,+11,+16,+and+18+&author=LL+Villa&author=KA+Ault&author=AR+Giuliano&author=RL+Costa&author=CA+Petta&author=RP+Andrade&publication_year=2006&hl=en']",16753240,https://doi.org/10.1016/j.vaccine.2006.04.068," Phase2 trial (ph2,4v) {published data only}  ",included,CD009069-bbs2-0027,
CD009069-bib-0056,"Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR. ","Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial", Lancet Oncology ,2005,6,    ,['citation-journal']," Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial.  Lancet Oncology 2005;6(5):271‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S1470-2045(05)70101-7', 'https://www.ncbi.nlm.nih.gov/pubmed/15863374', 'https://scholar.google.com/scholar_lookup?title=Prophylactic+quadrivalent+human+papillomavirus+(types+6,+11,+16,+and+18)+L1+virus‐like+particle+vaccine+in+young+women:+a+randomised+double‐blind+placebo‐controlled+multicentre+phase+II+efficacy+trial+&author=LL+Villa&author=RL+Costa&author=CA+Petta&author=RP+Andrade&author=KA+Ault&author=AR+Giuliano&publication_year=2005&hl=en']",15863374,https://doi.org/10.1016/S1470-2045(05)70101-7," Phase2 trial (ph2,4v) {published data only}  ",included,CD009069-bbs2-0027,
CD009069-bib-0057,"Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE. ",High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up, British Journal of Cancer ,2006,95,    ,['citation-journal']," Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up.  British Journal of Cancer 2006;95(11):1459‐66. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1038/sj.bjc.6603469', 'https://www.ncbi.nlm.nih.gov/pubmed/17117182', 'https://scholar.google.com/scholar_lookup?title=High+sustained+efficacy+of+a+prophylactic+quadrivalent+human+papillomavirus+types+6/11/16/18+L1+virus‐like+particle+vaccine+through+5+years+of+follow‐up+&author=LL+Villa&author=RL+Costa&author=CA+Petta&author=RP+Andrade&author=J+Paavonen&author=OE+Iversen&publication_year=2006&hl=en']",17117182,https://doi.org/10.1038/sj.bjc.6603469," Phase2 trial (ph2,4v) {published data only}  ",included,CD009069-bbs2-0027,
CD009069-bib-0058,"Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano‐Ponce E, Salmeron J. ","Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study", Lancet ,2014,384,    ,['citation-journal']," Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano‐Ponce E, Salmeron J. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study.  Lancet 2014;384(9961):2213‐27. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0140-6736(14)60920-X', 'https://www.ncbi.nlm.nih.gov/pubmed/25189358', 'https://scholar.google.com/scholar_lookup?title=Efficacy,+safety,+and+immunogenicity+of+the+human+papillomavirus+16/18+AS04‐adjuvanted+vaccine+in+women+older+than+25+years:+4‐year+interim+follow‐up+of+the+phase+3,+double‐blind,+randomised+controlled+VIVIANE+study+&author=SR+Skinner&author=A+Szarewski&author=B+Romanowski&author=SM+Garland&author=E+Lazcano‐Ponce&author=J+Salmeron&publication_year=2014&hl=en']",25189358,https://doi.org/10.1016/S0140-6736(14)60920-X," VIVIANE trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0028,
CD009069-bib-0059,"Wheeler CM, Skinner SR, Del Rosario‐Raymundo MR, Garland SM, Chatterjee A, Lazcano‐Ponce E, et al. ","Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study", Lancet Infectious Diseases ,2016,16,    ,['citation-journal']," Wheeler CM, Skinner SR, Del Rosario‐Raymundo MR, Garland SM, Chatterjee A, Lazcano‐Ponce E, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study.  Lancet Infectious Diseases 2016;16(10):1154–68. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/S1473-3099(16)30120-7', 'https://scholar.google.com/scholar_lookup?title=Efficacy,+safety,+and+immunogenicity+of+the+human+papillomavirus+16/18+AS04‐adjuvanted+vaccine+in+women+older+than+25+years:+7‐year+interim+follow‐up+of+the+phase+3,+double‐blind,+randomised+controlled+VIVIANE+study+&author=CM+Wheeler&author=SR+Skinner&author=MR+Rosario‐Raymundo&author=SM+Garland&author=A+Chatterjee&author=E+Lazcano‐Ponce&publication_year=2016&hl=en']",,https://doi.org/10.1016/S1473-3099(16)30120-7," VIVIANE trial (ph3,2v) {published data only}  ",included,CD009069-bbs2-0028,
CD009069-bib-0060,"Angelo MG, David MP, Zima J, Baril L, Dubin G, Arellano F, et al. ",Pooled analysis of large and long‐term safety data from the human papillomavirus‐16/18‐AS04‐adjuvanted vaccine clinical trial programme, Pharmacoepidemiology and Drug Safety ,2014,23,    ,['citation-journal']," Angelo MG, David MP, Zima J, Baril L, Dubin G, Arellano F, et al. Pooled analysis of large and long‐term safety data from the human papillomavirus‐16/18‐AS04‐adjuvanted vaccine clinical trial programme.  Pharmacoepidemiology and Drug Safety 2014;23(1099‐557 (Electronic), 1053‐8569 (Linking), 5):466‐79. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1002/pds.3554', 'https://www.ncbi.nlm.nih.gov/pubmed/24644063', 'https://scholar.google.com/scholar_lookup?title=Pooled+analysis+of+large+and+long‐term+safety+data+from+the+human+papillomavirus‐16/18‐AS04‐adjuvanted+vaccine+clinical+trial+programme+&author=MG+Angelo&author=MP+David&author=J+Zima&author=L+Baril&author=G+Dubin&author=F+Arellano&publication_year=2014&hl=en']",24644063,https://doi.org/10.1002/pds.3554, Angelo 2014 {published data only}  ,excluded,CD009069-bbs2-0029, Post‐licensure safety surveillance over more than 4 years of routine use of HPV bivalent vaccine. Not a randomised controlled trial.  
CD009069-bib-0061,"Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, et al. ","Safety and immunogenicity of one dose of MenACWY‐CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines", Vaccine ,2010,28,    ,['citation-journal']," Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, et al. Safety and immunogenicity of one dose of MenACWY‐CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.  Vaccine 2010;28(1873‐2518 (Electronic), 0264‐410X (Linking), 18):3171‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2010.02.045', 'https://www.ncbi.nlm.nih.gov/pubmed/20189491', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+one+dose+of+MenACWY‐CRM,+an+investigational+quadrivalent+meningococcal+glycoconjugate+vaccine,+when+administered+to+adolescents+concomitantly+or+sequentially+with+Tdap+and+HPV+vaccines+&author=A+Arguedas&author=C+Soley&author=C+Loaiza&author=G+Rincon&author=S+Guevara&author=A+Perez&publication_year=2010&hl=en']",20189491,https://doi.org/10.1016/j.vaccine.2010.02.045, Arguedas 2010 {published data only}  ,excluded,CD009069-bbs2-0030, Randomised trial to evaluate Novartis vaccines co‐administrated with Tdap vaccine and HPV vaccine. No HPV alone group.  
CD009069-bib-0062,"Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF. ",A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine, Vaccine ,2004,22,    ,['citation-journal']," Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, Smith JF. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.  Vaccine 2004;22(23‐24):3004‐7. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2004.02.020', 'https://www.ncbi.nlm.nih.gov/pubmed/15297048', 'https://scholar.google.com/scholar_lookup?title=A+phase+I+study+to+evaluate+a+human+papillomavirus+(HPV)+type+18+L1+VLP+vaccine&author=KA+Ault&author=AR+Giuliano&author=RP+Edwards&author=G+Tamms&author=LL+Kim&author=JF+Smith&publication_year=2004&hl=en']",15297048,https://doi.org/10.1016/j.vaccine.2004.02.020, Ault 2004 {published data only}  ,excluded,CD009069-bbs2-0031, Phase I trial. 
CD009069-bib-0063,"Ault KA, Future II Study Group. ","Effect of prophylactic human papillomavirus L1 virus‐like‐particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials", Lancet ,2007,369,    ,['citation-journal']," Ault KA, Future II Study Group. Effect of prophylactic human papillomavirus L1 virus‐like‐particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.  Lancet 2007;369(9576):1861‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0140-6736(07)60852-6', 'https://www.ncbi.nlm.nih.gov/pubmed/17544766', 'https://scholar.google.com/scholar_lookup?title=Effect+of+prophylactic+human+papillomavirus+L1+virus‐like‐particle+vaccine+on+risk+of+cervical+intraepithelial+neoplasia+grade+2,+grade+3,+and+adenocarcinoma+in+situ:+a+combined+analysis+of+four+randomised+clinical+trials+&author=KA+Ault&publication_year=2007&hl=en']",17544766,https://doi.org/10.1016/S0140-6736(07)60852-6, Ault 2007 {published data only}  ,excluded,CD009069-bbs2-0032, Pooled analysis of 4 RCTs on both bivalent and quadrivalent vaccine. No new original data were presented.  
CD009069-bib-0064,"Basu P, Banerjee D, Singh P, Bhattacharya C, Biswas J. ",Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs, South Asian Journal of Cancer ,2013,2,    ,['citation-journal']," Basu P, Banerjee D, Singh P, Bhattacharya C, Biswas J. Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs.  South Asian Journal of Cancer 2013;2(4):187‐92. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4103/2278-330X.119877', 'https://www.ncbi.nlm.nih.gov/pubmed/24455618', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+human+papillomavirus+vaccine+for+primary+prevention+of+cervical+cancer:+A+review+of+evidence+from+phase+III+trials+and+national+programs+&author=P+Basu&author=D+Banerjee&author=P+Singh&author=C+Bhattacharya&author=J+Biswas&publication_year=2013&hl=en']",24455618,https://doi.org/10.4103/2278-330X.119877, Basu 2013 {published data only}  ,excluded,CD009069-bbs2-0033, A review of evidence from phase III trials and national immunisation programs regarding efficacy and safety of HPV vaccines.  
CD009069-bib-0065,"Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, et al. ","Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection", Journal of the National Cancer Institute ,2016,108,    ,['citation-journal']," Beachler DC, Kreimer AR, Schiffman M, Herrero R, Wacholder S, Rodriguez AC, et al. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection.  Journal of the National Cancer Institute 2016;108(1):djv302. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/jnci/djv302', 'https://www.ncbi.nlm.nih.gov/pubmed/26467666', 'https://scholar.google.com/scholar_lookup?title=Multisite+HPV16/18+vaccine+efficacy+against+cervical,+anal,+and+oral+HPV+infection&author=DC+Beachler&author=AR+Kreimer&author=M+Schiffman&author=R+Herrero&author=S+Wacholder&author=AC+Rodriguez&publication_year=2016&hl=en']",26467666,https://doi.org/10.1093/jnci/djv302, Beachler 2016 {published data only}  ,excluded,CD009069-bbs2-0034," Efficacy of the bivalent vaccine against cervical, anal and oral infection in a sub‐cohort nested in the CVT trial. Cervical outcomes already included.  "
CD009069-bib-0066,"Brown DR, Fife KH, Wheeler CM, Koutsky LA, Lupinacci LM, Railkar R. ",Early assessment of the efficacy of a human papillomavirus type 16 L1 virus‐like particle vaccine, Vaccine ,2004,22,    ,['citation-journal']," Brown DR, Fife KH, Wheeler CM, Koutsky LA, Lupinacci LM, Railkar R. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus‐like particle vaccine.  Vaccine 2004;22(21‐22):2936‐42. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2003.11.059', 'https://www.ncbi.nlm.nih.gov/pubmed/15246630', 'https://scholar.google.com/scholar_lookup?title=Early+assessment+of+the+efficacy+of+a+human+papillomavirus+type+16+L1+virus‐like+particle+vaccine+&author=DR+Brown&author=KH+Fife&author=CM+Wheeler&author=LA+Koutsky&author=LM+Lupinacci&author=R+Railkar&publication_year=2004&hl=en']",15246630,https://doi.org/10.1016/j.vaccine.2003.11.059, Brown 2004 {published data only}  ,excluded,CD009069-bbs2-0035, Post hoc analysis using combined data from two Phase I tolerability/immunogenicity trials.  
CD009069-bib-0067,"Couto E, Saeterdal I, Juvet LK, Klemp M. ",HPV catch‐up vaccination of young women: a systematic review and meta‐analysis, BMC Public Health ,2014,14,    ,['citation-journal']," Couto E, Saeterdal I, Juvet LK, Klemp M. HPV catch‐up vaccination of young women: a systematic review and meta‐analysis.  BMC Public Health 2014;14(1471‐2458 (Electronic), 1471‐2458 (Linking)):867. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/1471-2458-14-867', 'https://www.ncbi.nlm.nih.gov/pubmed/25149765', 'https://scholar.google.com/scholar_lookup?title=HPV+catch‐up+vaccination+of+young+women:+a+systematic+review+and+meta‐analysis&author=E+Couto&author=I+Saeterdal&author=LK+Juvet&author=M+Klemp&publication_year=2014&hl=en']",25149765,https://doi.org/10.1186/1471-2458-14-867, Couto 2014 {published data only}  ,excluded,CD009069-bbs2-0036," Systemactic review and meta‐analysis of protection of HPV vaccines against CIN, VIN, VAIN, and genital warts in catch‐up populations. No Original data, not a randomised controlled trial.  "
CD009069-bib-0068,"D'Addario M, Redmond S, Scott P, Egli‐Gany D, Riveros‐Balta AX, Henao Restrepo AM, et al. ",Two‐dose schedules for human papillomavirus vaccine: Systematic review and meta‐analysis, Vaccine ,2017,35,    ,['citation-journal']," D'Addario M, Redmond S, Scott P, Egli‐Gany D, Riveros‐Balta AX, Henao Restrepo AM, et al. Two‐dose schedules for human papillomavirus vaccine: Systematic review and meta‐analysis.  Vaccine 2017;35(1873‐2518 (Electronic), 0264‐410X (Linking), 22):2892‐901. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2017.03.096', 'https://www.ncbi.nlm.nih.gov/pubmed/28455170', ""https://scholar.google.com/scholar_lookup?title=Two‐dose+schedules+for+human+papillomavirus+vaccine:+Systematic+review+and+meta‐analysis&author=M+D'Addario&author=S+Redmond&author=P+Scott&author=D+Egli‐Gany&author=AX+Riveros‐Balta&author=AM+HenaoRestrepo&publication_year=2017&hl=en""]",28455170,https://doi.org/10.1016/j.vaccine.2017.03.096, D'Addario 2017 {published data only}  ,excluded,CD009069-bbs2-0037, Systematic review and meta‐analysis of the immunogenicity of the 2‐dose vaccination schedule versus 3‐dose schedule.  
CD009069-bib-0069,"D'Souza C, Mort GS, Zyngier S, Robinson P, Schlotterlein M. ",Preventive innovation: an Australian case study on HPV vaccination, Health Marketing Quartely ,2013,30,    ,['citation-journal']," D'Souza C, Mort GS, Zyngier S, Robinson P, Schlotterlein M. Preventive innovation: an Australian case study on HPV vaccination.  Health Marketing Quartely 2013;30(3):206‐20. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1080/07359683.2013.814486', ""https://scholar.google.com/scholar_lookup?title=Preventive+innovation:+an+Australian+case+study+on+HPV+vaccination&author=C+D'Souza&author=GS+Mort&author=S+Zyngier&author=P+Robinson&author=M+Schlotterlein&publication_year=2013&hl=en""]",,https://doi.org/10.1080/07359683.2013.814486, D'Souza 2013 {published data only}  ,excluded,CD009069-bbs2-0038, A case‐study on HPV vaccination national programme in Australia for future innovation prevention.  
CD009069-bib-0070,"Delere Y, Bohmer MM, Walter D, Wichmann O. ",HPV vaccination coverage among women aged 18‐20 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross‐sectional survey, Human Vaccines & Immunotherapeutics ,2013,9,    ,['citation-journal']," Delere Y, Bohmer MM, Walter D, Wichmann O. HPV vaccination coverage among women aged 18‐20 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross‐sectional survey.  Human Vaccines & Immunotherapeutics 2013;9(8):1706‐11. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4161/hv.24904', 'https://www.ncbi.nlm.nih.gov/pubmed/23732901', 'https://scholar.google.com/scholar_lookup?title=HPV+vaccination+coverage+among+women+aged+18‐20+years+in+Germany+three+years+after+recommendation+of+HPV+vaccination+for+adolescent+girls:+results+from+a+cross‐sectional+survey+&author=Y+Delere&author=MM+Bohmer&author=D+Walter&author=O+Wichmann&publication_year=2013&hl=en']",23732901,https://doi.org/10.4161/hv.24904, Delere 2013 {published data only}  ,excluded,CD009069-bbs2-0039, Assessment of HPV vaccine update and post‐vaccination cervical cancer prevention in Germany. Not a randomised controlled trial.  
CD009069-bib-0071,"Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K. ",Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine in HIV‐positive women in South Africa: A partially‐blind randomised placebo‐controlled study, Vaccine ,2013,31,    ,['citation-journal']," Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K. Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine in HIV‐positive women in South Africa: A partially‐blind randomised placebo‐controlled study.  Vaccine 2013;31(48):5745‐53. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2013.09.032', 'https://www.ncbi.nlm.nih.gov/pubmed/24091311', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+in+HIV‐positive+women+in+South+Africa:+A+partially‐blind+randomised+placebo‐controlled+study+&author=L+Denny&author=B+Hendricks&author=C+Gordon&author=F+Thomas&author=M+Hezareh&author=K+Dobbelaere&publication_year=2013&hl=en']",24091311,https://doi.org/10.1016/j.vaccine.2013.09.032, Denny 2013 {published data only}  ,excluded,CD009069-bbs2-0040, Randomised trial assessing safety and immunogenicity in HIV‐positive women (N = 120 randomised to bivalent vaccine or placebo). 30 HIV seronegative women all received the bivalent vaccine.  
CD009069-bib-0072,"Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T. ",Safety of human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials, Human Vaccines & Immunotherapeutics ,2009,5,    ,['citation-journal']," Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T. Safety of human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials.  Human Vaccines & Immunotherapeutics 2009;5(5):332‐40. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.4161/hv.5.5.7211', 'https://scholar.google.com/scholar_lookup?title=Safety+of+human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+vaccine+for+cervical+cancer+prevention:+a+pooled+analysis+of+11+clinical+trials+&author=D+Descamps&author=K+Hardt&author=B+Spiessens&author=P+Izurieta&author=T+Verstraeten&author=T+Breuer&publication_year=2009&hl=en']",,https://doi.org/10.4161/hv.5.5.7211, Descamps 2009 {published data only}  ,excluded,CD009069-bbs2-0041, Pooled analysis on safety of the bivalent vaccine including 11 studies. Not all were randomised trials.  
CD009069-bib-0073,"De Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G. ",Long‐term efficacy and safety of human papillomavirus vaccination, International Journal of Womens Health ,2014,6,    ,['citation-journal']," De Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G. Long‐term efficacy and safety of human papillomavirus vaccination.  International Journal of Womens Health 2014;6(1179‐411 (Electronic), 1179‐411 (Linking)):999‐1010. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.2147/IJWH.S50365', 'https://scholar.google.com/scholar_lookup?title=Long‐term+efficacy+and+safety+of+human+papillomavirus+vaccination&author=R+Vincenzo&author=C+Conte&author=C+Ricci&author=G+Scambia&author=G+Capelli&publication_year=2014&hl=en']",,https://doi.org/10.2147/IJWH.S50365, De Vincenzo 2014 {published data only}  ,excluded,CD009069-bbs2-0042, Review of the long‐term efficacy and safety of HPV vaccines. No original data. 
CD009069-bib-0074,"Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M. ",Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial, JAMA ,2013,309,    ,['citation-journal']," Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.  JAMA 2013;309(17):1793‐802. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/jama.2013.1625', 'https://www.ncbi.nlm.nih.gov/pubmed/23632723', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+of+2+doses+of+HPV+vaccine+in+younger+adolescents+vs+3+doses+in+young+women:+a+randomized+clinical+trial+&author=SR+Dobson&author=S+McNeil&author=M+Dionne&author=M+Dawar&author=G+Ogilvie&author=M+Krajden&publication_year=2013&hl=en']",23632723,https://doi.org/10.1001/jama.2013.1625, Dobson 2013 {published data only}  ,excluded,CD009069-bbs2-0043, Randomised phase III trial assessing immunogenicity after two versus three doses of the quadrivalent vaccine. No vaccine efficacy data.  
CD009069-bib-0075,"Draper E, Bissett SL, Howell‐Jones R, Edwards D, Munslow G, Soldan K. ",Neutralization of non‐vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera, Vaccine ,2011,29,    ,['citation-journal']," Draper E, Bissett SL, Howell‐Jones R, Edwards D, Munslow G, Soldan K. Neutralization of non‐vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.  Vaccine 2011;29(47):8585‐90. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2011.09.021', 'https://www.ncbi.nlm.nih.gov/pubmed/21939712', 'https://scholar.google.com/scholar_lookup?title=Neutralization+of+non‐vaccine+human+papillomavirus+pseudoviruses+from+the+A7+and+A9+species+groups+by+bivalent+HPV+vaccine+sera+&author=E+Draper&author=SL+Bissett&author=R+Howell‐Jones&author=D+Edwards&author=G+Munslow&author=K+Soldan&publication_year=2011&hl=en']",21939712,https://doi.org/10.1016/j.vaccine.2011.09.021, Draper 2011 {published data only}  ,excluded,CD009069-bbs2-0044, Non randomised study assessing presence of neutralising antibodies of non‐vaccine HPV types in girls vaccinated with the bivalent vaccine.  
CD009069-bib-0076,"Draper E, Bissett SL, Howell‐Jones R, Waight P, Soldan K, Jit M. ","A randomized, observer‐blinded immunogenicity trial of cervarix((R)) and gardasil((R)) human papillomavirus vaccines in 12‐15 year old girls", PLOS One ,2013,8,    ,['citation-journal']," Draper E, Bissett SL, Howell‐Jones R, Waight P, Soldan K, Jit M. A randomized, observer‐blinded immunogenicity trial of cervarix((R)) and gardasil((R)) human papillomavirus vaccines in 12‐15 year old girls.  PLOS One 2013;8(5):e61825. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1371/journal.pone.0061825', 'https://www.ncbi.nlm.nih.gov/pubmed/23650505', 'https://scholar.google.com/scholar_lookup?title=A+randomized,+observer‐blinded+immunogenicity+trial+of+cervarix((R))+and+gardasil((R))+human+papillomavirus+vaccines+in+12‐15+year+old+girls+&author=E+Draper&author=SL+Bissett&author=R+Howell‐Jones&author=P+Waight&author=K+Soldan&author=M+Jit&publication_year=2013&hl=en']",23650505,https://doi.org/10.1371/journal.pone.0061825, Draper 2013 {published data only}  ,excluded,CD009069-bbs2-0045, Randomised trial comparing generation of cross‐protecting antibodies in serum and vaginal mucus among girls receiving bivalent versus quadrivalent vaccine. No vaccine efficacy data. No placebo group included in the RCT.  
CD009069-bib-0077,"Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F. ",Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18 to 45 years, Human Vaccines & Immunotherapeutics ,2009,5,    ,['citation-journal']," Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18 to 45 years.  Human Vaccines & Immunotherapeutics 2009;5(10):705‐19. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.4161/hv.5.10.9518', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+the+immunogenicity+and+safety+of+Cervarix+and+Gardasil+human+papillomavirus+(HPV)+cervical+cancer+vaccines+in+healthy+women+aged+18+to+45+years+&author=MH+Einstein&author=M+Baron&author=MJ+Levin&author=A+Chatterjee&author=RP+Edwards&author=F+Zepp&publication_year=2009&hl=en']",,https://doi.org/10.4161/hv.5.10.9518, Einstein 2009 {published data only}  ,excluded,CD009069-bbs2-0046, Randomised trial comparing safety and generation of antiHPV16/18 antibodies in serum and vaginal mucus among girls receiving bivalent versus quadrivalent vaccine (7 months after 3rd dose). No vaccine efficacy data. No placebo group included in the RCT.  
CD009069-bib-0078,"Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S. ",Comparative immunogenicity and safety of human papillomavirus (HPV) 16/18 vaccine and HPV‐6/11/16/18 vaccine: Follow‐up from months 12 to 24 in a Phase III randomized study of healthy women aged 18 to 45 years, Human Vaccines & Immunotherapeutics ,2011,7,    ,['citation-journal']," Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S. Comparative immunogenicity and safety of human papillomavirus (HPV) 16/18 vaccine and HPV‐6/11/16/18 vaccine: Follow‐up from months 12 to 24 in a Phase III randomized study of healthy women aged 18 to 45 years.  Human Vaccines & Immunotherapeutics 2011;7(12):1343‐58. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.4161/hv.7.12.18281', 'https://scholar.google.com/scholar_lookup?title=Comparative+immunogenicity+and+safety+of+human+papillomavirus+(HPV)+16/18+vaccine+and+HPV‐6/11/16/18+vaccine:+Follow‐up+from+months+12+to+24+in+a+Phase+III+randomized+study+of+healthy+women+aged+18+to+45+years+&author=MH+Einstein&author=M+Baron&author=MJ+Levin&author=A+Chatterjee&author=B+Fox&author=S+Scholar&publication_year=2011&hl=en']",,https://doi.org/10.4161/hv.7.12.18281, Einstein 2011 {published data only}  ,excluded,CD009069-bbs2-0047, Randomised trial comparing safety and generation of antiHPV16/18 antibodies in serum and vaginal mucus among girls receiving bivalent versus quadrivalent vaccine (12 months after 3rd dose). No vaccine efficacy data. No placebo group included in the RCT.  
CD009069-bib-0079,"Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA. ",A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers, Journal of Infectious Diseases ,2001,183,    ,['citation-journal']," Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers.  Journal of Infectious Diseases 2001;183(0022‐1899, 10):1485‐93. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1086/320190', 'https://scholar.google.com/scholar_lookup?title=A+Phase+1+study+of+a+recombinant+viruslike+particle+vaccine+against+human+papillomavirus+type+11+in+healthy+adult+volunteers+&author=TG+Evans&author=W+Bonnez&author=RC+Rose&author=S+Koenig&author=L+Demeter&author=JA+Suzich&publication_year=2001&hl=en']",,https://doi.org/10.1086/320190, Evans 2001 {published data only}  ,excluded,CD009069-bbs2-0048, Dose‐escalation phase I trial addressing immunological response and safety after administration of an L1 HPV11 vaccine.  
CD009069-bib-0080,"Forinash AB, Yancey AM, Pitlick JM, Myles TD. ",Safety of the HPV bivalent and quadrivalent vaccines during pregnancy, Annals of Pharmacotherapy ,2011,45,    ,['citation-journal']," Forinash AB, Yancey AM, Pitlick JM, Myles TD. Safety of the HPV bivalent and quadrivalent vaccines during pregnancy.  Annals of Pharmacotherapy 2011;45(3):1‐5. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1345/aph.1P396', 'https://scholar.google.com/scholar_lookup?title=Safety+of+the+HPV+bivalent+and+quadrivalent+vaccines+during+pregnancy&author=AB+Forinash&author=AM+Yancey&author=JM+Pitlick&author=TD+Myles&publication_year=2011&hl=en']",,https://doi.org/10.1345/aph.1P396, Forinash 2011 {published data only}  ,excluded,CD009069-bbs2-0049, Systematic review on pregnancy outcomes of bi‐ and quadrivalent vaccines using data from RCTs and post‐marketing surveillance.  
CD009069-bib-0081,"Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmeron J, Chow SN, et al. ",Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial, International Journal of Cancer ,2016,139,    ,['citation-journal']," Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmeron J, Chow SN, et al. Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial.  International Journal of Cancer 2016;139(1097‐0215 (Electronic), 0020‐7136 (Linking), 12):2812‐26. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1002/ijc.30391', 'https://www.ncbi.nlm.nih.gov/pubmed/27541373', 'https://scholar.google.com/scholar_lookup?title=Prior+human+papillomavirus‐16/18+AS04‐adjuvanted+vaccination+prevents+recurrent+high+grade+cervical+intraepithelial+neoplasia+after+definitive+surgical+therapy:+Post‐hoc+analysis+from+a+randomized+controlled+trial+&author=SM+Garland&author=J+Paavonen&author=U+Jaisamrarn&author=P+Naud&author=J+Salmeron&author=SN+Chow&publication_year=2016&hl=en']",27541373,https://doi.org/10.1002/ijc.30391, Garland 2016 {published data only}  ,excluded,CD009069-bbs2-0050, Post‐hoc analysis of the bivalent HPV vaccine against the recurrent of the high‐grade CIN after surgical therapy.  
CD009069-bib-0082,"Giuliano AR, Lazcano‐Ponce E, Villa L, Nolan T, Marchant C, Radley D. ","Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus‐like‐particle vaccine", Journal of Infectious Diseases ,2007,196,    ,['citation-journal']," Giuliano AR, Lazcano‐Ponce E, Villa L, Nolan T, Marchant C, Radley D. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus‐like‐particle vaccine.  Journal of Infectious Diseases 2007;196(8):1153‐62. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1086/521679', 'https://scholar.google.com/scholar_lookup?title=Impact+of+baseline+covariates+on+the+immunogenicity+of+a+quadrivalent+(types+6,+11,+16,+and+18)+human+papillomavirus+virus‐like‐particle+vaccine+&author=AR+Giuliano&author=E+Lazcano‐Ponce&author=L+Villa&author=T+Nolan&author=C+Marchant&author=D+Radley&publication_year=2007&hl=en']",,https://doi.org/10.1086/521679, Giuliano 2007 {published data only}  ,excluded,CD009069-bbs2-0051, Pooled analysis of phase II/III trials assessing immunogenicity according to baseline covariates. No original data. No vaccine‐efficacy or safety data.  
CD009069-bib-0083,"Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C. ",Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males, New England Journal of Medcine ,2011,364,    ,['citation-journal']," Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males.  New England Journal of Medcine 2011;364(5):401‐11. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1056/NEJMoa0909537', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+quadrivalent+HPV+vaccine+against+HPV+infection+and+disease+in+males&author=AR+Giuliano&author=JM+Palefsky&author=S+Goldstone&author=ED+Moreira&author=ME+Penny&author=C+Aranda&publication_year=2011&hl=en']",,https://doi.org/10.1056/NEJMoa0909537, Giuliano 2011 {published data only}  ,excluded,CD009069-bbs2-0052, Phase III trial assessing safety and efficacy of vaccination with the quadrivalent vaccine in men.  
CD009069-bib-0084,"Giuliano AR, Isaacs‐Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA, et al. ",Immunogenicity and safety of Gardasil among mid‐adult aged men (27 to 45 years) The MAM Study, Vaccine ,2015,33,    ,['citation-journal']," Giuliano AR, Isaacs‐Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA, et al. Immunogenicity and safety of Gardasil among mid‐adult aged men (27 to 45 years) The MAM Study.  Vaccine 2015;33(1873‐2518 (Electronic), 0264‐410X (Linking), 42):5640‐6. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2015.08.072', 'https://www.ncbi.nlm.nih.gov/pubmed/26343499', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+Gardasil+among+mid‐adult+aged+men+(27+to+45+years)+The+MAM+Study+&author=AR+Giuliano&author=K+Isaacs‐Soriano&author=BN+Torres&author=M+Abrahamsen&author=DJ+Ingles&author=BA+Sirak&publication_year=2015&hl=en']",26343499,https://doi.org/10.1016/j.vaccine.2015.08.072, Giuliano 2015 {published data only}  ,excluded,CD009069-bbs2-0053, Immunogenicity and safety of Gardasil vaccine among mid‐adult aged men of 27 to 45 years. No data on women.  
CD009069-bib-0085,"Goldstone SE, Jessen H, Palefsky JM, Giuliano AR, Moreira ED, Vardas E, et al. ",Quadrivalent HPV vaccine efficacy against disease related to vaccine and non‐vaccine HPV types in males, Vaccine ,2013,31,    ,['citation-journal']," Goldstone SE, Jessen H, Palefsky JM, Giuliano AR, Moreira ED, Vardas E, et al. Quadrivalent HPV vaccine efficacy against disease related to vaccine and non‐vaccine HPV types in males.  Vaccine 2013;31(37):3849‐55. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2013.06.057', 'https://www.ncbi.nlm.nih.gov/pubmed/23831322', 'https://scholar.google.com/scholar_lookup?title=Quadrivalent+HPV+vaccine+efficacy+against+disease+related+to+vaccine+and+non‐vaccine+HPV+types+in+males+&author=SE+Goldstone&author=H+Jessen&author=JM+Palefsky&author=AR+Giuliano&author=ED+Moreira&author=E+Vardas&publication_year=2013&hl=en']",23831322,https://doi.org/10.1016/j.vaccine.2013.06.057, Goldstone 2013 {published data only}  ,excluded,CD009069-bbs2-0054, Quadrivalent HPV vaccine efficacy against disease related to vaccine and non‐vaccine HPV types in men.  
CD009069-bib-0086,"Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ. ",Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus‐like particle vaccine, Journal of the National Cancer Institute ,2001,93,    ,['citation-journal']," Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus‐like particle vaccine.  Journal of the National Cancer Institute 2001;93(4):284‐92. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/jnci/93.4.284', 'https://www.ncbi.nlm.nih.gov/pubmed/11181775', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+trial+in+adult+volunteers+of+a+human+papillomavirus+16+L1+virus‐like+particle+vaccine+&author=CD+Harro&author=YY+Pang&author=RB+Roden&author=A+Hildesheim&author=Z+Wang&author=MJ+Reynolds&publication_year=2001&hl=en']",11181775,https://doi.org/10.1093/jnci/93.4.284, Harro 2001 {published data only}  ,excluded,CD009069-bbs2-0055, Phase I dose‐escalation trial assessing immunogenicity and safety of a mono‐valent HPV16 vaccine.  
CD009069-bib-0087,"Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA. ",Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection, International Journal of Cancer ,2011,129,    ,['citation-journal']," Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA. Impact of an HPV6/11/16/18 L1 virus‐like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.  International Journal of Cancer 2011;129(11):2632‐42. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1002/ijc.25940', 'https://www.ncbi.nlm.nih.gov/pubmed/21491420', 'https://scholar.google.com/scholar_lookup?title=Impact+of+an+HPV6/11/16/18+L1+virus‐like+particle+vaccine+on+progression+to+cervical+intraepithelial+neoplasia+in+seropositive+women+with+HPV16/18+infection+&author=RM+Haupt&author=CM+Wheeler&author=DR+Brown&author=SM+Garland&author=DG+Ferris&author=JA+Paavonen&publication_year=2011&hl=en']",21491420,https://doi.org/10.1002/ijc.25940, Haupt 2011 {published data only}  ,excluded,CD009069-bbs2-0056, Pooled analysis of 2 RCTs assessing the incidence of CIN2+/AIS+ related to HPV 16/18 in women who received the quadrivalent vaccine or placebo and who were HPV16/18 DNA and seropositive. The data of the separate studies are already included in the review.  
CD009069-bib-0088,"Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM, et al. ",Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study, Annals of the RheumaticDiseases ,2014,73,    ,['citation-journal']," Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.  Annals of the RheumaticDiseases 2014;73(1468‐2060 (Electronic), 0003‐4967 (Linking), 8):1500‐7. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1136/annrheumdis-2013-203429', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+the+bivalent+HPV+vaccine+in+female+patients+with+juvenile+idiopathic+arthritis:+a+prospective+controlled+observational+cohort+study+&author=MW+Heijstek&author=M+Scherpenisse&author=N+Groot&author=C+Tacke&author=RM+Schepp&author=AM+Buisman&publication_year=2014&hl=en']",,https://doi.org/10.1136/annrheumdis-2013-203429, Heijstek 2014 {published data only}  ,excluded,CD009069-bbs2-0057, Cohort study on immunogenicity and safety of the bivalent HPV vaccines in female patients with juvenile idiopathic arthritis. Not a randomised controlled trial.  
CD009069-bib-0089,"Hernandez‐Avila M, Torres‐Ibarra L, Stanley M, Salmeron J, Cruz‐Valdez A, Munoz N, et al. ",Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes, Human Vaccines & Immunotherapeutics ,2016,12,    ,['citation-journal']," Hernandez‐Avila M, Torres‐Ibarra L, Stanley M, Salmeron J, Cruz‐Valdez A, Munoz N, et al. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.  Human Vaccines & Immunotherapeutics 2016;12(2164‐554X (Electronic), 2164‐5515 (Linking), 1):30‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1080/21645515.2015.1058458', 'https://www.ncbi.nlm.nih.gov/pubmed/26211489', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+the+immunogenicity+of+the+quadrivalent+HPV+vaccine+using+2+versus+3+doses+at+month+21:+An+epidemiological+surveillance+mechanism+for+alternate+vaccination+schemes+&author=M+Hernandez‐Avila&author=L+Torres‐Ibarra&author=M+Stanley&author=J+Salmeron&author=A+Cruz‐Valdez&author=N+Munoz&publication_year=2016&hl=en']",26211489,https://doi.org/10.1080/21645515.2015.1058458, Hernandez‐Avila 2016 {published data only}  ,excluded,CD009069-bbs2-0058," Non randomised trial to evaluate the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses, An observational surveillance study to evaluate alternative vaccination schedules.  "
CD009069-bib-0090,"Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA. ",Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica, PLOS One ,2013,8,    ,['citation-journal']," Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.  PLOS One 2013;8(7):e68329. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1371/journal.pone.0068329', 'https://www.ncbi.nlm.nih.gov/pubmed/23873171', 'https://scholar.google.com/scholar_lookup?title=Reduced+prevalence+of+oral+human+papillomavirus+(HPV)+4+years+after+bivalent+HPV+vaccination+in+a+randomized+clinical+trial+in+Costa+Rica+&author=R+Herrero&author=W+Quint&author=A+Hildesheim&author=P+Gonzalez&author=L+Struijk&author=HA+Katki&publication_year=2013&hl=en']",23873171,https://doi.org/10.1371/journal.pone.0068329, Herrero 2013 {published data only}  ,excluded,CD009069-bbs2-0059, Report from the Costa Rica vaccination trial assessing effect of the bivalent vaccine on oral HPV infection.  
CD009069-bib-0091,"Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC. ",Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial, JAMA ,2007,298,    ,['citation-journal']," Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial.  JAMA 2007;298(7):743‐53. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/jama.298.7.743', 'https://www.ncbi.nlm.nih.gov/pubmed/17699008', 'https://scholar.google.com/scholar_lookup?title=Effect+of+human+papillomavirus+16/18+L1+viruslike+particle+vaccine+among+young+women+with+preexisting+infection:+a+randomized+trial+&author=A+Hildesheim&author=R+Herrero&author=S+Wacholder&author=AC+Rodriguez&author=D+Solomon&author=MC+Bratti&publication_year=2007&hl=en']",17699008,https://doi.org/10.1001/jama.298.7.743, Hildesheim 2007 {published data only}  ,excluded,CD009069-bbs2-0060, Report of the Costa Rica trial assessing the effect of the bivalent vaccine on clearance of existing HPV infection.  
CD009069-bib-0092,"Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Vardas E. ",The immunogenicity of quadrivalent HPV (type 6/11/16/18) vaccine in males aged 16 to 26, Clinical and Vaccine Immunology ,2011,19,    ,['citation-journal']," Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Vardas E. The immunogenicity of quadrivalent HPV (type 6/11/16/18) vaccine in males aged 16 to 26.  Clinical and Vaccine Immunology 2011;19:261‐7. CENTRAL    PubMed     Google Scholar     ","['', 'https://www.ncbi.nlm.nih.gov/pubmed/22155768', 'https://scholar.google.com/scholar_lookup?title=The+immunogenicity+of+quadrivalent+HPV+(type+6/11/16/18)+vaccine+in+males+aged+16+to+26+&author=RJ+Hillman&author=AR+Giuliano&author=JM+Palefsky&author=S+Goldstone&author=ED+Moreira&author=E+Vardas&publication_year=2011&hl=en']",22155768,, Hillman 2011 {published data only}  ,excluded,CD009069-bbs2-0061, Phase III randomised trial assessing immunogenicity of the quadrivalent vaccine in men.  
CD009069-bib-0093,"Joura EA, Leodolter S, Hernandez‐Avila M, Wheeler CM, Perez G, Koutsky LA. ","Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like‐particle vaccine against high‐grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials", Lancet ,2007,369,    ,['citation-journal']," Joura EA, Leodolter S, Hernandez‐Avila M, Wheeler CM, Perez G, Koutsky LA. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like‐particle vaccine against high‐grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.  Lancet 2007;369(9574):1693‐702. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0140-6736(07)60777-6', 'https://www.ncbi.nlm.nih.gov/pubmed/17512854', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+a+quadrivalent+prophylactic+human+papillomavirus+(types+6,+11,+16,+and+18)+L1+virus‐like‐particle+vaccine+against+high‐grade+vulval+and+vaginal+lesions:+a+combined+analysis+of+three+randomised+clinical+trials+&author=EA+Joura&author=S+Leodolter&author=M+Hernandez‐Avila&author=CM+Wheeler&author=G+Perez&author=LA+Koutsky&publication_year=2007&hl=en']",17512854,https://doi.org/10.1016/S0140-6736(07)60777-6, Joura 2007 {published data only}  ,excluded,CD009069-bbs2-0062, Pooled analyses of three randomised trials assessing protection of the quadrivalent vaccine against vulval and vaginal intraepithelial lesions. Protection against cervical lesions was not addressed.  
CD009069-bib-0094,"Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, et al. ","Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV‐infected young women", Clinical Infectious Diseases ,2013,57,    ,['citation-journal']," Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV‐infected young women.  Clinical Infectious Diseases 2013;57(5):735‐44. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/cid/cit319', 'https://www.ncbi.nlm.nih.gov/pubmed/23667266', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+the+human+papillomavirus+6,+11,+16,+18+vaccine+in+HIV‐infected+young+women+&author=JA+Kahn&author=J+Xu&author=BG+Kapogiannis&author=B+Rudy&author=R+Gonin&author=N+Liu&publication_year=2013&hl=en']",23667266,https://doi.org/10.1093/cid/cit319, Kahn 2013 {published data only}  ,excluded,CD009069-bbs2-0063," Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV‐infected young women.  "
CD009069-bib-0095,"Kang WD, Choi HS, Kim SM. ",Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high‐grade cervical intraepithelial neoplasia (CIN2‐3)?, Gynecologic Oncology ,2013,130,    ,['citation-journal']," Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high‐grade cervical intraepithelial neoplasia (CIN2‐3)?.  Gynecologic Oncology 2013;130(2):264‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ygyno.2013.04.050', 'https://www.ncbi.nlm.nih.gov/pubmed/23623831', 'https://scholar.google.com/scholar_lookup?title=Is+vaccination+with+quadrivalent+HPV+vaccine+after+loop+electrosurgical+excision+procedure+effective+in+preventing+recurrence+in+patients+with+high‐grade+cervical+intraepithelial+neoplasia+(CIN2‐3)?+&author=WD+Kang&author=HS+Choi&author=SM+Kim&publication_year=2013&hl=en']",23623831,https://doi.org/10.1016/j.ygyno.2013.04.050, Kang 2013 {published data only}  ,excluded,CD009069-bbs2-0064, Non randomised study assessing effect of the quadrivalent vaccine on the incidence of recurrence of CIN in women treated by excision for high‐grade CIN.  
CD009069-bib-0096,"Khatun S, Akram Hussain SM, Chowdhury S, Ferdous J, Hossain F, Begum SR. ",Safety and immunogenicity profile of human papillomavirus‐16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh, Japanese Journal of Clinical Oncology ,2012,42,    ,['citation-journal']," Khatun S, Akram Hussain SM, Chowdhury S, Ferdous J, Hossain F, Begum SR. Safety and immunogenicity profile of human papillomavirus‐16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh.  Japanese Journal of Clinical Oncology 2012;42(1):36‐41. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1093/jjco/hyr173', 'https://www.ncbi.nlm.nih.gov/pubmed/22194637', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+profile+of+human+papillomavirus‐16/18+AS04+adjuvant+cervical+cancer+vaccine:+a+randomized+controlled+trial+in+healthy+adolescent+girls+of+Bangladesh+&author=S+Khatun&author=SM+AkramHussain&author=S+Chowdhury&author=J+Ferdous&author=F+Hossain&author=SR+Begum&publication_year=2012&hl=en']",22194637,https://doi.org/10.1093/jjco/hyr173, Khatun 2012 {published data only}  ,excluded,CD009069-bbs2-0065," Girls randomised to the experimental arm received the bivalent vaccine, those in the control arm did not receive anything. The trial was not placebo‐controlled. Observation of effects were restricted to participants in the experimental arm.  "
CD009069-bib-0097,"Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM, Perez G, et al. ",A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high‐grade cervical and external genital lesions," Cancer Prevention Research (Philadelphia, Pa.) ",2009,2,    ,['citation-journal']," Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high‐grade cervical and external genital lesions.  Cancer Prevention Research (Philadelphia, Pa.) 2009;2(1940‐6215 (Electronic), 10):868‐78. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1158/1940-6207.CAPR-09-0031', 'https://www.ncbi.nlm.nih.gov/pubmed/19789295', 'https://scholar.google.com/scholar_lookup?title=A+pooled+analysis+of+continued+prophylactic+efficacy+of+quadrivalent+human+papillomavirus+(Types+6/11/16/18)+vaccine+against+high‐grade+cervical+and+external+genital+lesions+&author=SK+Kjaer&author=K+Sigurdsson&author=OE+Iversen&author=M+Hernandez‐Avila&author=CM+Wheeler&author=G+Perez&publication_year=2009&hl=en']",19789295,https://doi.org/10.1158/1940-6207.CAPR-09-0031, Kjaer 2009 {published data only}  ,excluded,CD009069-bbs2-0066, A pooled analysis of efficacy of quadrivalent HPV vaccines against cervical and genital lesions. No separate data on FUTURE I and FUTURE II trials. The data of the separate studies are already included in the review.  
CD009069-bib-0098,"Kreimer AR, Sherman ME, Sahasrabuddhe VV, Safaeian M. ",The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents, Journal of the National Cancer Institute ,2015,107,    ,['citation-journal']," Kreimer AR, Sherman ME, Sahasrabuddhe VV, Safaeian M. The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents.  Journal of the National Cancer Institute 2015;107(3 1460‐2105 (Electronic)):1‐4 0027‐8874 (Linking). CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1093/jnci/dju436', 'https://scholar.google.com/scholar_lookup?title=The+case+for+conducting+a+randomized+clinical+trial+to+assess+the+efficacy+of+a+single+dose+of+prophylactic+HPV+vaccines+among+adolescents+&author=AR+Kreimer&author=ME+Sherman&author=VV+Sahasrabuddhe&author=M+Safaeian&publication_year=2015&hl=en']",,https://doi.org/10.1093/jnci/dju436, Kreimer 2015 {published data only}  ,excluded,CD009069-bbs2-0067, Discussion about conducting a randomised clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescent. No original data.  
CD009069-bib-0099,"Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM. ",Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose, Journal of Infectious Diseases ,2013,208,    ,['citation-journal']," Lamontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.  Journal of Infectious Diseases 2013;208(8):1325‐34. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1093/infdis/jit363', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+of+quadrivalent+HPV+vaccine+among+girls+11+to+13+Years+of+age+vaccinated+using+alternative+dosing+schedules:+results+29+to+32+months+after+third+dose+&author=DS+Lamontagne&author=VD+Thiem&author=VM+Huong&author=Y+Tang&author=KM+Neuzil&publication_year=2013&hl=en']",,https://doi.org/10.1093/infdis/jit363, Lamontagne 2013 {published data only}  ,excluded,CD009069-bbs2-0068, Immunogenicity of quadrivalent HPV vaccine among girls aged 11 to 13 years of age vaccinated using alternative dosing schedules.  
CD009069-bib-0100,"Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, et al. ",Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial, Journal of Infectious Diseases ,2014,210,    ,['citation-journal']," Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, et al. Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.  Journal of Infectious Diseases 2014;210(12):1890‐9. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1093/infdis/jiu357', 'https://scholar.google.com/scholar_lookup?title=Reduced+prevalence+of+vulvar+HPV16/18+infection+among+women+who+received+the+HPV16/18+bivalent+vaccine:+a+nested+analysis+within+the+Costa+Rica+Vaccine+Trial+&author=KA+LangKuhs&author=P+Gonzalez&author=AC+Rodriguez&author=LJ+Doorn&author=M+Schiffman&author=L+Struijk&publication_year=2014&hl=en']",,https://doi.org/10.1093/infdis/jiu357, Lang 2014 {published data only}  ,excluded,CD009069-bbs2-0069, A nested analysis of CVT trial on vaccine efficacy against vulvar HPV infection. Cervical outcomes from the trial have been included in the review.  
CD009069-bib-0101,"Lazcano‐Ponce E, Stanley M, Munoz N, Torres L, Cruz‐Valdez A, Salmeron J, et al. ",Overcoming barriers to HPV vaccination: non‐inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two‐dose vs. a three‐dose schedule at 21 months, Vaccine ,2014,32,    ,['citation-journal']," Lazcano‐Ponce E, Stanley M, Munoz N, Torres L, Cruz‐Valdez A, Salmeron J, et al. Overcoming barriers to HPV vaccination: non‐inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two‐dose vs. a three‐dose schedule at 21 months.  Vaccine 2014;32(6):725‐32. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2013.11.059', 'https://www.ncbi.nlm.nih.gov/pubmed/24355090', 'https://scholar.google.com/scholar_lookup?title=Overcoming+barriers+to+HPV+vaccination:+non‐inferiority+of+antibody+response+to+human+papillomavirus+16/18+vaccine+in+adolescents+vaccinated+with+a+two‐dose+vs.+a+three‐dose+schedule+at+21+months+&author=E+Lazcano‐Ponce&author=M+Stanley&author=N+Munoz&author=L+Torres&author=A+Cruz‐Valdez&author=J+Salmeron&publication_year=2014&hl=en']",24355090,https://doi.org/10.1016/j.vaccine.2013.11.059, Lazcano‐Ponce 2014 {published data only}  ,excluded,CD009069-bbs2-0070, Non‐inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with alternative dosing schedules.  
CD009069-bib-0102,"Lehtinen M, Eriksson T, Apter D, Hokkanen M, Natunen K, Paavonen J, et al. ",Safety of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in adolescents aged 12‐15 years: Interim analysis of a large community‐randomized controlled trial, Human Vaccines & Immunotherapeutics ,2016,12,    ,['citation-journal']," Lehtinen M, Eriksson T, Apter D, Hokkanen M, Natunen K, Paavonen J, et al. Safety of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in adolescents aged 12‐15 years: Interim analysis of a large community‐randomized controlled trial.  Human Vaccines & Immunotherapeutics 2016;12(2164‐554X (Electronic), 2164‐5515 (Linking), 12):3177‐85. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1080/21645515.2016.1183847', 'https://www.ncbi.nlm.nih.gov/pubmed/27841725', 'https://scholar.google.com/scholar_lookup?title=Safety+of+the+human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+vaccine+in+adolescents+aged+12‐15+years:+Interim+analysis+of+a+large+community‐randomized+controlled+trial+&author=M+Lehtinen&author=T+Eriksson&author=D+Apter&author=M+Hokkanen&author=K+Natunen&author=J+Paavonen&publication_year=2016&hl=en']",27841725,https://doi.org/10.1080/21645515.2016.1183847, Lehtinen 2016 {published data only}  ,excluded,CD009069-bbs2-0071," Phase IV RCT to evaluate the effectiveness, safety and immunogenicity of Cervarix in boys and girls aged 12‐15 years in Finland.  "
CD009069-bib-0103,"Leroux‐Roels G, Haelterman E, Maes C, Levy J, De Boever F, Licini L. ",Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04‐adjuvanted cervical cancer vaccine, Clinical Vaccine Immunology ,2011,18,    ,['citation-journal']," Leroux‐Roels G, Haelterman E, Maes C, Levy J, De Boever F, Licini L. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04‐adjuvanted cervical cancer vaccine.  Clinical Vaccine Immunology 2011;18(9):1510‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1128/CVI.00539-10', 'https://www.ncbi.nlm.nih.gov/pubmed/21734063', 'https://scholar.google.com/scholar_lookup?title=Randomized+trial+of+the+immunogenicity+and+safety+of+the+Hepatitis+B+vaccine+given+in+an+accelerated+schedule+coadministered+with+the+human+papillomavirus+type+16/18+AS04‐adjuvanted+cervical+cancer+vaccine+&author=G+Leroux‐Roels&author=E+Haelterman&author=C+Maes&author=J+Levy&author=F+Boever&author=L+Licini&publication_year=2011&hl=en']",21734063,https://doi.org/10.1128/CVI.00539-10, Leroux‐Roels 2011 {published data only}  ,excluded,CD009069-bbs2-0072, Randomised trial assessing safety and immunogenicity of vaccination with the hepatitis‐B vaccine alone versus co‐administration of the hepatitis‐B vaccine with the bivalent HPV vaccine. No HPV alone group.  
CD009069-bib-0104,"Leung TF, Liu AP, Lim FS, Thollot F, Oh HM, Lee BW, et al. ",Comparative immunogenicity and safety of human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine and HPV‐6/11/16/18 vaccine administered according to 2‐ and 3‐dose schedules in girls aged 9‐14 years: Results to month 12 from a randomized trial, Human Vaccines & Immunotherapeutics ,2015,11,    ,['citation-journal']," Leung TF, Liu AP, Lim FS, Thollot F, Oh HM, Lee BW, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine and HPV‐6/11/16/18 vaccine administered according to 2‐ and 3‐dose schedules in girls aged 9‐14 years: Results to month 12 from a randomized trial.  Human Vaccines & Immunotherapeutics 2015;11(2164‐554X (Electronic), 2164‐5515 (Linking), 7):1689‐702. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1080/21645515.2015.1050570', 'https://www.ncbi.nlm.nih.gov/pubmed/26062002', 'https://scholar.google.com/scholar_lookup?title=Comparative+immunogenicity+and+safety+of+human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+vaccine+and+HPV‐6/11/16/18+vaccine+administered+according+to+2‐+and+3‐dose+schedules+in+girls+aged+9‐14+years:+Results+to+month+12+from+a+randomized+trial+&author=TF+Leung&author=AP+Liu&author=FS+Lim&author=F+Thollot&author=HM+Oh&author=BW+Lee&publication_year=2015&hl=en']",26062002,https://doi.org/10.1080/21645515.2015.1050570, Leung 2015 {published data only}  ,excluded,CD009069-bbs2-0073," Non RCT to compare immunogenicity and safety of 2‐dose bivalent, 2‐dose quadrivalent and 3‐dose quadrivalent vaccination schedule among girls aged 9‐14 years.  "
CD009069-bib-0105,"Li R, Li Y, Radley D, Liu Y, Huang T, Sings HL. ","Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double‐blind, placebo‐controlled trial in Chinese males and females", Vaccine ,2012,30,    ,['citation-journal']," Li R, Li Y, Radley D, Liu Y, Huang T, Sings HL. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double‐blind, placebo‐controlled trial in Chinese males and females.  Vaccine 2012;30(28):4284‐91. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2012.02.079', 'https://www.ncbi.nlm.nih.gov/pubmed/22433961', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+a+vaccine+targeting+human+papillomavirus+types+6,+11,+16+and+18:+a+randomized,+double‐blind,+placebo‐controlled+trial+in+Chinese+males+and+females+&author=R+Li&author=Y+Li&author=D+Radley&author=Y+Liu&author=T+Huang&author=HL+Sings&publication_year=2012&hl=en']",22433961,https://doi.org/10.1016/j.vaccine.2012.02.079, Li 2012 {published data only}  ,excluded,CD009069-bbs2-0074, Randomised trial assessing safety and immunogenicity of the quadrivalent vaccine in a group of Chinese women and men. Outcomes are presented jointly. Data separated by gender were requested from the authors with no response.  
CD009069-bib-0106,"Lin CJ, Zimmerman RK, Nowalk MP, Huang HH, Raviotta JM. ",Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males, Vaccine ,2014,32,    ,['citation-journal']," Lin CJ, Zimmerman RK, Nowalk MP, Huang HH, Raviotta JM. Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males.  Vaccine 2014;32(6):693‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2013.11.098', 'https://www.ncbi.nlm.nih.gov/pubmed/24342252', 'https://scholar.google.com/scholar_lookup?title=Randomized+controlled+trial+of+two+dosing+schedules+for+human+papillomavirus+vaccination+among+college+age+males+&author=CJ+Lin&author=RK+Zimmerman&author=MP+Nowalk&author=HH+Huang&author=JM+Raviotta&publication_year=2014&hl=en']",24342252,https://doi.org/10.1016/j.vaccine.2013.11.098, Lin 2014 {published data only}  ,excluded,CD009069-bbs2-0075, Randomised controlled trial of two dosing schedules for human papillomavirus vaccination among college‐age men.  
CD009069-bib-0107,"Lu B, Kumar A, Castellsague X, Giuliano AR. ",Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta‐analysis, BMC Infectious Disease ,2011,11,    ,['citation-journal']," Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta‐analysis.  BMC Infectious Disease 2011;11(1):13. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1186/1471-2334-11-13', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+prophylactic+vaccines+against+cervical+HPV+infection+and+diseases+among+women:+a+systematic+review+&+meta‐analysis+&author=B+Lu&author=A+Kumar&author=X+Castellsague&author=AR+Giuliano&publication_year=2011&hl=en']",,https://doi.org/10.1186/1471-2334-11-13, Lu 2011 {published data only}  ,excluded,CD009069-bbs2-0076, Systematic review and meta‐analysis of vaccine efficacy and safety of the bivalent vaccine.  
CD009069-bib-0108,"Luna J, Plata M, Gonzalez M, Correa A, Maldonado I, Nossa C. ","Long‐term follow‐up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women", PLOS One ,2013,8,    ,['citation-journal']," Luna J, Plata M, Gonzalez M, Correa A, Maldonado I, Nossa C. Long‐term follow‐up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women.  PLOS One 2013;8(12):e83431. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1371/journal.pone.0083431', 'https://www.ncbi.nlm.nih.gov/pubmed/24391768', 'https://scholar.google.com/scholar_lookup?title=Long‐term+follow‐up+observation+of+the+safety,+immunogenicity,+and+effectiveness+of+Gardasil+in+adult+women+&author=J+Luna&author=M+Plata&author=M+Gonzalez&author=A+Correa&author=I+Maldonado&author=C+Nossa&publication_year=2013&hl=en']",24391768,https://doi.org/10.1371/journal.pone.0083431, Luna 2013 {published data only}  ,excluded,CD009069-bbs2-0077," Follow‐up report (up to 6 years after dose 1) of the Columbian cohort of the FUTURE III trial, assessing the safety, immunogenicity and protection against the joint ocutome of CIN and extra‐genital lesions combined of the quadrivalent vaccine. No separated data for protection against CIN2+ were reported.  "
CD009069-bib-0109,"Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J. ",Cross‐protective efficacy of two human papillomavirus vaccines: a systematic review and meta‐analysis, Lancet Infectious Diseases ,2012,12,    ,['citation-journal']," Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J. Cross‐protective efficacy of two human papillomavirus vaccines: a systematic review and meta‐analysis.  Lancet Infectious Diseases 2012;12(10):781‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S1473-3099(12)70187-1', 'https://www.ncbi.nlm.nih.gov/pubmed/22920953', 'https://scholar.google.com/scholar_lookup?title=Cross‐protective+efficacy+of+two+human+papillomavirus+vaccines:+a+systematic+review+and+meta‐analysis+&author=T+Malagon&author=M+Drolet&author=MC+Boily&author=EL+Franco&author=M+Jit&author=J+Brisson&publication_year=2012&hl=en']",22920953,https://doi.org/10.1016/S1473-3099(12)70187-1, Malagon 2012 {published data only}  ,excluded,CD009069-bbs2-0078, Systematic review and meta‐analysis on cross‐protection of the bi‐ and quadrivalent vaccines.  
CD009069-bib-0110,"McCormack PL, Joura EA. ","Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women", BioDrugs ,2011,25,    ,['citation-journal']," McCormack PL, Joura EA. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.  BioDrugs 2011;25(5):339‐43. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2165/11205060-000000000-00000', 'https://www.ncbi.nlm.nih.gov/pubmed/21942919', 'https://scholar.google.com/scholar_lookup?title=Spotlight+on+quadrivalent+human+papillomavirus+(types+6,+11,+16,+18)+recombinant+vaccine(Gardasil®)+in+the+prevention+of+premalignant+genital+lesions,+genital+cancer,+and+genital+warts+in+women+&author=PL+McCormack&author=EA+Joura&publication_year=2011&hl=en']",21942919,https://doi.org/10.2165/11205060-000000000-00000, McCormack 2011 {published data only}  ,excluded,CD009069-bbs2-0079, Review paper on the efficacy of the quadrivalent vaccine. 
CD009069-bib-0111,"McKeage K, Romanowski B. ",Spotlight on AS04‐adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®), BioDrugs ,2011,25,    ,['citation-journal']," McKeage K, Romanowski B. Spotlight on AS04‐adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).  BioDrugs 2011;25(4):265‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.2165/11206830-000000000-00000', 'https://www.ncbi.nlm.nih.gov/pubmed/21815703', 'https://scholar.google.com/scholar_lookup?title=Spotlight+on+AS04‐adjuvanted+human+papillomavirus+(HPV)+types+16+and+18+vaccine+(Cervarix®)+&author=K+McKeage&author=B+Romanowski&publication_year=2011&hl=en']",21815703,https://doi.org/10.2165/11206830-000000000-00000, McKeage 2011 {published data only}  ,excluded,CD009069-bbs2-0080, Review paper on the efficacy of the bivalent vaccine. 
CD009069-bib-0112,"Money DM, Moses E, Blitz S, Vandriel SM, Lipsky N, Walmsley SL, et al. ",HIV viral suppression results in higher antibody responses in HIV‐positive women vaccinated with the quadrivalent human papillomavirus vaccine, Vaccine ,2016,34,    ,['citation-journal']," Money DM, Moses E, Blitz S, Vandriel SM, Lipsky N, Walmsley SL, et al. HIV viral suppression results in higher antibody responses in HIV‐positive women vaccinated with the quadrivalent human papillomavirus vaccine.  Vaccine 2016;34(40):4799‐806. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2016.08.016', 'https://www.ncbi.nlm.nih.gov/pubmed/27544584', 'https://scholar.google.com/scholar_lookup?title=HIV+viral+suppression+results+in+higher+antibody+responses+in+HIV‐positive+women+vaccinated+with+the+quadrivalent+human+papillomavirus+vaccine+&author=DM+Money&author=E+Moses&author=S+Blitz&author=SM+Vandriel&author=N+Lipsky&author=SL+Walmsley&publication_year=2016&hl=en']",27544584,https://doi.org/10.1016/j.vaccine.2016.08.016, Money 2016 {published data only}  ,excluded,CD009069-bbs2-0081, Not a randomised trial. Only HIV+ girls or women enrolled. 
CD009069-bib-0113,"Moreira ED, Palefsky JM, Giuliano AR, Goldstone S, Aranda C, Jessen H. ","Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral‐like‐particle vaccine in older adolescents and young adults", Human Vaccines & Immunotherapeutics ,2011,7,    ,['citation-journal']," Moreira ED, Palefsky JM, Giuliano AR, Goldstone S, Aranda C, Jessen H. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral‐like‐particle vaccine in older adolescents and young adults.  Human Vaccines & Immunotherapeutics 2011;7(7):768‐75. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.4161/hv.7.7.15579', 'https://scholar.google.com/scholar_lookup?title=Safety+and+reactogenicity+of+a+quadrivalent+human+papillomavirus+(types+6,+11,+16,+18)+L1+viral‐like‐particle+vaccine+in+older+adolescents+and+young+adults+&author=ED+Moreira&author=JM+Palefsky&author=AR+Giuliano&author=S+Goldstone&author=C+Aranda&author=H+Jessen&publication_year=2011&hl=en']",,https://doi.org/10.4161/hv.7.7.15579, Moreira 2011 {published data only}  ,excluded,CD009069-bbs2-0082, Randomised trial assessing the safety of vaccination with the quadrivalent vaccine in men  
CD009069-bib-0114,"Nakalembe M, Mirembe FM, Banura C. ","Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy", Infectious Agents and Cancer ,2015,10,    ,['citation-journal']," Nakalembe M, Mirembe FM, Banura C. Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy.  Infectious Agents and Cancer 2015;10(1750‐9378 (Electronic), 1750‐9378 (Linking)):17. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1186/s13027-015-0012-2', 'https://www.ncbi.nlm.nih.gov/pubmed/26075018', 'https://scholar.google.com/scholar_lookup?title=Vaccines+against+human+papillomavirus+in+low+and+middle+income+countries:+a+review+of+safety,+immunogenicity+and+efficacy+&author=M+Nakalembe&author=FM+Mirembe&author=C+Banura&publication_year=2015&hl=en']",26075018,https://doi.org/10.1186/s13027-015-0012-2, Nakalembe 2015 {published data only}  ,excluded,CD009069-bbs2-0083," Review of safety, immunogenicity and efficacy of HPV vaccines in low‐ and middle‐income countries. No original data.  "
CD009069-bib-0115,"Nelson EA, Lam HS, Choi KC, Ho WCS, Fung LWE, Cheng FWT. ","A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18‐26 years", Vaccine ,2013,31,    ,['citation-journal']," Nelson EA, Lam HS, Choi KC, Ho WCS, Fung LWE, Cheng FWT. A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18‐26 years.  Vaccine 2013;31(34):3452‐60. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2013.06.034', 'https://www.ncbi.nlm.nih.gov/pubmed/23770335', 'https://scholar.google.com/scholar_lookup?title=A+pilot+randomized+study+to+assess+immunogenicity,+reactogenicity,+safety+and+tolerability+of+two+human+papillomavirus+vaccines+administered+intramuscularly+and+intradermally+to+females+aged+18‐26+years+&author=EA+Nelson&author=HS+Lam&author=KC+Choi&author=WCS+Ho&author=LWE+Fung&author=FWT+Cheng&publication_year=2013&hl=en']",23770335,https://doi.org/10.1016/j.vaccine.2013.06.034, Nelson 2013 {published data only}  ,excluded,CD009069-bbs2-0084, Randomised comparison of safety and immunogenicity of the bi‐ and quadrivalent vaccine administered by intra‐muscular versus intradermal injection. No placebo comparison group.  
CD009069-bib-0116,"Neuzil KM, Canh DG, Thiem VD, Janmohamed A, Huong VM, Tang Y. ",Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial, JAMA ,2011,305,    ,['citation-journal']," Neuzil KM, Canh DG, Thiem VD, Janmohamed A, Huong VM, Tang Y. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.  JAMA 2011;305(14):1424‐31. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1001/jama.2011.407', 'https://www.ncbi.nlm.nih.gov/pubmed/21486975', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+reactogenicity+of+alternative+schedules+of+HPV+vaccine+in+Vietnam:+a+cluster+randomized+noninferiority+trial+&author=KM+Neuzil&author=DG+Canh&author=VD+Thiem&author=A+Janmohamed&author=VM+Huong&author=Y+Tang&publication_year=2011&hl=en']",21486975,https://doi.org/10.1001/jama.2011.407, Neuzil 2011 {published data only}  ,excluded,CD009069-bbs2-0085, Randomised trial assessing safety and immunogenicity of four alternative schedules of administration of the quadrivalent vaccine in Vietnamese girls. No placebo group.  
CD009069-bib-0117,"Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM, et al. ",Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection, Human Vaccines ,2009,5,    ,['citation-journal']," Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.  Human Vaccines 2009;5(1554‐8619 (Electronic), 10):696‐704. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4161/hv.5.10.9515', 'https://www.ncbi.nlm.nih.gov/pubmed/19855170', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+quadrivalent+HPV+6/11/16/18+vaccine+efficacy+against+cervical+and+anogenital+disease+in+subjects+with+serological+evidence+of+prior+vaccine+type+HPV+infection+&author=SE+Olsson&author=SK+Kjaer&author=K+Sigurdsson&author=OE+Iversen&author=M+Hernandez‐Avila&author=CM+Wheeler&publication_year=2009&hl=en']",19855170,https://doi.org/10.4161/hv.5.10.9515, Olsson 2009 {published data only}  ,excluded,CD009069-bbs2-0086, A pooled analysis of efficacy and safety of quadrivalent HPV vaccines on women with previous HPV infection. No separate data on FUTURE I and FUTURE II trials. The data of the separate studies are already included in the review.  
CD009069-bib-0118,"Palefsky JM, Giuliano AR, Goldstone SE, Moreira ED, Aranda C, Jessen H. ",HPV vaccine against anal HPV infection and anal intraepithelial neoplasia, New England Journal of Medicine ,2011,365,    ,['citation-journal']," Palefsky JM, Giuliano AR, Goldstone SE, Moreira ED, Aranda C, Jessen H. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.  New England Journal of Medicine 2011;365(17):1576‐85. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1056/NEJMoa1010971', 'https://scholar.google.com/scholar_lookup?title=HPV+vaccine+against+anal+HPV+infection+and+anal+intraepithelial+neoplasia&author=JM+Palefsky&author=AR+Giuliano&author=SE+Goldstone&author=ED+Moreira&author=C+Aranda&author=H+Jessen&publication_year=2011&hl=en']",,https://doi.org/10.1056/NEJMoa1010971, Palefsky 2011 {published data only}  ,excluded,CD009069-bbs2-0087, Randomised trial assessing the effect of vaccination with the quadrivalent vaccine on anal HPV infection and AIN in men  
CD009069-bib-0119,"Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al. ",Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus‐like particle vaccine containing AS04 adjuvant, Journal of Adolescent Health ,2007,40,    ,['citation-journal']," Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus‐like particle vaccine containing AS04 adjuvant.  Journal of Adolescent Health 2007;40(6):564‐71. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jadohealth.2007.02.015', 'https://scholar.google.com/scholar_lookup?title=Immunization+of+early+adolescent+females+with+human+papillomavirus+type+16+and+18+L1+virus‐like+particle+vaccine+containing+AS04+adjuvant+&author=C+Pedersen&author=T+Petaja&author=G+Strauss&author=HC+Rumke&author=A+Poder&author=JH+Richardus&publication_year=2007&hl=en']",,https://doi.org/10.1016/j.jadohealth.2007.02.015, Pedersen 2007 {published data only}  ,excluded,CD009069-bbs2-0088, Immunobridging study assessing immunogenicity and safety of the bivalent HPV vaccines in women aged 15‐25 years and 10‐14 years. Not a randomised controlled trial and all participants received the bivalent vaccines.  
CD009069-bib-0120,"Perez G, Lazcano‐Ponce E, Hernandez‐Avila M, Garcia PJ, Munoz N, Villa LL. ","Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus‐like‐particle vaccine in Latin American women", International Journal of Cancer ,2008,122,    ,['citation-journal']," Perez G, Lazcano‐Ponce E, Hernandez‐Avila M, Garcia PJ, Munoz N, Villa LL. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus‐like‐particle vaccine in Latin American women.  International Journal of Cancer 2008;122(6):1311‐8. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1002/ijc.23260', 'https://www.ncbi.nlm.nih.gov/pubmed/18000825', 'https://scholar.google.com/scholar_lookup?title=Safety,+immunogenicity,+and+efficacy+of+quadrivalent+human+papillomavirus+(types+6,+11,+16,+18)+L1+virus‐like‐particle+vaccine+in+Latin+American+women+&author=G+Perez&author=E+Lazcano‐Ponce&author=M+Hernandez‐Avila&author=PJ+Garcia&author=N+Munoz&author=LL+Villa&publication_year=2008&hl=en']",18000825,https://doi.org/10.1002/ijc.23260, Perez 2008 {published data only}  ,excluded,CD009069-bbs2-0089," Pooled analysis of RCTs of the efficacy of the quadrivalent vaccine regarding protection against HPV‐related lesions, restricted to the Latin‐American cohorts included in the phase II and III trials (FUTURE II trial (ph3,4v); FUTURE I trial (ph3,4v); Phase2 trial (ph2,4v)). The data of the separate studies are already included in the review.  "
CD009069-bib-0121,"Petaja T, Keranen H, Karppa T, Kawa A, Lantela S, Siitari‐Mattila M. ",Immunogenicity and safety of human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in healthy boys aged 10‐18 years, Journal of Adolescent Health ,2009,44,    ,['citation-journal']," Petaja T, Keranen H, Karppa T, Kawa A, Lantela S, Siitari‐Mattila M. Immunogenicity and safety of human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in healthy boys aged 10‐18 years.  Journal of Adolescent Health 2009;44(1):33‐40. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1016/j.jadohealth.2008.10.002', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+vaccine+in+healthy+boys+aged+10‐18+years+&author=T+Petaja&author=H+Keranen&author=T+Karppa&author=A+Kawa&author=S+Lantela&author=M+Siitari‐Mattila&publication_year=2009&hl=en']",,https://doi.org/10.1016/j.jadohealth.2008.10.002, Petaja 2009 {published data only}  ,excluded,CD009069-bbs2-0090, Randomised trial assessing the immunogenicity and safety of vaccination with the bivalent vaccine in boys.  
CD009069-bib-0122,"Petaja T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, et al. ",Long‐term persistence of systemic and mucosal immune response to HPV‐16/18 AS04‐adjuvanted vaccine in preteen/adolescent girls and young women, International Journal of Cancer ,2011,129,    ,['citation-journal']," Petaja T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, et al. Long‐term persistence of systemic and mucosal immune response to HPV‐16/18 AS04‐adjuvanted vaccine in preteen/adolescent girls and young women.  International Journal of Cancer 2011;129(9):2147‐57. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1002/ijc.25887', 'https://www.ncbi.nlm.nih.gov/pubmed/21190190', 'https://scholar.google.com/scholar_lookup?title=Long‐term+persistence+of+systemic+and+mucosal+immune+response+to+HPV‐16/18+AS04‐adjuvanted+vaccine+in+preteen/adolescent+girls+and+young+women+&author=T+Petaja&author=C+Pedersen&author=A+Poder&author=G+Strauss&author=G+Catteau&author=F+Thomas&publication_year=2011&hl=en']",21190190,https://doi.org/10.1002/ijc.25887, Petaja 2011 {published data only}  ,excluded,CD009069-bbs2-0091, Trial assessing long‐term (at 48 months) safety and immunogenicity (antibodies in serum and cervicovaginal secretions) of the bivalent vaccine. No placebo group.  
CD009069-bib-0123,"Poland GA, Jacobson RM, Koutsky LA, Tamms GM, Railkar R, Smith JF. ",Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2‐year randomized controlled clinical trial, Mayo Clinic Proceedings ,2005,80,    ,['citation-journal']," Poland GA, Jacobson RM, Koutsky LA, Tamms GM, Railkar R, Smith JF. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2‐year randomized controlled clinical trial.  Mayo Clinic Proceedings 2005;80(5):601‐10. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4065/80.5.601', 'https://www.ncbi.nlm.nih.gov/pubmed/15887427', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+reactogenicity+of+a+novel+vaccine+for+human+papillomavirus+16:+a+2‐year+randomized+controlled+clinical+trial+&author=GA+Poland&author=RM+Jacobson&author=LA+Koutsky&author=GM+Tamms&author=R+Railkar&author=JF+Smith&publication_year=2005&hl=en']",15887427,https://doi.org/10.4065/80.5.601, Poland 2005 {published data only}  ,excluded,CD009069-bbs2-0092, Dose‐ranging study assessing safety and immunogenicity of a monovalent HPV16 vaccine. 
CD009069-bib-0124,"Puthanakit T, Huang LM, Chiu CH, Tang RB, Schwarz TF, Esposito S, et al. ",Randomized open trial comparing 2‐dose regimens of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in girls aged 9‐14 years versus a 3‐dose regimen in women aged 15‐25 years, Journal of Infectious Diseases ,2016,214,    ,['citation-journal']," Puthanakit T, Huang LM, Chiu CH, Tang RB, Schwarz TF, Esposito S, et al. Randomized open trial comparing 2‐dose regimens of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in girls aged 9‐14 years versus a 3‐dose regimen in women aged 15‐25 years.  Journal of Infectious Diseases 2016;214(4):525‐36. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1093/infdis/jiw036', 'https://scholar.google.com/scholar_lookup?title=Randomized+open+trial+comparing+2‐dose+regimens+of+the+human+papillomavirus+16/18+AS04‐adjuvanted+vaccine+in+girls+aged+9‐14+years+versus+a+3‐dose+regimen+in+women+aged+15‐25+years+&author=T+Puthanakit&author=LM+Huang&author=CH+Chiu&author=RB+Tang&author=TF+Schwarz&author=S+Esposito&publication_year=2016&hl=en']",,https://doi.org/10.1093/infdis/jiw036, Puthanakit 2016 {published data only}  ,excluded,CD009069-bbs2-0093, Randomised open trial to compare 2‐dose versus 3‐dose regimens of the bivalent vaccine in terms of immunogenicity and safety. No placebo group.  
CD009069-bib-0125,"Ramanakumar AV, Naud P, Roteli‐Martins CM, de Carvalho NS, de Borba PC, Teixeira JC, et al. ",Incidence and duration of type‐specific human papillomavirus infection in high‐risk HPV‐naive women: results from the control arm of a phase II HPV‐16/18 vaccine trial, BMJ Open. ,2016,6,    ,['citation-journal']," Ramanakumar AV, Naud P, Roteli‐Martins CM, de Carvalho NS, de Borba PC, Teixeira JC, et al. Incidence and duration of type‐specific human papillomavirus infection in high‐risk HPV‐naive women: results from the control arm of a phase II HPV‐16/18 vaccine trial.  BMJ Open. 2016;6(2044‐6055 (Electronic), 2044‐6055 (Linking), 8):e011371. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1136/bmjopen-2016-011371', 'https://www.ncbi.nlm.nih.gov/pubmed/27566633', 'https://scholar.google.com/scholar_lookup?title=Incidence+and+duration+of+type‐specific+human+papillomavirus+infection+in+high‐risk+HPV‐naive+women:+results+from+the+control+arm+of+a+phase+II+HPV‐16/18+vaccine+trial+&author=AV+Ramanakumar&author=P+Naud&author=CM+Roteli‐Martins&author=NS+Carvalho&author=PC+Borba&author=JC+Teixeira&publication_year=2016&hl=en']",27566633,https://doi.org/10.1136/bmjopen-2016-011371, Ramanakumar 2016 {published data only}  ,excluded,CD009069-bbs2-0094," Incidence and duration of type‐specific human papillomavirus infection in high‐risk HPV‐naive women. Post study results of Phase2 trial (ph2,2v) trial.  "
CD009069-bib-0126,"Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. ",The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme, Sexually Transmitted Infections ,2011,87,    ,['citation-journal']," Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme.  Sexually Transmitted Infections 2011;87(7):544‐7. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1136/sextrans-2011-050234', 'https://www.ncbi.nlm.nih.gov/pubmed/21970896', 'https://scholar.google.com/scholar_lookup?title=The+near+disappearance+of+genital+warts+in+young+women+4+years+after+commencing+a+national+human+papillomavirus+(HPV)+vaccination+programme+&author=TR+Read&author=JS+Hocking&author=MY+Chen&author=B+Donovan&author=CS+Bradshaw&author=CK+Fairley&publication_year=2011&hl=en']",21970896,https://doi.org/10.1136/sextrans-2011-050234, Read 2011 {published data only}  ,excluded,CD009069-bbs2-0095, Surveillance of the incidence of genital warts before and after introduction of HPV vaccination in Australia. Not a randomised controlled trial.  
CD009069-bib-0127,"Reisinger KS, Block SL, Lazcano‐Ponce E, Samakoses R, Esser MT, Erick J, et al. ","Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus‐like particle vaccine in preadolescents and adolescents: a randomized controlled trial", Pediatric Infectious Disease Journal ,2007,26,    ,['citation-journal']," Reisinger KS, Block SL, Lazcano‐Ponce E, Samakoses R, Esser MT, Erick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus‐like particle vaccine in preadolescents and adolescents: a randomized controlled trial.  Pediatric Infectious Disease Journal 2007;26(3):201‐9. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1097/01.inf.0000253970.29190.5a', 'https://scholar.google.com/scholar_lookup?title=Safety+and+persistent+immunogenicity+of+a+quadrivalent+human+papillomavirus+types+6,+11,+16,+18+L1+virus‐like+particle+vaccine+in+preadolescents+and+adolescents:+a+randomized+controlled+trial+&author=KS+Reisinger&author=SL+Block&author=E+Lazcano‐Ponce&author=R+Samakoses&author=MT+Esser&author=J+Erick&publication_year=2007&hl=en']",,https://doi.org/10.1097/01.inf.0000253970.29190.5a, Reisinger 2007 {published data only}  ,excluded,CD009069-bbs2-0096, Randomised controlled trial assessing the safety and persistent immunogenicity of quadrivalent HPV vaccine in a group of boys and girls. Outcomes were presented jointly. Author was contacted to request data separated by gender. The author responded that separated data were not available.  
CD009069-bib-0128,"Reisinger KS, Block SL, Collins‐Ogle M, Marchant C, Catlett M, Radley D, et al. ","Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel", Pediatrics ,2010,125,    ,['citation-journal']," Reisinger KS, Block SL, Collins‐Ogle M, Marchant C, Catlett M, Radley D, et al. Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel.  Pediatrics 2010;125(6):1142‐51. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1542/peds.2009-2336', 'https://www.ncbi.nlm.nih.gov/pubmed/20439595', 'https://scholar.google.com/scholar_lookup?title=Safety,+tolerability,+and+immunogenicity+of+gardasil+given+concomitantly+with+Menactra+and+Adacel+&author=KS+Reisinger&author=SL+Block&author=M+Collins‐Ogle&author=C+Marchant&author=M+Catlett&author=D+Radley&publication_year=2010&hl=en']",20439595,https://doi.org/10.1542/peds.2009-2336, Reisinger 2010 {published data only}  ,excluded,CD009069-bbs2-0097," Randomised open‐label study to assess the safety, tolerability and immunogenicity of quadrivalent vaccine co‐administrated with enactra and Adacel vaccine. No quadrivalent only group and no separate data between girls and boys.  "
CD009069-bib-0129,"Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, et al. ",Sustained immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine administered as a two‐dose schedule in adolescent girls: Five‐year clinical data and modeling predictions from a randomized study, Human Vaccines & Immunotherapeutics ,2016,12,    ,['citation-journal']," Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, et al. Sustained immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine administered as a two‐dose schedule in adolescent girls: Five‐year clinical data and modeling predictions from a randomized study.  Human Vaccines & Immunotherapeutics 2016;12(2164‐554X (Electronic), 2164‐5515 (Linking), 1):20‐9. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1080/21645515.2015.1065363', 'https://www.ncbi.nlm.nih.gov/pubmed/26176261', 'https://scholar.google.com/scholar_lookup?title=Sustained+immunogenicity+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+administered+as+a+two‐dose+schedule+in+adolescent+girls:+Five‐year+clinical+data+and+modeling+predictions+from+a+randomized+study+&author=B+Romanowski&author=TF+Schwarz&author=L+Ferguson&author=K+Peters&author=M+Dionne&author=U+Behre&publication_year=2016&hl=en']",26176261,https://doi.org/10.1080/21645515.2015.1065363, Romanowski 2016 {published data only}  ,excluded,CD009069-bbs2-0098, Five‐year sustained immunogenicity of the bivalent vaccine administered as a 2‐dose schedule in girls aged 9‐14 years. No placebo group.  
CD009069-bib-0130,"Rowhani‐Rahbar A, Alvarez FB, Bryan JT, Hughes JP, Hawes SE, Weiss NS. ",Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine, Journal of Clinical Virology ,2012,53,    ,['citation-journal']," Rowhani‐Rahbar A, Alvarez FB, Bryan JT, Hughes JP, Hawes SE, Weiss NS. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine.  Journal of Clinical Virology 2012;53(3):239‐43. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.jcv.2011.12.009', 'https://www.ncbi.nlm.nih.gov/pubmed/22209292', 'https://scholar.google.com/scholar_lookup?title=Evidence+of+immune+memory+8.5+years+following+administration+of+a+prophylactic+human+papillomavirus+type+16+vaccine+&author=A+Rowhani‐Rahbar&author=FB+Alvarez&author=JT+Bryan&author=JP+Hughes&author=SE+Hawes&author=NS+Weiss&publication_year=2012&hl=en']",22209292,https://doi.org/10.1016/j.jcv.2011.12.009, Rowhani‐Rahbar 2012 {published data only}  ,excluded,CD009069-bbs2-0099, Trial demonstrating immune memory after administration of a dose of quadrivalent vaccine to women enrolled 8.5 years before in a phase II trial assessing the effects of the monovalent HPV16 vaccine.  
CD009069-bib-0131,"Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, et al. ",Cross‐protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial, Human Vaccines & Immunotherapeutics ,2013,9,    ,['citation-journal']," Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, et al. Cross‐protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.  Human Vaccines & Immunotherapeutics 2013;9(7):1399‐406. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.4161/hv.24340', 'https://www.ncbi.nlm.nih.gov/pubmed/23571174', 'https://scholar.google.com/scholar_lookup?title=Cross‐protective+vaccine+efficacy+of+the+bivalent+HPV+vaccine+against+HPV31+is+associated+with+humoral+immune+responses:+results+from+the+Costa+Rica+Vaccine+Trial+&author=M+Safaeian&author=TJ+Kemp&author=DY+Pan&author=C+Porras&author=AC+Rodriguez&author=M+Schiffman&publication_year=2013&hl=en']",23571174,https://doi.org/10.4161/hv.24340, Safaeian 2013 {published data only}  ,excluded,CD009069-bbs2-0100," Cross‐protection efficacy against HPV 31 of bivalent vaccine, results from Costa Rica trials.  "
CD009069-bib-0132,"Schwarz TF, Leo O. ",Immune response to human papillomavirus after prophylactic vaccination with AS04‐adjuvanted HPV‐16/18 vaccine: improving upon nature, Gynecologic Oncology ,2008,110,    ,['citation-journal']," Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04‐adjuvanted HPV‐16/18 vaccine: improving upon nature.  Gynecologic Oncology 2008;110(3 Suppl 1):S1‐10. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.ygyno.2008.05.036', 'https://www.ncbi.nlm.nih.gov/pubmed/18653222', 'https://scholar.google.com/scholar_lookup?title=Immune+response+to+human+papillomavirus+after+prophylactic+vaccination+with+AS04‐adjuvanted+HPV‐16/18+vaccine:+improving+upon+nature+&author=TF+Schwarz&author=O+Leo&publication_year=2008&hl=en']",18653222,https://doi.org/10.1016/j.ygyno.2008.05.036, Schwarz 2008 {published data only}  ,excluded,CD009069-bbs2-0101," Review of the immunological response, including the induction of immune memory after vaccination with the bivalent vaccine. No original data.  "
CD009069-bib-0133,"Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P. ",Immunogenicity and tolerability of an HPV‐16/18 AS04‐adjuvanted prophylactic cervical cancer vaccine in women aged 15‐55 years, Vaccine ,2009,27,    ,['citation-journal']," Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P. Immunogenicity and tolerability of an HPV‐16/18 AS04‐adjuvanted prophylactic cervical cancer vaccine in women aged 15‐55 years.  Vaccine 2009;27(4):581‐7. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2008.10.088', 'https://www.ncbi.nlm.nih.gov/pubmed/19022320', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+tolerability+of+an+HPV‐16/18+AS04‐adjuvanted+prophylactic+cervical+cancer+vaccine+in+women+aged+15‐55+years+&author=TF+Schwarz&author=M+Spaczynski&author=A+Schneider&author=J+Wysocki&author=A+Galaj&author=P+Perona&publication_year=2009&hl=en']",19022320,https://doi.org/10.1016/j.vaccine.2008.10.088, Schwarz 2009 {published data only}  ,excluded,CD009069-bbs2-0102, Non randomised trial assessing immunogenicity and tolerability of the bivalent vaccine in female participants aged 15‐55 years from Germany and Poland.  
CD009069-bib-0134,"Schwarz TF, Kocken M, Petaja T, Einstein MH, Spaczynski M, Louwers JA. ",Correlation between levels of human papillomavirus (HPV) 16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV‐16/18 AS04‐adjuvanted vaccine, Human Vaccine & Immunotherapeutics ,2010,6,    ,['citation-journal']," Schwarz TF, Kocken M, Petaja T, Einstein MH, Spaczynski M, Louwers JA. Correlation between levels of human papillomavirus (HPV) 16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV‐16/18 AS04‐adjuvanted vaccine.  Human Vaccine & Immunotherapeutics 2010;6(12):1054‐61. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.4161/hv.6.12.13399', 'https://scholar.google.com/scholar_lookup?title=Correlation+between+levels+of+human+papillomavirus+(HPV)+16+and+18+antibodies+in+serum+and+cervicovaginal+secretions+in+girls+and+women+vaccinated+with+the+HPV‐16/18+AS04‐adjuvanted+vaccine+&author=TF+Schwarz&author=M+Kocken&author=T+Petaja&author=MH+Einstein&author=M+Spaczynski&author=JA+Louwers&publication_year=2010&hl=en']",,https://doi.org/10.4161/hv.6.12.13399, Schwarz 2010 {published data only}  ,excluded,CD009069-bbs2-0103, Non randomised trial assessing presence of HPV antibodies in serum and cervicovaginal secretions of induced by the bivalent vaccine in female participants aged 15‐55 years from Germany and Poland.  
CD009069-bib-0135,"Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K. ",Persistence of immune response to HPV‐16/18 AS04‐adjuvanted cervical cancer vaccine in women aged 15‐55 years, Human Vaccines & Immunotherapeutics ,2011,7,    ,['citation-journal']," Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K. Persistence of immune response to HPV‐16/18 AS04‐adjuvanted cervical cancer vaccine in women aged 15‐55 years.  Human Vaccines & Immunotherapeutics 2011;7(9):958‐65. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.4161/hv.7.9.15999', 'https://scholar.google.com/scholar_lookup?title=Persistence+of+immune+response+to+HPV‐16/18+AS04‐adjuvanted+cervical+cancer+vaccine+in+women+aged+15‐55+years+&author=TF+Schwarz&author=M+Spaczynski&author=A+Schneider&author=J+Wysocki&author=A+Galaj&author=K+Schulze&publication_year=2011&hl=en']",,https://doi.org/10.4161/hv.7.9.15999, Schwarz 2011 {published data only}  ,excluded,CD009069-bbs2-0104, Follow‐up study to the Schwarz 2009 report.  
CD009069-bib-0136,"Schwarz TF, Huang LM, Lin TY, Wittermann C, Panzer F, Valencia A, et al. ","Long‐term immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in 10‐ to 14‐year‐old girls: open 6‐year follow‐up of an initial observer‐blinded, randomized trial", Pediatric Infectious Disease Journal ,2014,33,    ,['citation-journal']," Schwarz TF, Huang LM, Lin TY, Wittermann C, Panzer F, Valencia A, et al. Long‐term immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in 10‐ to 14‐year‐old girls: open 6‐year follow‐up of an initial observer‐blinded, randomized trial.  Pediatric Infectious Disease Journal 2014;33(1532‐0987 (Electronic), 0891‐3668 (Linking), 12):1255‐61. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1097/INF.0000000000000460', 'https://scholar.google.com/scholar_lookup?title=Long‐term+immunogenicity+and+safety+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+in+10‐+to+14‐year‐old+girls:+open+6‐year+follow‐up+of+an+initial+observer‐blinded,+randomized+trial+&author=TF+Schwarz&author=LM+Huang&author=TY+Lin&author=C+Wittermann&author=F+Panzer&author=A+Valencia&publication_year=2014&hl=en']",,https://doi.org/10.1097/INF.0000000000000460, Schwarz 2014 {published data only}  ,excluded,CD009069-bbs2-0105, An open follow‐up study of an RCT on safety and immunogenicity of bivalent vaccine in girls aged 10‐13 years. Medina 2010 trial.  
CD009069-bib-0137,"Sengupta A, Shenoi A, Sarojini NB, Madhavi Y. ",Human papillomavirus vaccine trials in India, Lancet ,2011,377,    ,['citation-journal']," Sengupta A, Shenoi A, Sarojini NB, Madhavi Y. Human papillomavirus vaccine trials in India.  Lancet 2011;377(9767):719. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/S0140-6736(11)60270-5', 'https://www.ncbi.nlm.nih.gov/pubmed/21353902', 'https://scholar.google.com/scholar_lookup?title=Human+papillomavirus+vaccine+trials+in+India&author=A+Sengupta&author=A+Shenoi&author=NB+Sarojini&author=Y+Madhavi&publication_year=2011&hl=en']",21353902,https://doi.org/10.1016/S0140-6736(11)60270-5, Sengupta 2011 {published data only}  ,excluded,CD009069-bbs2-0106, Correspondence about HPV vaccine trials in India. No extractable original data. 
CD009069-bib-0138,Singhal SC. ,Human papilloma virus vaccines and current controversy, Indian Pediatrics ,2011,48,    ,['citation-journal'], Singhal SC. Human papilloma virus vaccines and current controversy.  Indian Pediatrics 2011;48(3):248‐9. CENTRAL    PubMed     Google Scholar     ,"['', 'https://www.ncbi.nlm.nih.gov/pubmed/21478564', 'https://scholar.google.com/scholar_lookup?title=Human+papilloma+virus+vaccines+and+current+controversy&author=SC+Singhal&publication_year=2011&hl=en']",21478564,, Singhal 2011 {published data only}  ,excluded,CD009069-bbs2-0107, Correspondence about HPV vaccine trials in India. No extractable original data. 
CD009069-bib-0139,"Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J, et al. ",Human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine for the prevention of cervical cancer and HPV‐related diseases, Expert Review of Vaccines ,2016,15,    ,['citation-journal']," Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J, et al. Human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine for the prevention of cervical cancer and HPV‐related diseases.  Expert Review of Vaccines 2016;15(1744‐8395 (Electronic), 1476‐0584 (Linking), 3):367‐87. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1586/14760584.2016.1124763', 'https://www.ncbi.nlm.nih.gov/pubmed/26902666', 'https://scholar.google.com/scholar_lookup?title=Human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+vaccine+for+the+prevention+of+cervical+cancer+and+HPV‐related+diseases+&author=SR+Skinner&author=D+Apter&author=N+Carvalho&author=DM+Harper&author=R+Konno&author=J+Paavonen&publication_year=2016&hl=en']",26902666,https://doi.org/10.1586/14760584.2016.1124763, Skinner 2016 {published data only}  ,excluded,CD009069-bbs2-0108, Systematic review on the efficacy of bivalent vaccine summarized from 6 RCTs. No original data.  
CD009069-bib-0140,Smith‐McCune K. ,"Quadrivalent HPV vaccine administered to women who became pregnant during trials did not appear to adversely affect pregnancy outcome; however, use during pregnancy is not recommended", Evidence Based Medicine ,2010,15,    ,['citation-journal']," Smith‐McCune K. Quadrivalent HPV vaccine administered to women who became pregnant during trials did not appear to adversely affect pregnancy outcome; however, use during pregnancy is not recommended.  Evidence Based Medicine 2010;15(3):80‐1. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1136/ebm1066', 'https://www.ncbi.nlm.nih.gov/pubmed/20522684', 'https://scholar.google.com/scholar_lookup?title=Quadrivalent+HPV+vaccine+administered+to+women+who+became+pregnant+during+trials+did+not+appear+to+adversely+affect+pregnancy+outcome;+however,+use+during+pregnancy+is+not+recommended+&author=K+Smith‐McCune&publication_year=2010&hl=en']",20522684,https://doi.org/10.1136/ebm1066, Smith‐McCune 2010 {published data only}  ,excluded,CD009069-bbs2-0109, Short review on pregnancy outcomes after vaccination against HPV. No original data. 
CD009069-bib-0141,Srinivasan S. ,HPV vaccine trials and sleeping watchdogs, Indian Journal of Medical Ethics ,2011,8,    ,['citation-journal'], Srinivasan S. HPV vaccine trials and sleeping watchdogs.  Indian Journal of Medical Ethics 2011;8(2):73‐4. CENTRAL    Link to article     PubMed     Google Scholar     ,"['', 'https://doi.org/10.20529/IJME.2011.031', 'https://www.ncbi.nlm.nih.gov/pubmed/22106613', 'https://scholar.google.com/scholar_lookup?title=HPV+vaccine+trials+and+sleeping+watchdogs&author=S+Srinivasan&publication_year=2011&hl=en']",22106613,https://doi.org/10.20529/IJME.2011.031, Srinivasan 2011 {published data only}  ,excluded,CD009069-bbs2-0110, Review article. No original data. 
CD009069-bib-0142,"Toft L, Storgaard M, Muller M, Sehr P, Bonde J, Tolstrup M, et al. ","Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV‐infected adults: a randomized, double‐blind clinical trial", Journal of Infectious Diseases ,2014,209,    ,['citation-journal']," Toft L, Storgaard M, Muller M, Sehr P, Bonde J, Tolstrup M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV‐infected adults: a randomized, double‐blind clinical trial.  Journal of Infectious Diseases 2014;209(8):1165‐73. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1093/infdis/jit657', 'https://scholar.google.com/scholar_lookup?title=Comparison+of+the+immunogenicity+and+reactogenicity+of+Cervarix+and+Gardasil+human+papillomavirus+vaccines+in+HIV‐infected+adults:+a+randomized,+double‐blind+clinical+trial+&author=L+Toft&author=M+Storgaard&author=M+Muller&author=P+Sehr&author=J+Bonde&author=M+Tolstrup&publication_year=2014&hl=en']",,https://doi.org/10.1093/infdis/jit657, Toft 2014 {published data only}  ,excluded,CD009069-bbs2-0111, RCT to compare of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV‐infected adults.  
CD009069-bib-0143,"Klooster TM, Kemmeren JM, van der Maas NA, de Melker HE. ",Reported adverse events in girls aged 13‐16 years after vaccination with the human papillomavirus (HPV)‐16/18 vaccine in the Netherlands, Vaccine ,2011,29,    ,['citation-journal']," Klooster TM, Kemmeren JM, van der Maas NA, de Melker HE. Reported adverse events in girls aged 13‐16 years after vaccination with the human papillomavirus (HPV)‐16/18 vaccine in the Netherlands.  Vaccine 2011;29(28):4601‐7. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2011.04.050', 'https://www.ncbi.nlm.nih.gov/pubmed/21549785', 'https://scholar.google.com/scholar_lookup?title=Reported+adverse+events+in+girls+aged+13‐16+years+after+vaccination+with+the+human+papillomavirus+(HPV)‐16/18+vaccine+in+the+Netherlands+&author=TM+Klooster&author=JM+Kemmeren&author=NA+Maas&author=HE+Melker&publication_year=2011&hl=en']",21549785,https://doi.org/10.1016/j.vaccine.2011.04.050, Van Klooster 2011 {published data only}  ,excluded,CD009069-bbs2-0112, Surveillance study assessing occurrence of adverse effects reported after HPV vaccination in the Netherlands.  
CD009069-bib-0144,"Vesikari T, Van Damme P, Lindblad N, Pfletschinger U, Radley D, Ryan D, et al. ","An open‐label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age", Pediatric Infectious Disease Journal ,2010,29,    ,['citation-journal']," Vesikari T, Van Damme P, Lindblad N, Pfletschinger U, Radley D, Ryan D, et al. An open‐label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.  Pediatric Infectious Disease Journal 2010;29(4):314‐8. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=An+open‐label,+randomized,+multicenter+study+of+the+safety,+tolerability,+and+immunogenicity+of+quadrivalent+human+papillomavirus+(types+6/11/16/18)+vaccine+given+concomitantly+with+diphtheria,+tetanus,+pertussis,+and+poliomyelitis+vaccine+in+healthy+adolescents+11+to+17+years+of+age+&author=T+Vesikari&author=P+Damme&author=N+Lindblad&author=U+Pfletschinger&author=D+Radley&author=D+Ryan&publication_year=2010&hl=en']",,, Vesikari 2010 {published data only}  ,excluded,CD009069-bbs2-0113," Randomised open‐label study to assess the safety, tolerability and immunogenicity of quadrivalent vaccine co‐administrated with REPEVAX vaccine. No quadrivalent only group and no separate data between girls and boys.  "
CD009069-bib-0145,"Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E. ",Safety and immunogenicity of co‐administered quadrivalent human papillomavirus (HPV)‐6/11/16/18 L1 virus‐like particle (VLP) and hepatitis B (HBV) vaccines, Vaccine ,2008,26,    ,['citation-journal']," Wheeler CM, Bautista OM, Tomassini JE, Nelson M, Sattler CA, Barr E. Safety and immunogenicity of co‐administered quadrivalent human papillomavirus (HPV)‐6/11/16/18 L1 virus‐like particle (VLP) and hepatitis B (HBV) vaccines.  Vaccine 2008;26(0264‐410X (Print), 5):686‐96. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1016/j.vaccine.2007.11.043', 'https://www.ncbi.nlm.nih.gov/pubmed/18164106', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+co‐administered+quadrivalent+human+papillomavirus+(HPV)‐6/11/16/18+L1+virus‐like+particle+(VLP)+and+hepatitis+B+(HBV)+vaccines+&author=CM+Wheeler&author=OM+Bautista&author=JE+Tomassini&author=M+Nelson&author=CA+Sattler&author=E+Barr&publication_year=2008&hl=en']",18164106,https://doi.org/10.1016/j.vaccine.2007.11.043, Wheeler 2008 {published data only}  ,excluded,CD009069-bbs2-0114," Randomised open‐label study to assess the safety, tolerability and immunogenicity of quadrivalent vaccine co‐administrated with Hepatitis B vaccine. No quadrivalent only group.  "
CD009069-bib-0146,"Wheeler CM, Harvey BM, Pichichero ME, Simon MW, Combs SP, Blatter MM. ","Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial", Pediatric Infectious Disease Journal ,2011,30,    ,['citation-journal']," Wheeler CM, Harvey BM, Pichichero ME, Simon MW, Combs SP, Blatter MM. Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.  Pediatric Infectious Disease Journal 2011;30(12):e225‐34. CENTRAL    Google Scholar     ","['', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+human+papillomavirus‐16/18+AS04‐adjuvanted+vaccine+coadministered+with+tetanus+toxoid,+reduced+diphtheria+toxoid,+and+acellular+pertussis+vaccine+and/or+meningococcal+conjugate+vaccine+to+healthy+girls+11+to+18+years+of+age:+results+from+a+randomized+open+trial+&author=CM+Wheeler&author=BM+Harvey&author=ME+Pichichero&author=MW+Simon&author=SP+Combs&author=MM+Blatter&publication_year=2011&hl=en']",,, Wheeler 2011 {published data only}  ,excluded,CD009069-bbs2-0115," Trial assessing reactogenicity and immunogenicity of Tdap (tetanosdiphteria, pertussis) and MCV4 (meningococcal polysaccharide & diphtheria toxoid) vaccines when given alone or co‐administrated with the bivalent HPV vaccine. Not a randomised controlled trial.  "
CD009069-bib-0147,"Yancey AM, Pitlick JM, Forinash AB. ",The prophylactic role for the human papillomavirus quadrivalent vaccine in males, Annals of Pharmacotherapy ,2010,44,    ,['citation-journal']," Yancey AM, Pitlick JM, Forinash AB. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.  Annals of Pharmacotherapy 2010;44(7‐8):1314‐8. CENTRAL    Link to article     Google Scholar     ","['', 'https://doi.org/10.1345/aph.1P017', 'https://scholar.google.com/scholar_lookup?title=The+prophylactic+role+for+the+human+papillomavirus+quadrivalent+vaccine+in+males&author=AM+Yancey&author=JM+Pitlick&author=AB+Forinash&publication_year=2010&hl=en']",,https://doi.org/10.1345/aph.1P017, Yancey 2010 {published data only}  ,excluded,CD009069-bbs2-0116, Systematic review on vaccine immunogenicity and efficacy in men. 
CD009069-bib-0148,"Zhu FC, Li CG, Pan HX, Zhang YJ, Bi D, Tang HW. ",Safety and immunogenicity of human papillomavirus‐16/18 AS04‐adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial, Chinese Journal of Cancer ,2011,30,    ,['citation-journal']," Zhu FC, Li CG, Pan HX, Zhang YJ, Bi D, Tang HW. Safety and immunogenicity of human papillomavirus‐16/18 AS04‐adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial.  Chinese Journal of Cancer 2011;30(8):559‐64. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.5732/cjc.010.10564', 'https://www.ncbi.nlm.nih.gov/pubmed/21801604', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+human+papillomavirus‐16/18+AS04‐adjuvanted+vaccine+in+healthy+Chinese+females+aged+15+to+45+years:+a+phase+I+trial+&author=FC+Zhu&author=CG+Li&author=HX+Pan&author=YJ+Zhang&author=D+Bi&author=HW+Tang&publication_year=2011&hl=en']",21801604,https://doi.org/10.5732/cjc.010.10564, Zhu 2011 {published data only}  ,excluded,CD009069-bbs2-0117," Non randomised phase I trial on safety and immunogenicity of the bivalent vaccine,conducted in China (female participants aged 15‐45 years).  "
CD009069-bib-0149,"Zimmerman RK, Nowalk MP, Lin CJ, Fox DE, Ko FS, Wettick E. ",Randomized trial of an alternate human papillomavirus vaccine administration schedule in college‐aged women, Journal of Women's Health ,2010,19,    ,['citation-journal']," Zimmerman RK, Nowalk MP, Lin CJ, Fox DE, Ko FS, Wettick E. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college‐aged women.  Journal of Women's Health 2010;19(8):1441‐7. CENTRAL    Link to article     PubMed     Google Scholar     ","['', 'https://doi.org/10.1089/jwh.2009.1753', 'https://www.ncbi.nlm.nih.gov/pubmed/20629576', 'https://scholar.google.com/scholar_lookup?title=Randomized+trial+of+an+alternate+human+papillomavirus+vaccine+administration+schedule+in+college‐aged+women+&author=RK+Zimmerman&author=MP+Nowalk&author=CJ+Lin&author=DE+Fox&author=FS+Ko&author=E+Wettick&publication_year=2010&hl=en']",20629576,https://doi.org/10.1089/jwh.2009.1753, Zimmerman 2010 {published data only}  ,excluded,CD009069-bbs2-0118," Randomised trial assessing the immunogenicity of the quadrivalent vaccine with two alternative schedules (months 0,2 & 6, versus months 0, 2 & 12).  "
CD009069-bib-0150,"Andrews N, Stowe J, Miller E. ",No increased risk of Guillain‐Barré syndrome after human papilloma virus vaccine: A self‐controlled case‐series study in England, Vaccine ,2017,35,    ,['citation-journal']," Andrews N, Stowe J, Miller E. No increased risk of Guillain‐Barré syndrome after human papilloma virus vaccine: A self‐controlled case‐series study in England.  Vaccine 2017;35(1):1729‐32.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2017.01.076', 'https://www.ncbi.nlm.nih.gov/pubmed/28245941', 'https://scholar.google.com/scholar_lookup?title=No+increased+risk+of+Guillain‐Barré+syndrome+after+human+papilloma+virus+vaccine:+A+self‐controlled+case‐series+study+in+England+&author=N+Andrews&author=J+Stowe&author=E+Miller&publication_year=2017&hl=en']",28245941,https://doi.org/10.1016/j.vaccine.2017.01.076, Andrews 2017 ,additional,CD009069-bbs2-0119,
CD009069-bib-0151,ANSM/SANTE. ,Risk of auto‐immune diseases after vaccination against HPV: a pharmacoepidemiological study, http://ansm.sante.fr/S‐informer/Points‐d‐information‐Points‐d‐information/Vaccination‐contre‐les‐infections‐a‐HPV‐et‐risque‐de‐maladies‐auto‐immunes‐une‐etude‐Cnamts‐ANSM‐rassurante‐Point‐d‐information ,September 2015,Website accessed 10‐12‐15,    ,['citation-journal'], ANSM/SANTE. Risk of auto‐immune diseases after vaccination against HPV: a pharmacoepidemiological study [Vaccins anti‐HPV et risque de maladies auto‐immunes : étude pharmacoépidémiologique].  http://ansm.sante.fr/S‐informer/Points‐d‐information‐Points‐d‐information/Vaccination‐contre‐les‐infections‐a‐HPV‐et‐risque‐de‐maladies‐auto‐immunes‐une‐etude‐Cnamts‐ANSM‐rassurante‐Point‐d‐information September 2015;Website accessed 10‐12‐15:1‐91.    Google Scholar     ,['https://scholar.google.com/scholar_lookup?title=Risk+of+auto‐immune+diseases+after+vaccination+against+HPV:+a+pharmacoepidemiological+study+&author=+ANSM/SANTE&publication_year=September2015&hl=en'],,, ANSM/SANTE 2015 ,additional,CD009069-bbs2-0120,
CD009069-bib-0152,"Arbyn M, Dillner J. ",Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening, Journal of Clinical Virology ,2007,38,    ,['citation-journal']," Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.  Journal of Clinical Virology 2007;38(3):189‐97.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jcv.2006.12.009', 'https://www.ncbi.nlm.nih.gov/pubmed/17258503', 'https://scholar.google.com/scholar_lookup?title=Review+of+current+knowledge+on+HPV+vaccination:+an+appendix+to+the+European+Guidelines+for+Quality+Assurance+in+Cervical+Cancer+Screening+&author=M+Arbyn&author=J+Dillner&publication_year=2007&hl=en']",17258503,https://doi.org/10.1016/j.jcv.2006.12.009, Arbyn 2007 ,additional,CD009069-bbs2-0121,
CD009069-bib-0153,"Arbyn M, Rebolj M, de Kok IM, Becker N, O'Reilly M, Andrae B. ",The challenges for organising cervical screening programmes in the 15 old member states of the European Union, European Journal of Cancer ,2009,45,    ,['citation-journal']," Arbyn M, Rebolj M, de Kok IM, Becker N, O'Reilly M, Andrae B. The challenges for organising cervical screening programmes in the 15 old member states of the European Union.  European Journal of Cancer 2009;45(15):2671‐8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.ejca.2009.07.016', 'https://www.ncbi.nlm.nih.gov/pubmed/19695867', ""https://scholar.google.com/scholar_lookup?title=The+challenges+for+organising+cervical+screening+programmes+in+the+15+old+member+states+of+the+European+Union+&author=M+Arbyn&author=M+Rebolj&author=IM+Kok&author=N+Becker&author=M+O'Reilly&author=B+Andrae&publication_year=2009&hl=en""]",19695867,https://doi.org/10.1016/j.ejca.2009.07.016, Arbyn 2009 ,additional,CD009069-bbs2-0122,
CD009069-bib-0154,"Arbyn M, Van Veen EB, Andersson K, Bogers J, Boulet G, Bergeron C, et al. ",Cervical cytology biobanking in Europe, Internatonal Journal of Biological Markers ,2010,25,    ,['citation-journal']," Arbyn M, Van Veen EB, Andersson K, Bogers J, Boulet G, Bergeron C, et al. Cervical cytology biobanking in Europe.  Internatonal Journal of Biological Markers 2010;25(3):117‐25.    Link to article     Google Scholar     ","['https://doi.org/10.1177/172460081002500301', 'https://scholar.google.com/scholar_lookup?title=Cervical+cytology+biobanking+in+Europe&author=M+Arbyn&author=EB+Veen&author=K+Andersson&author=J+Bogers&author=G+Boulet&author=C+Bergeron&publication_year=2010&hl=en']",,https://doi.org/10.1177/172460081002500301, Arbyn 2010 ,additional,CD009069-bbs2-0123,
CD009069-bib-0155,"Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. ",Worldwide burden of cervical cancer in 2008, Annals of Oncology ,2011,22,    ,['citation-journal']," Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008.  Annals of Oncology 2011;22:2675‐86.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/annonc/mdr015', 'https://www.ncbi.nlm.nih.gov/pubmed/21471563', 'https://scholar.google.com/scholar_lookup?title=Worldwide+burden+of+cervical+cancer+in+2008&author=M+Arbyn&author=X+Castellsagué&author=S+Sanjosé&author=L+Bruni&author=M+Saraiya&author=F+Bray&publication_year=2011&hl=en']",21471563,https://doi.org/10.1093/annonc/mdr015, Arbyn 2011 ,additional,CD009069-bbs2-0124,
CD009069-bib-0156,"Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. ",Evidence regarding HPV testing in secondary prevention of cervical cancer, Vaccine ,2012,30,    ,['citation-journal']," Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding HPV testing in secondary prevention of cervical cancer.  Vaccine 2012;30(Suppl 5):F88‐F99.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/23199969', 'https://scholar.google.com/scholar_lookup?title=Evidence+regarding+HPV+testing+in+secondary+prevention+of+cervical+cancer&author=M+Arbyn&author=G+Ronco&author=A+Anttila&author=CJ+Meijer&author=M+Poljak&author=G+Ogilvie&publication_year=2012&hl=en']",23199969,, Arbyn 2012 ,additional,CD009069-bbs2-0125,
CD009069-bib-0157,"Arbyn M, Tommasino M, Depuydt C, Dillner J. ",Are 20 human papillomavirus types causing cervical cancer?, Journal of Pathology ,2014,234,    ,['citation-journal']," Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer?.  Journal of Pathology 2014;234(4):431‐5.    Link to article     Google Scholar     ","['https://doi.org/10.1002/path.4424', 'https://scholar.google.com/scholar_lookup?title=Are+20+human+papillomavirus+types+causing+cervical+cancer?&author=M+Arbyn&author=M+Tommasino&author=C+Depuydt&author=J+Dillner&publication_year=2014&hl=en']",,https://doi.org/10.1002/path.4424, Arbyn 2014 ,additional,CD009069-bbs2-0126,
CD009069-bib-0158,"Arbyn M, Vanden Broeck D, Benoy I, Bogers J, Depuydt C, Praet M, et al. ",Surveillance of effects of HPV vaccination in Belgium, Cancer Epidemiology ,2016,41,    ,['citation-journal']," Arbyn M, Vanden Broeck D, Benoy I, Bogers J, Depuydt C, Praet M, et al. Surveillance of effects of HPV vaccination in Belgium.  Cancer Epidemiology 2016;41:152‐8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.canep.2015.12.011', 'https://www.ncbi.nlm.nih.gov/pubmed/26895623', 'https://scholar.google.com/scholar_lookup?title=Surveillance+of+effects+of+HPV+vaccination+in+Belgium&author=M+Arbyn&author=D+VandenBroeck&author=I+Benoy&author=J+Bogers&author=C+Depuydt&author=M+Praet&publication_year=2016&hl=en']",26895623,https://doi.org/10.1016/j.canep.2015.12.011, Arbyn 2016 ,additional,CD009069-bbs2-0127,
CD009069-bib-0159,"Arbyn M, Redman CW, Verdoodt F, Kyrgiou M, Tzafetas M, Ghaem‐Maghami S, et al. ",Incomplete excision of cervical pre‐cancer as predictor of treatment failure: a systematic review and meta‐analysis, Lancet Oncology ,2017,18,    ,['citation-journal']," Arbyn M, Redman CW, Verdoodt F, Kyrgiou M, Tzafetas M, Ghaem‐Maghami S, et al. Incomplete excision of cervical pre‐cancer as predictor of treatment failure: a systematic review and meta‐analysis.  Lancet Oncology 2017;18(12):1665‐79.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1470-2045(17)30700-3', 'https://www.ncbi.nlm.nih.gov/pubmed/29126708', 'https://scholar.google.com/scholar_lookup?title=Incomplete+excision+of+cervical+pre‐cancer+as+predictor+of+treatment+failure:+a+systematic+review+and+meta‐analysis+&author=M+Arbyn&author=CW+Redman&author=F+Verdoodt&author=M+Kyrgiou&author=M+Tzafetas&author=S+Ghaem‐Maghami&publication_year=2017&hl=en']",29126708,https://doi.org/10.1016/S1470-2045(17)30700-3, Arbyn 2017 ,additional,CD009069-bbs2-0128,
CD009069-bib-0160,"Arnheim‐Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. ","Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study", BMJ ,2013,347,    ,['citation-journal']," Arnheim‐Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study.  BMJ 2013;347:f5906.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.f5906', 'https://www.ncbi.nlm.nih.gov/pubmed/24108159', 'https://scholar.google.com/scholar_lookup?title=Autoimmune,+neurological,+and+venous+thromboembolic+adverse+events+after+immunisation+of+adolescent+girls+with+quadrivalent+human+papillomavirus+vaccine+in+Denmark+and+Sweden:+cohort+study+&author=L+Arnheim‐Dahlstrom&author=B+Pasternak&author=H+Svanstrom&author=P+Sparen&author=A+Hviid&publication_year=2013&hl=en']",24108159,https://doi.org/10.1136/bmj.f5906, Arnheim‐Dahlstrom 2013 ,additional,CD009069-bbs2-0129,
CD009069-bib-0161,"Baldur‐Felskov B, Dehlendorff C, Munk C, Kjaer SK. ",Early impact of human papillomavirus vaccination on cervical neoplasia‐nationwide follow‐up of young Danish women, Journal of the National Cancer Institute ,2014,106,    ,['citation-journal']," Baldur‐Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia‐nationwide follow‐up of young Danish women.  Journal of the National Cancer Institute 2014;106(3):dtj460.    Link to article     Google Scholar     ","['https://doi.org/10.1093/jnci/djt460', 'https://scholar.google.com/scholar_lookup?title=Early+impact+of+human+papillomavirus+vaccination+on+cervical+neoplasia‐nationwide+follow‐up+of+young+Danish+women+&author=B+Baldur‐Felskov&author=C+Dehlendorff&author=C+Munk&author=SK+Kjaer&publication_year=2014&hl=en']",,https://doi.org/10.1093/jnci/djt460, Baldur‐Felskov 2014 ,additional,CD009069-bbs2-0130,
CD009069-bib-0162,"Baril L, Rosillon D, Willame C, Angelo MG, Zima J, van den Bosch JH, et al. ",Risk of spontaneous abortion and other pregnancy outcomes in 15‐25 year old women exposed to human papillomavirus‐16/18 AS04‐adjuvanted vaccine in the United Kingdom, Vaccine ,2015,33,    ,['citation-journal']," Baril L, Rosillon D, Willame C, Angelo MG, Zima J, van den Bosch JH, et al. Risk of spontaneous abortion and other pregnancy outcomes in 15‐25 year old women exposed to human papillomavirus‐16/18 AS04‐adjuvanted vaccine in the United Kingdom.  Vaccine 2015;33:6884‐91.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2015.07.024', 'https://www.ncbi.nlm.nih.gov/pubmed/26206268', 'https://scholar.google.com/scholar_lookup?title=Risk+of+spontaneous+abortion+and+other+pregnancy+outcomes+in+15‐25+year+old+women+exposed+to+human+papillomavirus‐16/18+AS04‐adjuvanted+vaccine+in+the+United+Kingdom+&author=L+Baril&author=D+Rosillon&author=C+Willame&author=MG+Angelo&author=J+Zima&author=JH+Bosch&publication_year=2015&hl=en']",26206268,https://doi.org/10.1016/j.vaccine.2015.07.024, Baril 2015 ,additional,CD009069-bbs2-0131,
CD009069-bib-0163,"Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, et al. ",Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine in healthy Indian women, Journal of Obstetrics and Gynaecology Research ,2010,36,    ,['citation-journal']," Bhatla N, Suri V, Basu P, Shastri S, Datta SK, Bi D, et al. Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine in healthy Indian women.  Journal of Obstetrics and Gynaecology Research 2010;36(1):123‐32.    Link to article     Google Scholar     ","['https://doi.org/10.1111/j.1447-0756.2009.01167.x', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+human+papillomavirus‐16/18+AS04‐adjuvanted+cervical+cancer+vaccine+in+healthy+Indian+women+&author=N+Bhatla&author=V+Suri&author=P+Basu&author=S+Shastri&author=SK+Datta&author=D+Bi&publication_year=2010&hl=en']",,https://doi.org/10.1111/j.1447-0756.2009.01167.x, Bhatla 2010 ,additional,CD009069-bbs2-0132,
CD009069-bib-0164,"Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. ",The causal relation between human papillomavirus and cervical cancer, Journal of Clinical Pathology ,2002,55,    ,['citation-journal']," Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer.  Journal of Clinical Pathology 2002;55:244‐65.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/jcp.55.4.244', 'https://www.ncbi.nlm.nih.gov/pubmed/11919208', 'https://scholar.google.com/scholar_lookup?title=The+causal+relation+between+human+papillomavirus+and+cervical+cancer&author=FX+Bosch&author=A+Lorincz&author=N+Munoz&author=CJ+Meijer&author=KV+Shah&publication_year=2002&hl=en']",11919208,https://doi.org/10.1136/jcp.55.4.244, Bosch 2002 ,additional,CD009069-bbs2-0133,
CD009069-bib-0165,"Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. ",Epidemiology and natural history of human papillomavirus infections and type‐specific implications in cervical neoplasia, Vaccine ,2008,26,    ,['citation-journal']," Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type‐specific implications in cervical neoplasia.  Vaccine 2008;26(Suppl 10):K1‐K16.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2008.05.064', 'https://www.ncbi.nlm.nih.gov/pubmed/18847553', 'https://scholar.google.com/scholar_lookup?title=Epidemiology+and+natural+history+of+human+papillomavirus+infections+and+type‐specific+implications+in+cervical+neoplasia+&author=FX+Bosch&author=AN+Burchell&author=M+Schiffman&author=AR+Giuliano&author=S+Sanjose&author=L+Bruni&publication_year=2008&hl=en']",18847553,https://doi.org/10.1016/j.vaccine.2008.05.064, Bosch 2008 ,additional,CD009069-bbs2-0134,
CD009069-bib-0166,"Bosch FX, Robles C, Diaz M, Arbyn M, Baussano I, Clavel C, et al. ",HPV‐FASTER: broadening the scope for prevention of HPV‐related cancer," Nature Reviews, Clinical Oncology ",2016,13,    ,['citation-journal']," Bosch FX, Robles C, Diaz M, Arbyn M, Baussano I, Clavel C, et al. HPV‐FASTER: broadening the scope for prevention of HPV‐related cancer.  Nature Reviews, Clinical Oncology 2016;13:119‐32.    Link to article     Google Scholar     ","['https://doi.org/10.1038/nrclinonc.2015.146', 'https://scholar.google.com/scholar_lookup?title=HPV‐FASTER:+broadening+the+scope+for+prevention+of+HPV‐related+cancer&author=FX+Bosch&author=C+Robles&author=M+Diaz&author=M+Arbyn&author=I+Baussano&author=C+Clavel&publication_year=2016&hl=en']",,https://doi.org/10.1038/nrclinonc.2015.146, Bosch 2016 ,additional,CD009069-bbs2-0135,
CD009069-bib-0167,"Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. ",A review of human carcinogens ‐ Part B: biological agents, Lancet Oncology ,2009,10,    ,['citation-journal']," Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. A review of human carcinogens ‐ Part B: biological agents.  Lancet Oncology 2009;10(4):321‐2.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1470-2045(09)70096-8', 'https://www.ncbi.nlm.nih.gov/pubmed/19350698', 'https://scholar.google.com/scholar_lookup?title=A+review+of+human+carcinogens+‐+Part+B:+biological+agents&author=V+Bouvard&author=R+Baan&author=K+Straif&author=Y+Grosse&author=B+Secretan&author=F+Ghissassi&publication_year=2009&hl=en']",19350698,https://doi.org/10.1016/S1470-2045(09)70096-8, Bouvard 2009 ,additional,CD009069-bbs2-0136,
CD009069-bib-0168,"Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G. ",Incidence trends of adenocarcinoma of the cervix in 13 European countries," Cancer Epidemiology, Biomarkers and Prevention ",2005,14,    ,['citation-journal']," Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G. Incidence trends of adenocarcinoma of the cervix in 13 European countries.  Cancer Epidemiology, Biomarkers and Prevention 2005;14(9):2191‐9.    Link to article     Google Scholar     ","['https://doi.org/10.1158/1055-9965.EPI-05-0231', 'https://scholar.google.com/scholar_lookup?title=Incidence+trends+of+adenocarcinoma+of+the+cervix+in+13+European+countries&author=F+Bray&author=B+Carstensen&author=H+Moller&author=M+Zappa&author=MP+Zakelj&author=G+Lawrence&publication_year=2005&hl=en']",,https://doi.org/10.1158/1055-9965.EPI-05-0231, Bray 2005 ,additional,CD009069-bbs2-0137,
CD009069-bib-0169,"Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H. ",Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening," Cancer Epidemiology, Biomarkers and Prevention ",2005,14,    ,['citation-journal']," Bray F, Loos AH, McCarron P, Weiderpass E, Arbyn M, Moller H. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening.  Cancer Epidemiology, Biomarkers and Prevention 2005;14(3):677‐86.    Link to article     Google Scholar     ","['https://doi.org/10.1158/1055-9965.EPI-04-0569', 'https://scholar.google.com/scholar_lookup?title=Trends+in+cervical+squamous+cell+carcinoma+incidence+in+13+European+countries:+changing+risk+and+the+effects+of+screening+&author=F+Bray&author=AH+Loos&author=P+McCarron&author=E+Weiderpass&author=M+Arbyn&author=H+Moller&publication_year=2005&hl=en']",,https://doi.org/10.1158/1055-9965.EPI-04-0569, Bray 2005a ,additional,CD009069-bbs2-0138,
CD009069-bib-0170,"Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin‐Dinh‐Desmarquet C, Orth G. ",Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection, Journal of Virology ,1995,69,    ,['citation-journal']," Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin‐Dinh‐Desmarquet C, Orth G. Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.  Journal of Virology 1995;69(6):3959‐63.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1128/jvi.69.6.3959-3963.1995', 'https://www.ncbi.nlm.nih.gov/pubmed/7745754', 'https://scholar.google.com/scholar_lookup?title=Immunization+with+virus+like+particles+from+cottontail+rabbit+papillomavirus+(CRPV)+can+protect+against+experimental+CRPV+infection+&author=F+Breitburd&author=R+Kirnbauer&author=NL+Hubbert&author=B+Nonnenmacher&author=C+Trin‐Dinh‐Desmarquet&author=G+Orth&publication_year=1995&hl=en']",7745754,https://doi.org/10.1128/jvi.69.6.3959-3963.1995, Breitburd 1995 ,additional,CD009069-bbs2-0139,
CD009069-bib-0171,"Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. ","Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study", Lancet ,2011,377,    ,['citation-journal']," Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study.  Lancet 2011;377(1474‐547X (Electronic), 0140‐6736 (Linking), 9783):2085‐92.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(11)60551-5', 'https://www.ncbi.nlm.nih.gov/pubmed/21684381', 'https://scholar.google.com/scholar_lookup?title=Early+effect+of+the+HPV+vaccination+programme+on+cervical+abnormalities+in+Victoria,+Australia:+an+ecological+study+&author=JM+Brotherton&author=M+Fridman&author=CL+May&author=G+Chappell&author=AM+Saville&author=DM+Gertig&publication_year=2011&hl=en']",21684381,https://doi.org/10.1016/S0140-6736(11)60551-5, Brotherton 2011 ,additional,CD009069-bbs2-0140,
CD009069-bib-0172,"Brotherton JML, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. ",Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia, Papillomavirus Research ,2015,1,    ,['citation-journal']," Brotherton JML, Malloy M, Budd AC, Saville M, Drennan KT, Gertig DM. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia.  Papillomavirus Research 2015;1(1):59‐73.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.pvr.2015.05.005', 'https://scholar.google.com/scholar_lookup?title=Effectiveness+of+less+than+three+doses+of+quadrivalent+human+papillomavirus+vaccine+against+cervical+intraepithelial+neoplasia+when+administered+using+a+standard+dose+spacing+schedule:+Observational+cohort+of+young+women+in+Australia+&author=JML+Brotherton&author=M+Malloy&author=AC+Budd&author=M+Saville&author=KT+Drennan&author=DM+Gertig&publication_year=2015&hl=en']",,https://doi.org/10.1016/j.pvr.2015.05.005, Brotherton 2015 ,additional,CD009069-bbs2-0141,
CD009069-bib-0173,"Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM. ",Neutralization of human papillomavirus type 11 (HPV‐11) by serum from women vaccinated with yeast‐derived HPV‐11 L1 virus‐like particles: correlation with competitive radioimmunoassay titer, Journal of Infectious Diseases ,2001,184,    ,['citation-journal']," Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM. Neutralization of human papillomavirus type 11 (HPV‐11) by serum from women vaccinated with yeast‐derived HPV‐11 L1 virus‐like particles: correlation with competitive radioimmunoassay titer.  Journal of Infectious Diseases 2001;184(9):1183‐6.    Link to article     Google Scholar     ","['https://doi.org/10.1086/323645', 'https://scholar.google.com/scholar_lookup?title=Neutralization+of+human+papillomavirus+type+11+(HPV‐11)+by+serum+from+women+vaccinated+with+yeast‐derived+HPV‐11+L1+virus‐like+particles:+correlation+with+competitive+radioimmunoassay+titer+&author=DR+Brown&author=JT+Bryan&author=JM+Schroeder&author=TS+Robinson&author=KH+Fife&author=CM+Wheeler&publication_year=2001&hl=en']",,https://doi.org/10.1086/323645, Brown 2001 ,additional,CD009069-bbs2-0142,
CD009069-bib-0174,"Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. ",A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types, Virology ,2013,445,    ,['citation-journal']," Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types.  Virology 2013;445(1‐2):224‐31.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.virol.2013.07.015', 'https://www.ncbi.nlm.nih.gov/pubmed/23928291', 'https://scholar.google.com/scholar_lookup?title=A+systematic+review+of+the+prevalence+of+mucosal+and+cutaneous+human+papillomavirus+types+&author=D+Bzhalava&author=P+Guan&author=S+Franceschi&author=J+Dillner&author=G+Clifford&publication_year=2013&hl=en']",23928291,https://doi.org/10.1016/j.virol.2013.07.015, Bzhalava 2013 ,additional,CD009069-bbs2-0143,
CD009069-bib-0175,Cancer Researck UK. ,Cervical cancer incidence statistics,,Accessed Jan 2018,,.   ,['citation-other'], Cancer Researck UK. Cervical cancer incidence statistics. http://www.cancerresearchuk.org/health‐professional/cancer‐statistics/statistics‐by‐cancer‐type/cervical‐cancer/incidenceAccessed Jan 2018.    ,[],,, Cancer Research UK 2018 ,additional,CD009069-bbs2-0144,
CD009069-bib-0176,"Castellsagué X, Diaz M, De Sanjose S, Munoz N, Herrero R, Franceschi S. ",Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention, Journal of the National Cancer Institute ,2006,98,    ,['citation-journal']," Castellsagué X, Diaz M, De Sanjose S, Munoz N, Herrero R, Franceschi S. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.  Journal of the National Cancer Institute 2006;98(1460‐2105 (Electronic), 5):303‐15.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/jnci/djj067', 'https://www.ncbi.nlm.nih.gov/pubmed/16507827', 'https://scholar.google.com/scholar_lookup?title=Worldwide+human+papillomavirus+etiology+of+cervical+adenocarcinoma+and+its+cofactors:+implications+for+screening+and+prevention+&author=X+Castellsagué&author=M+Diaz&author=S+Sanjose&author=N+Munoz&author=R+Herrero&author=S+Franceschi&publication_year=2006&hl=en']",16507827,https://doi.org/10.1093/jnci/djj067, Castellsagué 2006 ,additional,CD009069-bbs2-0145,
CD009069-bib-0177,"Castellsagué X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K. ","End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24‐45 years of age", British Journal of Cancer ,2011,105,    ,['citation-journal']," Castellsagué X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K. End‐of‐study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24‐45 years of age.  British Journal of Cancer 2011;105(1):28‐37.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/bjc.2011.185', 'https://www.ncbi.nlm.nih.gov/pubmed/21629249', 'https://scholar.google.com/scholar_lookup?title=End‐of‐study+safety,+immunogenicity,+and+efficacy+of+quadrivalent+HPV+(types+6,+11,+16,+18)+recombinant+vaccine+in+adult+women+24‐45+years+of+age+&author=X+Castellsagué&author=N+Munoz&author=P+Pitisuttithum&author=D+Ferris&author=J+Monsonego&author=K+Ault&publication_year=2011&hl=en']",21629249,https://doi.org/10.1038/bjc.2011.185, Castellsagué 2011 ,additional,CD009069-bbs2-0146,
CD009069-bib-0178,"Cates M, Karner C. ",Clinical importance cannot be ruled out using mean difference alone, BMJ ,2015,351,    ,['citation-journal']," Cates M, Karner C. Clinical importance cannot be ruled out using mean difference alone.  BMJ 2015;351:h5496.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.h5496', 'https://www.ncbi.nlm.nih.gov/pubmed/26588935', 'https://scholar.google.com/scholar_lookup?title=Clinical+importance+cannot+be+ruled+out+using+mean+difference+alone&author=M+Cates&author=C+Karner&publication_year=2015&hl=en']",26588935,https://doi.org/10.1136/bmj.h5496, Cates 2015 ,additional,CD009069-bbs2-0147,
CD009069-bib-0179,"Sukumaran L, Advisory Committee on Immunization Practices ‐ Immunization Safety Office ‐ Centers for Disease Control and Prevention (CDC, Atlanta). ",Human Papillomavirus Vaccine Safety Update,,,,. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides‐2015‐10/hpv‐04‐sukumaran.pdf 21/10/2015.   ,['citation-other']," Sukumaran L, Advisory Committee on Immunization Practices ‐ Immunization Safety Office ‐ Centers for Disease Control and Prevention (CDC, Atlanta). Human Papillomavirus Vaccine Safety Update. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides‐2015‐10/hpv‐04‐sukumaran.pdf 21/10/2015.    ",[],,, CDC 2015 ,additional,CD009069-bbs2-0148,
CD009069-bib-0180,"Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, et al. ",Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine, Journal of Internal Medicine ,2012,271,    ,['citation-journal']," Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine.  Journal of Internal Medicine 2012;271(2):193‐203.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/j.1365-2796.2011.02467.x', 'https://www.ncbi.nlm.nih.gov/pubmed/21973261', 'https://scholar.google.com/scholar_lookup?title=Surveillance+of+autoimmune+conditions+following+routine+use+of+quadrivalent+human+papillomavirus+vaccine+&author=C+Chao&author=NP+Klein&author=CM+Velicer&author=LS+Sy&author=JM+Slezak&author=H+Takhar&publication_year=2012&hl=en']",21973261,https://doi.org/10.1111/j.1365-2796.2011.02467.x, Chao 2012 ,additional,CD009069-bbs2-0149,
CD009069-bib-0181,"Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. ",Carcinogenicity of human papillomaviruses, Lancet Oncology ,2005,6,    ,['citation-journal']," Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses.  Lancet Oncology 2005;6(1470‐2045, 4):204.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1470-2045(05)70086-3', 'https://www.ncbi.nlm.nih.gov/pubmed/15830458', 'https://scholar.google.com/scholar_lookup?title=Carcinogenicity+of+human+papillomaviruses&author=V+Cogliano&author=R+Baan&author=K+Straif&author=Y+Grosse&author=B+Secretan&author=F+Ghissassi&publication_year=2005&hl=en']",15830458,https://doi.org/10.1016/S1470-2045(05)70086-3, Cogliano 2005 ,additional,CD009069-bbs2-0150,
CD009069-bib-0182,"Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. ",Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case‐control study nested within a population based screening programme in Australia, BMJ ,2014,348,    ,['citation-journal']," Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case‐control study nested within a population based screening programme in Australia.  BMJ 2014;348(g1458):1‐10.    Link to article     Google Scholar     ","['https://doi.org/10.1136/bmj.g1458', 'https://scholar.google.com/scholar_lookup?title=Effectiveness+of+quadrivalent+human+papillomavirus+vaccine+for+the+prevention+of+cervical+abnormalities:+case‐control+study+nested+within+a+population+based+screening+programme+in+Australia+&author=E+Crowe&author=N+Pandeya&author=JM+Brotherton&author=AJ+Dobson&author=S+Kisely&author=SB+Lambert&publication_year=2014&hl=en']",,https://doi.org/10.1136/bmj.g1458, Crowe 2014 ,additional,CD009069-bbs2-0151,
CD009069-bib-0183,"Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG. ",mpact of partial bivalent HPV vaccination on vaccine‐type infection: a population‐based analysis, British Journal of Cancer ,2016,114,    ,['citation-journal']," Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG. mpact of partial bivalent HPV vaccination on vaccine‐type infection: a population‐based analysis.  British Journal of Cancer 2016;114(11):1261‐4.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/bjc.2016.97', 'https://www.ncbi.nlm.nih.gov/pubmed/27115467', 'https://scholar.google.com/scholar_lookup?title=mpact+of+partial+bivalent+HPV+vaccination+on+vaccine‐type+infection:+a+population‐based+analysis+&author=K+Cuschieri&author=K+Kavanagh&author=C+Moore&author=R+Bhatia&author=J+Love&author=KG+Pollock&publication_year=2016&hl=en']",27115467,https://doi.org/10.1038/bjc.2016.97, Cuschieri 2016 ,additional,CD009069-bbs2-0152,
CD009069-bib-0184,"Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S. ",Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine, Obstetrics and Gynaecology ,2009,114,    ,['citation-journal']," Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine.  Obstetrics and Gynaecology 2009;114(1873‐233X (Electronic), 6):1170‐8.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Pregnancy+outcomes+from+the+pregnancy+registry+of+a+human+papillomavirus+type+6/11/16/18+vaccine+&author=A+Dana&author=KM+Buchanan&author=MA+Goss&author=MM+Seminack&author=KE+Shields&author=S+Korn&publication_year=2009&hl=en'],,, Dana 2009 ,additional,CD009069-bbs2-0153,
CD009069-bib-0185,"De Carvalho N, Teixeira J, Roteli‐Martins CM, Naud P, De Borba P, Zahaf T. ",Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women, Vaccine ,2010,28,    ,['citation-journal']," De Carvalho N, Teixeira J, Roteli‐Martins CM, Naud P, De Borba P, Zahaf T. Sustained efficacy and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine up to 7.3 years in young adult women.  Vaccine 2010;28(38):6247‐55.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2010.07.007', 'https://www.ncbi.nlm.nih.gov/pubmed/20643092', 'https://scholar.google.com/scholar_lookup?title=Sustained+efficacy+and+immunogenicity+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+up+to+7.3+years+in+young+adult+women+&author=N+Carvalho&author=J+Teixeira&author=CM+Roteli‐Martins&author=P+Naud&author=P+Borba&author=T+Zahaf&publication_year=2010&hl=en']",20643092,https://doi.org/10.1016/j.vaccine.2010.07.007, De Carvalho 2010 ,additional,CD009069-bbs2-0154,
CD009069-bib-0186,"de Sanjose S, Diaz M, Castellsagué X, Clifford G, Bruni L, Munoz N. ",Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta‐analysis, Lancet Infectious Diseases ,2007,7,    ,['citation-journal']," de Sanjose S, Diaz M, Castellsagué X, Clifford G, Bruni L, Munoz N. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta‐analysis.  Lancet Infectious Diseases 2007;7(7):453‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1473-3099(07)70158-5', 'https://www.ncbi.nlm.nih.gov/pubmed/17597569', 'https://scholar.google.com/scholar_lookup?title=Worldwide+prevalence+and+genotype+distribution+of+cervical+human+papillomavirus+DNA+in+women+with+normal+cytology:+a+meta‐analysis+&author=S+Sanjose&author=M+Diaz&author=X+Castellsagué&author=G+Clifford&author=L+Bruni&author=N+Munoz&publication_year=2007&hl=en']",17597569,https://doi.org/10.1016/S1473-3099(07)70158-5, de Sanjose 2007 ,additional,CD009069-bbs2-0155,
CD009069-bib-0187,"de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. ",Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross‐sectional worldwide study, Lancet Oncology ,2010,11,    ,['citation-journal']," de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross‐sectional worldwide study.  Lancet Oncology 2010;11(11):1048‐56.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1470-2045(10)70230-8', 'https://www.ncbi.nlm.nih.gov/pubmed/20952254', 'https://scholar.google.com/scholar_lookup?title=Human+papillomavirus+genotype+attribution+in+invasive+cervical+cancer:+a+retrospective+cross‐sectional+worldwide+study+&author=S+Sanjose&author=WG+Quint&author=L+Alemany&author=DT+Geraets&author=JE+Klaustermeier&author=B+Lloveras&publication_year=2010&hl=en']",20952254,https://doi.org/10.1016/S1470-2045(10)70230-8, de Sanjose 2010 ,additional,CD009069-bbs2-0156,
CD009069-bib-0188,"Deeks JJ, Altman DG, Bradburn MJ. ",Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis,"In: Egger M, Davey Smith G, Altman DG (eds).  Systematic Reviews in Health Care: Meta‐Analysis in Context (2nd edition)",2001,,    ,['citation-book']," Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG (eds).  Systematic Reviews in Health Care: Meta‐Analysis in Context (2nd edition). London: BMJ Publication Group, 2001.    Link to article     Google Scholar     ","['https://doi.org/10.1002/9780470693926.ch15', 'https://scholar.google.com/scholar_lookup?title=Statistical+methods+for+examining+heterogeneity+and+combining+results+from+several+studies+in+meta‐analysis+&author=JJ+Deeks&author=DG+Altman&author=MJ+Bradburn&publication_year=2001&hl=en']",,https://doi.org/10.1002/9780470693926.ch15, Deeks 2001 ,additional,CD009069-bbs2-0157,
CD009069-bib-0189,"Delere Y, Wichmann O, Klug SJ, van der Sande M, Terhardt M, Zepp F. ",The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta‐analysis, Deutsches Arzteblatt International ,2014,111,    ,['citation-journal']," Delere Y, Wichmann O, Klug SJ, van der Sande M, Terhardt M, Zepp F. The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta‐analysis.  Deutsches Arzteblatt International 2014;111(35‐36):584‐91.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/25249360', 'https://scholar.google.com/scholar_lookup?title=The+efficacy+and+duration+of+vaccine+protection+against+human+papillomavirus:+a+systematic+review+and+meta‐analysis+&author=Y+Delere&author=O+Wichmann&author=SJ+Klug&author=M+Sande&author=M+Terhardt&author=F+Zepp&publication_year=2014&hl=en']",25249360,, Delere 2014 ,additional,CD009069-bbs2-0158,
CD009069-bib-0190,"DerSimonian R, Laird N. ",Meta‐analysis in clinical trials, Controlled Clinical Trials ,1986,7,    ,['citation-journal']," DerSimonian R, Laird N. Meta‐analysis in clinical trials.  Controlled Clinical Trials 1986;7:177‐88.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/0197-2456(86)90046-2', 'https://www.ncbi.nlm.nih.gov/pubmed/3802833', 'https://scholar.google.com/scholar_lookup?title=Meta‐analysis+in+clinical+trials&author=R+DerSimonian&author=N+Laird&publication_year=1986&hl=en']",3802833,https://doi.org/10.1016/0197-2456(86)90046-2, DerSimonian 1986 ,additional,CD009069-bbs2-0159,
CD009069-bib-0191,"Dillner J, Arbyn M, Unger E, Dillner L. ",Monitoring of human papillomavirus vaccination, Clinical & Experimental Immunology ,2011,163,    ,['citation-journal']," Dillner J, Arbyn M, Unger E, Dillner L. Monitoring of human papillomavirus vaccination.  Clinical & Experimental Immunology 2011;163(1):17‐25.    Link to article     Google Scholar     ","['https://doi.org/10.1111/j.1365-2249.2010.04268.x', 'https://scholar.google.com/scholar_lookup?title=Monitoring+of+human+papillomavirus+vaccination&author=J+Dillner&author=M+Arbyn&author=E+Unger&author=L+Dillner&publication_year=2011&hl=en']",,https://doi.org/10.1111/j.1365-2249.2010.04268.x, Dillner 2011 ,additional,CD009069-bbs2-0160,
CD009069-bib-0192,"Donegan K, Beau‐Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. ",Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK, Vaccine ,2013,31,    ,['citation-journal']," Donegan K, Beau‐Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK.  Vaccine 2013;31(43):4961‐7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2013.08.024', 'https://www.ncbi.nlm.nih.gov/pubmed/24001935', 'https://scholar.google.com/scholar_lookup?title=Bivalent+human+papillomavirus+vaccine+and+the+risk+of+fatigue+syndromes+in+girls+in+the+UK+&author=K+Donegan&author=R+Beau‐Lejdstrom&author=B+King&author=S+Seabroke&author=A+Thomson&author=P+Bryan&publication_year=2013&hl=en']",24001935,https://doi.org/10.1016/j.vaccine.2013.08.024, Donegan 2013 ,additional,CD009069-bbs2-0161,
CD009069-bib-0193,"Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. ",Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data, Lancet Infectious Diseases ,2011,11,    ,['citation-journal']," Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.  Lancet Infectious Diseases 2011;11(1474‐4457 (Electronic), 1473‐3099 (Linking), 1):39‐44.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1473-3099(10)70225-5', 'https://www.ncbi.nlm.nih.gov/pubmed/21067976', 'https://scholar.google.com/scholar_lookup?title=Quadrivalent+human+papillomavirus+vaccination+and+trends+in+genital+warts+in+Australia:+analysis+of+national+sentinel+surveillance+data+&author=B+Donovan&author=N+Franklin&author=R+Guy&author=AE+Grulich&author=DG+Regan&author=H+Ali&publication_year=2011&hl=en']",21067976,https://doi.org/10.1016/S1473-3099(10)70225-5, Donovan 2011 ,additional,CD009069-bbs2-0162,
CD009069-bib-0194,"Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. ",Population‐level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta‐analysis, Lancet Infectious Diseases ,2015,15,    ,['citation-journal']," Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population‐level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta‐analysis.  Lancet Infectious Diseases 2015;15(5):565‐80.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1473-3099(14)71073-4', 'https://www.ncbi.nlm.nih.gov/pubmed/25744474', 'https://scholar.google.com/scholar_lookup?title=Population‐level+impact+and+herd+effects+following+human+papillomavirus+vaccination+programmes:+a+systematic+review+and+meta‐analysis+&author=M+Drolet&author=E+Benard&author=MC+Boily&author=H+Ali&author=L+Baandrup&author=H+Bauer&publication_year=2015&hl=en']",25744474,https://doi.org/10.1016/S1473-3099(14)71073-4, Drolet 2015 ,additional,CD009069-bbs2-0163,
CD009069-bib-0195,European Medicines Agency. ,HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS,,,,. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/European_Commission_final_decision/WC500196773.pdf 16/01/2016.   ,['citation-other'], European Medicines Agency. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/European_Commission_final_decision/WC500196773.pdf 16/01/2016.    ,[],,, EMA 2016 ,additional,CD009069-bbs2-0164,
CD009069-bib-0196,European Medicines Agency. ,EMEA/H/C/000721‐Cervarix‐EPAR summary for the public 2014, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000721/WC500024634.pdf. ,Februrary 2014,Accessed 10‐12‐15,:1‐3.   ,['citation-journal'], European Medicines Agency. EMEA/H/C/000721‐Cervarix‐EPAR summary for the public 2014.  http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000721/WC500024634.pdf. Februrary 2014;Accessed 10‐12‐15:1‐3.    ,[],,, EMEA 2014a ,additional,CD009069-bbs2-0165,
CD009069-bib-0197,European Medicines Agency. ,EMEA/H/C/000703‐Gardasil‐EPAR summary for the public 2014, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000703/WC500021146.pdf ,August 2014,Accessed 10‐12‐15,:1‐4.   ,['citation-journal'], European Medicines Agency. EMEA/H/C/000703‐Gardasil‐EPAR summary for the public 2014.  http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000703/WC500021146.pdf August 2014;Accessed 10‐12‐15:1‐4.    ,[],,, EMEA 2014b ,additional,CD009069-bbs2-0166,
CD009069-bib-0198,EMEA. ,Review concludes evidence does not support that HPV vaccines cause CRPS or POTS,,,,. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/11/news_detail_002429.jsp&mid=WC0b01ac058004d5c1 05/11/2015.   ,['citation-other'], EMEA. Review concludes evidence does not support that HPV vaccines cause CRPS or POTS. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/11/news_detail_002429.jsp&mid=WC0b01ac058004d5c1 05/11/2015.    ,[],,, EMEA 2015 ,additional,CD009069-bbs2-0167,
CD009069-bib-0199,"Ferlay J, Steliarova‐Foucher E, Lortet‐Tieulent J, Rosso S, Coebergh JW, Comber H, et al. ",Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, European Journal of Cancer ,2013,49,    ,['citation-journal']," Ferlay J, Steliarova‐Foucher E, Lortet‐Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012.  European Journal of Cancer 2013;49(6):1374‐403.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.ejca.2012.12.027', 'https://www.ncbi.nlm.nih.gov/pubmed/23485231', 'https://scholar.google.com/scholar_lookup?title=Cancer+incidence+and+mortality+patterns+in+Europe:+Estimates+for+40+countries+in+2012&author=J+Ferlay&author=E+Steliarova‐Foucher&author=J+Lortet‐Tieulent&author=S+Rosso&author=JW+Coebergh&author=H+Comber&publication_year=2013&hl=en']",23485231,https://doi.org/10.1016/j.ejca.2012.12.027, Ferlay 2013 ,additional,CD009069-bbs2-0168,
CD009069-bib-0200,"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. ","Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", International Journal of Cancer ,2015,136,    ,['citation-journal']," Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.  International Journal of Cancer 2015;136(5):E359‐96.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/ijc.29210', 'https://www.ncbi.nlm.nih.gov/pubmed/25220842', 'https://scholar.google.com/scholar_lookup?title=Cancer+incidence+and+mortality+worldwide:+sources,+methods+and+major+patterns+in+GLOBOCAN+2012+&author=J+Ferlay&author=I+Soerjomataram&author=R+Dikshit&author=S+Eser&author=C+Mathers&author=M+Rebelo&publication_year=2015&hl=en']",25220842,https://doi.org/10.1002/ijc.29210, Ferlay 2015 ,additional,CD009069-bbs2-0169,
CD009069-bib-0201,"Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet‐Tieulent J, Bruni L, et al. ",Global burden of human papillomavirus and related diseases, Vaccine ,2012,30 Suppl 5,    ,['citation-journal']," Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet‐Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases.  Vaccine 2012;30 Suppl 5:F12‐23.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2012.07.055', 'https://www.ncbi.nlm.nih.gov/pubmed/23199955', 'https://scholar.google.com/scholar_lookup?title=Global+burden+of+human+papillomavirus+and+related+diseases&author=D+Forman&author=C+Martel&author=CJ+Lacey&author=I+Soerjomataram&author=J+Lortet‐Tieulent&author=L+Bruni&publication_year=2012&hl=en']",23199955,https://doi.org/10.1016/j.vaccine.2012.07.055, Forman 2012 ,additional,CD009069-bbs2-0170,
CD009069-bib-0202,Frazer IH. ,Prevention of cervical cancer through papillomavirus vaccination, Nature Reviews Immunology ,2004,4,    ,['citation-journal'], Frazer IH. Prevention of cervical cancer through papillomavirus vaccination.  Nature Reviews Immunology 2004;4:46‐55.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1038/nri1260', 'https://www.ncbi.nlm.nih.gov/pubmed/14704767', 'https://scholar.google.com/scholar_lookup?title=Prevention+of+cervical+cancer+through+papillomavirus+vaccination&author=IH+Frazer&publication_year=2004&hl=en']",14704767,https://doi.org/10.1038/nri1260, Frazer 2004 ,additional,CD009069-bbs2-0171,
CD009069-bib-0203,The FUTURE II study group. ,Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions, New England Journal of Medicine ,2007,356,    ,['citation-journal'], The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions.  New England Journal of Medicine 2007;356(19):1915‐27.    Link to article     ,['https://doi.org/10.1056/NEJMoa061741'],,https://doi.org/10.1056/NEJMoa061741, FUTURE‐II 2007 ,additional,CD009069-bbs2-0172,
CD009069-bib-0204,Galloway DA. ,Papillomavirus vaccines in clinical trials, Lancet ,2003,3,    ,['citation-journal'], Galloway DA. Papillomavirus vaccines in clinical trials.  Lancet 2003;3:469‐75.    Link to article     Google Scholar     ,"['https://doi.org/10.1016/S1473-3099(03)00720-5', 'https://scholar.google.com/scholar_lookup?title=Papillomavirus+vaccines+in+clinical+trials&author=DA+Galloway&publication_year=2003&hl=en']",,https://doi.org/10.1016/S1473-3099(03)00720-5, Galloway 2003 ,additional,CD009069-bbs2-0173,
CD009069-bib-0205,"Garcia‐Sicilia J, Schwarz TF, Carmona A, Peters K, Malkin JE, Tran PM. ",Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine coadministered with combined diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine to girls and young women, Journal of Adolescent Health ,2010,46,    ,['citation-journal']," Garcia‐Sicilia J, Schwarz TF, Carmona A, Peters K, Malkin JE, Tran PM. Immunogenicity and safety of human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine coadministered with combined diphtheria‐tetanus‐acellular pertussis‐inactivated poliovirus vaccine to girls and young women.  Journal of Adolescent Health 2010;46(2):142‐51.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.jadohealth.2009.11.205', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+human+papillomavirus‐16/18+AS04‐adjuvanted+cervical+cancer+vaccine+coadministered+with+combined+diphtheria‐tetanus‐acellular+pertussis‐inactivated+poliovirus+vaccine+to+girls+and+young+women+&author=J+Garcia‐Sicilia&author=TF+Schwarz&author=A+Carmona&author=K+Peters&author=JE+Malkin&author=PM+Tran&publication_year=2010&hl=en']",,https://doi.org/10.1016/j.jadohealth.2009.11.205, Garcia‐Sicilia 2010 ,additional,CD009069-bbs2-0174,
CD009069-bib-0206,"Garland SM, Hernandez‐Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S. ",Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases, New England Journal of Medicine ,2007,356,    ,['citation-journal']," Garland SM, Hernandez‐Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.  New England Journal of Medicine 2007;356(19):1928‐43.    Link to article     Google Scholar     ","['https://doi.org/10.1056/NEJMoa061760', 'https://scholar.google.com/scholar_lookup?title=Quadrivalent+vaccine+against+human+papillomavirus+to+prevent+anogenital+diseases&author=SM+Garland&author=M+Hernandez‐Avila&author=CM+Wheeler&author=G+Perez&author=DM+Harper&author=S+Leodolter&publication_year=2007&hl=en']",,https://doi.org/10.1056/NEJMoa061760, Garland 2007 ,additional,CD009069-bbs2-0175,
CD009069-bib-0207,"Garland SM, Steben M, Hernandez‐Avila M, Koutsky LA, Wheeler CM, Perez G, et al. ","An evaluation of non‐inferiority in antibody response to human papillomavirus (HPV) 16 in subjects vaccinated with monovalent (HPV 16) and quadrivalent (HPV 6, 11, 16, 18) L1 virus like particle vaccines", Clinical and Vaccine Immunology ,2007,10,    ,['citation-journal']," Garland SM, Steben M, Hernandez‐Avila M, Koutsky LA, Wheeler CM, Perez G, et al. An evaluation of non‐inferiority in antibody response to human papillomavirus (HPV) 16 in subjects vaccinated with monovalent (HPV 16) and quadrivalent (HPV 6, 11, 16, 18) L1 virus like particle vaccines.  Clinical and Vaccine Immunology 2007;10(1128):1‐17.    Google Scholar     ","['https://scholar.google.com/scholar_lookup?title=An+evaluation+of+non‐inferiority+in+antibody+response+to+human+papillomavirus+(HPV)+16+in+subjects+vaccinated+with+monovalent+(HPV+16)+and+quadrivalent+(HPV+6,+11,+16,+18)+L1+virus+like+particle+vaccines+&author=SM+Garland&author=M+Steben&author=M+Hernandez‐Avila&author=LA+Koutsky&author=CM+Wheeler&author=G+Perez&publication_year=2007&hl=en']",,, Garland 2007a ,additional,CD009069-bbs2-0176,
CD009069-bib-0208,"Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. ",Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 Vaccine: a combined analysis of five randomized controlled trials, Obstetrics and Gynecology ,2009,114,    ,['citation-journal']," Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 Vaccine: a combined analysis of five randomized controlled trials.  Obstetrics and Gynecology 2009;114(6):1179‐88.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/AOG.0b013e3181c2ca21', 'https://www.ncbi.nlm.nih.gov/pubmed/19935017', 'https://scholar.google.com/scholar_lookup?title=Pregnancy+and+infant+outcomes+in+the+clinical+trials+of+a+human+papillomavirus+type+6/11/16/18+Vaccine:+a+combined+analysis+of+five+randomized+controlled+trials+&author=SM+Garland&author=KA+Ault&author=SA+Gall&author=J+Paavonen&author=HL+Sings&author=KL+Ciprero&publication_year=2009&hl=en']",19935017,https://doi.org/10.1097/AOG.0b013e3181c2ca21, Garland 2009 ,additional,CD009069-bbs2-0177,
CD009069-bib-0209,"Gee J, Sukumaran L, Weintraub E. ",Risk of Guillain‐Barré syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink, Vaccine ,2017,35,    ,['citation-journal']," Gee J, Sukumaran L, Weintraub E. Risk of Guillain‐Barré syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink.  Vaccine 2017;35(43):5756‐8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2017.09.009', 'https://www.ncbi.nlm.nih.gov/pubmed/28935469', 'https://scholar.google.com/scholar_lookup?title=Risk+of+Guillain‐Barré+syndrome+following+quadrivalent+human+papillomavirus+vaccine+in+the+Vaccine+Safety+Datalink+&author=J+Gee&author=L+Sukumaran&author=E+Weintraub&publication_year=2017&hl=en']",28935469,https://doi.org/10.1016/j.vaccine.2017.09.009, Gee 2017 ,additional,CD009069-bbs2-0178,
CD009069-bib-0210,"Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. ",mpact of a population‐based HPV vaccination program on cervical abnormalities: a data linkage study, BMC Medicine ,2013,11,    ,['citation-journal']," Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. mpact of a population‐based HPV vaccination program on cervical abnormalities: a data linkage study.  BMC Medicine 2013;11:227.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1186/1741-7015-11-227', 'https://www.ncbi.nlm.nih.gov/pubmed/24148310', 'https://scholar.google.com/scholar_lookup?title=mpact+of+a+population‐based+HPV+vaccination+program+on+cervical+abnormalities:+a+data+linkage+study+&author=DM+Gertig&author=JM+Brotherton&author=AC+Budd&author=K+Drennan&author=G+Chappell&author=AM+Saville&publication_year=2013&hl=en']",24148310,https://doi.org/10.1186/1741-7015-11-227, Gertig 2013 ,additional,CD009069-bbs2-0179,
CD009069-bib-0211,"Ghim S, Newsome J, Bell J, Sundberg JP, Schlegel R, Jenson AB. ",Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus, Experimental and Molecular Pathology ,2000,68,    ,['citation-journal']," Ghim S, Newsome J, Bell J, Sundberg JP, Schlegel R, Jenson AB. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus.  Experimental and Molecular Pathology 2000;68(3):147‐51.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1006/exmp.1999.2298', 'https://www.ncbi.nlm.nih.gov/pubmed/10816383', 'https://scholar.google.com/scholar_lookup?title=Spontaneously+regressing+oral+papillomas+induce+systemic+antibodies+that+neutralize+canine+oral+papillomavirus+&author=S+Ghim&author=J+Newsome&author=J+Bell&author=JP+Sundberg&author=R+Schlegel&author=AB+Jenson&publication_year=2000&hl=en']",10816383,https://doi.org/10.1006/exmp.1999.2298, Ghim 2000 ,additional,CD009069-bbs2-0180,
CD009069-bib-0212,"Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. ",Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only, Vaccine ,2006,24,    ,['citation-journal']," Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.  Vaccine 2006;24:5937‐49.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2006.06.005', 'https://www.ncbi.nlm.nih.gov/pubmed/16828940', 'https://scholar.google.com/scholar_lookup?title=Enhanced+humoral+and+memory+B+cellular+immunity+using+HPV16/18+L1+VLP+vaccine+formulated+with+the+MPL/aluminium+salt+combination+(AS04)+compared+to+aluminium+salt+only+&author=SL+Giannini&author=E+Hanon&author=P+Moris&author=M+Mechelen&author=S+Morel&author=F+Dessy&publication_year=2006&hl=en']",16828940,https://doi.org/10.1016/j.vaccine.2006.06.005, Giannini 2006 ,additional,CD009069-bbs2-0181,
CD009069-bib-0213,"Goss MA, Lievano F, Buchanan KM, Seminack MM, Cunningham ML, Dana A. ",Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine, Vaccine ,2015,33,    ,['citation-journal']," Goss MA, Lievano F, Buchanan KM, Seminack MM, Cunningham ML, Dana A. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine.  Vaccine 2015;33:3422‐8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2015.04.014', 'https://www.ncbi.nlm.nih.gov/pubmed/25869893', 'https://scholar.google.com/scholar_lookup?title=Final+report+on+exposure+during+pregnancy+from+a+pregnancy+registry+for+quadrivalent+human+papillomavirus+vaccine+&author=MA+Goss&author=F+Lievano&author=KM+Buchanan&author=MM+Seminack&author=ML+Cunningham&author=A+Dana&publication_year=2015&hl=en']",25869893,https://doi.org/10.1016/j.vaccine.2015.04.014, Goss 2015 ,additional,CD009069-bbs2-0182,
CD009069-bib-0214,"Grimaldi‐Bensouda L, Guillemot D, Godeau B, Benichou J, Lebrun‐Frenay C, Papeix C, et al. ",Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects, Journal of Internal Medicine ,2014,275,    ,['citation-journal']," Grimaldi‐Bensouda L, Guillemot D, Godeau B, Benichou J, Lebrun‐Frenay C, Papeix C, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.  Journal of Internal Medicine 2014;275(4):398‐408.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/joim.12155', 'https://www.ncbi.nlm.nih.gov/pubmed/24206418', 'https://scholar.google.com/scholar_lookup?title=Autoimmune+disorders+and+quadrivalent+human+papillomavirus+vaccination+of+young+female+subjects+&author=L+Grimaldi‐Bensouda&author=D+Guillemot&author=B+Godeau&author=J+Benichou&author=C+Lebrun‐Frenay&author=C+Papeix&publication_year=2014&hl=en']",24206418,https://doi.org/10.1111/joim.12155, Grimaldi‐Bensouda 2014 ,additional,CD009069-bbs2-0183,
CD009069-bib-0215,"Grimaldi‐Bensouda L, Rossignol M, Kone‐Paut I, Krivitzky A, Lebrun‐Frenay C, Clet J, et al. ",Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case‐referent surveillance, Journal of Autoimmunity ,2017,79,    ,['citation-journal']," Grimaldi‐Bensouda L, Rossignol M, Kone‐Paut I, Krivitzky A, Lebrun‐Frenay C, Clet J, et al. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case‐referent surveillance.  Journal of Autoimmunity 2017;79:84‐90.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.jaut.2017.01.005', 'https://www.ncbi.nlm.nih.gov/pubmed/28190705', 'https://scholar.google.com/scholar_lookup?title=Risk+of+autoimmune+diseases+and+human+papilloma+virus+(HPV)+vaccines:+Six+years+of+case‐referent+surveillance+&author=L+Grimaldi‐Bensouda&author=M+Rossignol&author=I+Kone‐Paut&author=A+Krivitzky&author=C+Lebrun‐Frenay&author=J+Clet&publication_year=2017&hl=en']",28190705,https://doi.org/10.1016/j.jaut.2017.01.005, Grimaldi‐Bensouda 2017 ,additional,CD009069-bbs2-0184,
CD009069-bib-0216,"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. ",GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ ,2008,336,    ,['citation-journal']," Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.  BMJ 2008;336(7650):924‐6.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.39489.470347.AD', 'https://www.ncbi.nlm.nih.gov/pubmed/18436948', 'https://scholar.google.com/scholar_lookup?title=GRADE:+an+emerging+consensus+on+rating+quality+of+evidence+and+strength+of+recommendations&author=GH+Guyatt&author=AD+Oxman&author=GE+Vist&author=R+Kunz&author=Y+Falck‐Ytter&author=P+Alonso‐Coello&publication_year=2008&hl=en']",18436948,https://doi.org/10.1136/bmj.39489.470347.AD, Guyatt 2008 ,additional,CD009069-bbs2-0185,
CD009069-bib-0217,"Harbord RM, Harris RJ, Sterne JAC. ",Updated tests for small‐study effects in meta‐analyses, Stata Journal ,2009,9,    ,['citation-journal']," Harbord RM, Harris RJ, Sterne JAC. Updated tests for small‐study effects in meta‐analyses.  Stata Journal 2009;9(2):197‐210.    Link to article     Google Scholar     ","['https://doi.org/10.1177/1536867X0900900202', 'https://scholar.google.com/scholar_lookup?title=Updated+tests+for+small‐study+effects+in+meta‐analyses&author=RM+Harbord&author=RJ+Harris&author=JAC+Sterne&publication_year=2009&hl=en']",,https://doi.org/10.1177/1536867X0900900202, Harbord 2009 ,additional,CD009069-bbs2-0186,
CD009069-bib-0218,"Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A. ",Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, Lancet ,2004,364,    ,['citation-journal']," Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A. Efficacy of a bivalent L1 virus‐like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.  Lancet 2004;364(9447):1757‐65.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(04)17398-4', 'https://www.ncbi.nlm.nih.gov/pubmed/15541448', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+a+bivalent+L1+virus‐like+particle+vaccine+in+prevention+of+infection+with+human+papillomavirus+types+16+and+18+in+young+women:+a+randomised+controlled+trial+&author=DM+Harper&author=EL+Franco&author=C+Wheeler&author=DG+Ferris&author=D+Jenkins&author=A+Schuind&publication_year=2004&hl=en']",15541448,https://doi.org/10.1016/S0140-6736(04)17398-4, Harper 2004 ,additional,CD009069-bbs2-0187,
CD009069-bib-0219,"Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli‐Martins CM. ",Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial, Lancet ,2006,367,    ,['citation-journal']," Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli‐Martins CM. Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial.  Lancet 2006;367(9518):1247‐55.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(06)68439-0', 'https://www.ncbi.nlm.nih.gov/pubmed/16631880', 'https://scholar.google.com/scholar_lookup?title=Sustained+efficacy+up+to+4.5+years+of+a+bivalent+L1+virus‐like+particle+vaccine+against+human+papillomavirus+types+16+and+18:+follow‐up+from+a+randomised+control+trial+&author=DM+Harper&author=EL+Franco&author=CM+Wheeler&author=AB+Moscicki&author=B+Romanowski&author=CM+Roteli‐Martins&publication_year=2006&hl=en']",16631880,https://doi.org/10.1016/S0140-6736(06)68439-0, Harper 2006 ,additional,CD009069-bbs2-0188,
CD009069-bib-0220,Harper DM. ,Currently approved prophylactic HPV vaccines, Expert Review of Vaccines ,2009,8,    ,['citation-journal'], Harper DM. Currently approved prophylactic HPV vaccines.  Expert Review of Vaccines 2009;8(12):1663‐79.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1586/erv.09.123', 'https://www.ncbi.nlm.nih.gov/pubmed/19943762', 'https://scholar.google.com/scholar_lookup?title=Currently+approved+prophylactic+HPV+vaccines&author=DM+Harper&publication_year=2009&hl=en']",19943762,https://doi.org/10.1586/erv.09.123, Harper 2009 ,additional,CD009069-bbs2-0189,
CD009069-bib-0221,"Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P, Kreimer AR. ","Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in guanacaste, Costa Rica", Cancer Discovery ,2011,1,    ,['citation-journal']," Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P, Kreimer AR. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community‐based randomized clinical trial in guanacaste, Costa Rica.  Cancer Discovery 2011;1(5):408‐19.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1158/2159-8290.CD-11-0131', 'https://www.ncbi.nlm.nih.gov/pubmed/22586631', 'https://scholar.google.com/scholar_lookup?title=Prevention+of+persistent+human+papillomavirus+infection+by+an+HPV16/18+vaccine:+A+community‐based+randomized+clinical+trial+in+guanacaste,+Costa+Rica+&author=R+Herrero&author=S+Wacholder&author=AC+Rodriguez&author=D+Solomon&author=P+Gonzalez&author=AR+Kreimer&publication_year=2011&hl=en']",22586631,https://doi.org/10.1158/2159-8290.CD-11-0131, Herrero 2011 ,additional,CD009069-bbs2-0190,
CD009069-bib-0222,"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. ",Measuring inconsistency in meta‐analyses, BMJ ,2003,327,    ,['citation-journal']," Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses.  BMJ 2003;327:557‐60.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.327.7414.557', 'https://www.ncbi.nlm.nih.gov/pubmed/12958120', 'https://scholar.google.com/scholar_lookup?title=Measuring+inconsistency+in+meta‐analyses&author=JPT+Higgins&author=SG+Thompson&author=JJ+Deeks&author=DG+Altman&publication_year=2003&hl=en']",12958120,https://doi.org/10.1136/bmj.327.7414.557, Higgins 2003 ,additional,CD009069-bbs2-0191,
CD009069-bib-0223,"Higgins JPT, Green S (editors). ","Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011",,,,. Available from handbook.cochrane.org.   ,['citation-other']," Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.    ",[],,, Higgins 2011a ,additional,CD009069-bbs2-0192,
CD009069-bib-0224,"Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. ",The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ ,2011,343,    ,['citation-journal']," Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.  BMJ 2011;343:d5928.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.d5928', 'https://www.ncbi.nlm.nih.gov/pubmed/22008217', ""https://scholar.google.com/scholar_lookup?title=The+Cochrane+Collaboration's+tool+for+assessing+risk+of+bias+in+randomised+trials&author=JP+Higgins&author=DG+Altman&author=PC+Gøtzsche&author=P+Jüni&author=D+Moher&author=AD+Oxman&publication_year=2011&hl=en""]",22008217,https://doi.org/10.1136/bmj.d5928, Higgins 2011b ,additional,CD009069-bbs2-0193,
CD009069-bib-0225,"Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R. ",Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial, Vaccine ,2014,32,    ,['citation-journal']," Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R. Efficacy of the HPV‐16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV‐16/18 vaccine trial.  Vaccine 2014;32(39):5087‐97.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2014.06.038', 'https://www.ncbi.nlm.nih.gov/pubmed/25018097', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+the+HPV‐16/18+vaccine:+Final+according+to+protocol+results+from+the+blinded+phase+of+the+randomized+Costa+Rica+HPV‐16/18+vaccine+trial+&author=A+Hildesheim&author=S+Wacholder&author=G+Catteau&author=F+Struyf&author=G+Dubin&author=R+Herrero&publication_year=2014&hl=en']",25018097,https://doi.org/10.1016/j.vaccine.2014.06.038, Hildesheim 2014 ,additional,CD009069-bbs2-0194,
CD009069-bib-0226,"Ho GYF, Bierman R, Beardsley I, Chang CJ, Burk RD. ",Natural history of cervicovaginal papillomavirus infection in young women, New England Journal of Medicine ,1998,338,    ,['citation-journal']," Ho GYF, Bierman R, Beardsley I, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women.  New England Journal of Medicine 1998;338:423‐8.    Link to article     Google Scholar     ","['https://doi.org/10.1056/NEJM199802123380703', 'https://scholar.google.com/scholar_lookup?title=Natural+history+of+cervicovaginal+papillomavirus+infection+in+young+women&author=GYF+Ho&author=R+Bierman&author=I+Beardsley&author=CJ+Chang&author=RD+Burk&publication_year=1998&hl=en']",,https://doi.org/10.1056/NEJM199802123380703, Ho 1998 ,additional,CD009069-bbs2-0195,
CD009069-bib-0227,"Hofstetter AM, Ompad DC, Stockwell MS, Rosenthal SL, Soren K. ",Human papillomavirus vaccination and cervical cytology outcomes among urban low‐income minority females, JAMA Pediatrics ,2016,170,    ,['citation-journal']," Hofstetter AM, Ompad DC, Stockwell MS, Rosenthal SL, Soren K. Human papillomavirus vaccination and cervical cytology outcomes among urban low‐income minority females.  JAMA Pediatrics 2016;170(5):445‐52.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jamapediatrics.2015.3926', 'https://www.ncbi.nlm.nih.gov/pubmed/26974250', 'https://scholar.google.com/scholar_lookup?title=Human+papillomavirus+vaccination+and+cervical+cytology+outcomes+among+urban+low‐income+minority+females+&author=AM+Hofstetter&author=DC+Ompad&author=MS+Stockwell&author=SL+Rosenthal&author=K+Soren&publication_year=2016&hl=en']",26974250,https://doi.org/10.1001/jamapediatrics.2015.3926, Hofstetter 2016 ,additional,CD009069-bbs2-0196,
CD009069-bib-0228,"Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. ","Final efficacy, immunogenicity, and safety analyses of a nine‐valent human papillomavirus vaccine in women aged 16‐26 years: a randomised, double‐blind trial", Lancet ,2017,390,    ,['citation-journal']," Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine‐valent human papillomavirus vaccine in women aged 16‐26 years: a randomised, double‐blind trial.  Lancet 2017;390(10108):2043‐59.    Link to article     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(17)31821-4', 'https://scholar.google.com/scholar_lookup?title=Final+efficacy,+immunogenicity,+and+safety+analyses+of+a+nine‐valent+human+papillomavirus+vaccine+in+women+aged+16‐26+years:+a+randomised,+double‐blind+trial+&author=WK+Huh&author=EA+Joura&author=AR+Giuliano&author=OE+Iversen&author=RP+Andrade&author=KA+Ault&publication_year=2017&hl=en']",,https://doi.org/10.1016/S0140-6736(17)31821-4, Huh 2017 ,additional,CD009069-bbs2-0197,
CD009069-bib-0229,"IARC Expert team cervical cancer screening, (Day N, Hakama M, Arbyn M). ",Cervix Cancer Screening,IARC Handbooks of Cancer Prevention,2005,10,    ,['citation-book']," IARC Expert team cervical cancer screening, (Day N, Hakama M, Arbyn M). Cervix Cancer Screening. IARC Handbooks of Cancer Prevention. Vol. 10, Lyon: IARC Press, 2005:1‐302.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Cervix+Cancer+Screening&author=N+(Day&author=M+Hakama&author=M)+Arbyn&publication_year=2005&hl=en'],,, IARC 2005 ,additional,CD009069-bbs2-0198,
CD009069-bib-0230,"IARC Monograph Working Group on Carcinogenesis (Coglinano V, Baan R, Straif K, Secretan B, El Ghissasi F, Zur Hausen H, et al)  . In: Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi F editor(s). ",,IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses,2007,90,:1‐670.   ,['citation-book']," IARC Monograph Working Group on Carcinogenesis (Coglinano V, Baan R, Straif K, Secretan B, El Ghissasi F, Zur Hausen H, et al)  . In: Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi F editor(s). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 90: Human Papillomaviruses. Vol. 90, Lyon: IARC Press, 2007:1‐670.    ",[],,, IARC 2007 ,additional,CD009069-bbs2-0199,
CD009069-bib-0231,IARC HPV Working Group. ,Primary end‐points for prophylactic HPV vaccine trials,IARC Working Group Reports,2013,7,:1‐120.   ,['citation-book']," IARC HPV Working Group. Primary end‐points for prophylactic HPV vaccine trials. IARC Working Group Reports. Vol. 7, Lyon, France: WHO Press, 2013:1‐120.    ",[],,, IARC 2013 ,additional,CD009069-bbs2-0200,
CD009069-bib-0232,"Iftner T, Villa LL. ",Chapter 12: Human papillomavirus technologies, Journal of National Cancer Institute Monographs ,2003,31,    ,['citation-journal']," Iftner T, Villa LL. Chapter 12: Human papillomavirus technologies.  Journal of National Cancer Institute Monographs 2003;31:80‐8.    Link to article     Google Scholar     ","['https://doi.org/10.1093/oxfordjournals.jncimonographs.a003487', 'https://scholar.google.com/scholar_lookup?title=Chapter+12:+Human+papillomavirus+technologies&author=T+Iftner&author=LL+Villa&publication_year=2003&hl=en']",,https://doi.org/10.1093/oxfordjournals.jncimonographs.a003487, Iftner 2003 ,additional,CD009069-bbs2-0201,
CD009069-bib-0233,Initiative for Vaccine Research of the Department of Immunization VaB. ,Human Papillomavirus (HPV) Vaccine Background Paper,,2009,,:1‐249.   ,['citation-other']," Initiative for Vaccine Research of the Department of Immunization VaB. Human Papillomavirus (HPV) Vaccine Background Paper. World Health Organization (WHO). Geneva, 2009:1‐249.    ",[],,, Initiative 2009 ,additional,CD009069-bbs2-0202,
CD009069-bib-0234,"Jordan J, Arbyn M, Martin‐Hirsch P, Schenck U, Baldauf J‐J, Da Silva D, et al. ","European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1", Cytopathology ,2008,19,    ,['citation-journal']," Jordan J, Arbyn M, Martin‐Hirsch P, Schenck U, Baldauf J‐J, Da Silva D, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.  Cytopathology 2008;19(6):342‐54.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/j.1365-2303.2008.00623.x', 'https://www.ncbi.nlm.nih.gov/pubmed/19040546', 'https://scholar.google.com/scholar_lookup?title=European+guidelines+for+quality+assurance+in+cervical+cancer+screening:+recommendations+for+clinical+management+of+abnormal+cervical+cytology,+part+1+&author=J+Jordan&author=M+Arbyn&author=P+Martin‐Hirsch&author=U+Schenck&author=J‐J+Baldauf&author=D+Silva&publication_year=2008&hl=en']",19040546,https://doi.org/10.1111/j.1365-2303.2008.00623.x, Jordan 2008 ,additional,CD009069-bbs2-0203,
CD009069-bib-0235,"Jordan J, Martin‐Hirsch P, Arbyn M, Schenck U, Baldauf J‐J, Da Silva D, et al. ","European guidelines for management of abnormal cervical cytology, Part 2", Cytopathology ,2009,20,    ,['citation-journal']," Jordan J, Martin‐Hirsch P, Arbyn M, Schenck U, Baldauf J‐J, Da Silva D, et al. European guidelines for management of abnormal cervical cytology, Part 2.  Cytopathology 2009;20(1):5‐16.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/j.1365-2303.2008.00636.x', 'https://www.ncbi.nlm.nih.gov/pubmed/19133067', 'https://scholar.google.com/scholar_lookup?title=European+guidelines+for+management+of+abnormal+cervical+cytology,+Part+2&author=J+Jordan&author=P+Martin‐Hirsch&author=M+Arbyn&author=U+Schenck&author=J‐J+Baldauf&author=D+Silva&publication_year=2009&hl=en']",19133067,https://doi.org/10.1111/j.1365-2303.2008.00636.x, Jordan 2009 ,additional,CD009069-bbs2-0204,
CD009069-bib-0236,"Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. ",A 9‐Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women, New England Journal of Medicine ,2015,372,    ,['citation-journal']," Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9‐Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women.  New England Journal of Medicine 2015;372(8):711‐23.    Link to article     Google Scholar     ","['https://doi.org/10.1056/NEJMoa1405044', 'https://scholar.google.com/scholar_lookup?title=A+9‐Valent+HPV+Vaccine+against+Infection+and+Intraepithelial+Neoplasia+in+Women&author=EA+Joura&author=AR+Giuliano&author=OE+Iversen&author=C+Bouchard&author=C+Mao&author=J+Mehlsen&publication_year=2015&hl=en']",,https://doi.org/10.1056/NEJMoa1405044, Joura 2015 ,additional,CD009069-bbs2-0205,
CD009069-bib-0237,Kahn JA. ,HPV vaccination for the prevention of cervical intraepithelial neoplasia, New England Journal of Medicine ,2009,361,    ,['citation-journal'], Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia.  New England Journal of Medicine 2009;361(3):271‐8.    Link to article     Google Scholar     ,"['https://doi.org/10.1056/NEJMct0806938', 'https://scholar.google.com/scholar_lookup?title=HPV+vaccination+for+the+prevention+of+cervical+intraepithelial+neoplasia&author=JA+Kahn&publication_year=2009&hl=en']",,https://doi.org/10.1056/NEJMct0806938, Kahn 2009 ,additional,CD009069-bbs2-0206,
CD009069-bib-0238,"Kang S, Kim KH, Kim YT, Kim YT, Kim JH, Song YS. ","Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo‐controlled trial in 176 Korean subjects", International Journal of Gynecological Cancer ,2008,18,    ,['citation-journal']," Kang S, Kim KH, Kim YT, Kim YT, Kim JH, Song YS. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo‐controlled trial in 176 Korean subjects.  International Journal of Gynecological Cancer 2008;18(5):1013‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/j.1525-1438.2007.01123.x', 'https://www.ncbi.nlm.nih.gov/pubmed/17986242', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+a+vaccine+targeting+human+papillomavirus+types+6,+11,+16+and+18:+a+randomized,+placebo‐controlled+trial+in+176+Korean+subjects+&author=S+Kang&author=KH+Kim&author=YT+Kim&author=YT+Kim&author=JH+Kim&author=YS+Song&publication_year=2008&hl=en']",17986242,https://doi.org/10.1111/j.1525-1438.2007.01123.x, Kang 2008 ,additional,CD009069-bbs2-0207,
CD009069-bib-0239,"Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, et al. ",Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types, British Journal of Cancer ,2014,110,    ,['citation-journal']," Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types.  British Journal of Cancer 2014;110(11):2804‐11.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/bjc.2014.198', 'https://www.ncbi.nlm.nih.gov/pubmed/24736582', 'https://scholar.google.com/scholar_lookup?title=Introduction+and+sustained+high+coverage+of+the+HPV+bivalent+vaccine+leads+to+a+reduction+in+prevalence+of+HPV+16/18+and+closely+related+HPV+types+&author=K+Kavanagh&author=KG+Pollock&author=A+Potts&author=J+Love&author=K+Cuschieri&author=H+Cubie&publication_year=2014&hl=en']",24736582,https://doi.org/10.1038/bjc.2014.198, Kavanagh 2014 ,additional,CD009069-bbs2-0208,
CD009069-bib-0240,"Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. ",Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7‐year cross‐sectional study, Lancet Infectious Diseases ,2017,17,    ,['citation-journal']," Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7‐year cross‐sectional study.  Lancet Infectious Diseases 2017;17(12):1293‐302.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1473-3099(17)30468-1', 'https://www.ncbi.nlm.nih.gov/pubmed/28965955', 'https://scholar.google.com/scholar_lookup?title=Changes+in+the+prevalence+of+human+papillomavirus+following+a+national+bivalent+human+papillomavirus+vaccination+programme+in+Scotland:+a+7‐year+cross‐sectional+study+&author=K+Kavanagh&author=KG+Pollock&author=K+Cuschieri&author=T+Palmer&author=RL+Cameron&author=C+Watt&publication_year=2017&hl=en']",28965955,https://doi.org/10.1016/S1473-3099(17)30468-1, Kavanagh 2017 ,additional,CD009069-bbs2-0209,
CD009069-bib-0241,"Kim YJ, Kim KT, Kim JH, Cha SD, Kim JW, Bae DS, et al. ",Vaccination with a human papillomavirus (HPV)‐16/18 AS04‐adjuvanted cervical cancer vaccine in Korean girls aged 10‐14 years, Journal of Korean Medical Science ,2010,25,    ,['citation-journal']," Kim YJ, Kim KT, Kim JH, Cha SD, Kim JW, Bae DS, et al. Vaccination with a human papillomavirus (HPV)‐16/18 AS04‐adjuvanted cervical cancer vaccine in Korean girls aged 10‐14 years.  Journal of Korean Medical Science 2010;25(8):1197‐204.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.3346/jkms.2010.25.8.1197', 'https://www.ncbi.nlm.nih.gov/pubmed/20676333', 'https://scholar.google.com/scholar_lookup?title=Vaccination+with+a+human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+cervical+cancer+vaccine+in+Korean+girls+aged+10‐14+years+&author=YJ+Kim&author=KT+Kim&author=JH+Kim&author=SD+Cha&author=JW+Kim&author=DS+Bae&publication_year=2010&hl=en']",20676333,https://doi.org/10.3346/jkms.2010.25.8.1197, Kim 2010 ,additional,CD009069-bbs2-0210,
CD009069-bib-0242,"Kim SC, Song YS, Kim YT, Kim YT, Ryu KS, Gunapalaiah B. ",Human papillomavirus 16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in 15‐25 years old healthy Korean women, Journal of Gynecologic Oncology ,2011,22,    ,['citation-journal']," Kim SC, Song YS, Kim YT, Kim YT, Ryu KS, Gunapalaiah B. Human papillomavirus 16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in 15‐25 years old healthy Korean women.  Journal of Gynecologic Oncology 2011;22(2):67‐75.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.3802/jgo.2011.22.2.67', 'https://www.ncbi.nlm.nih.gov/pubmed/21860731', 'https://scholar.google.com/scholar_lookup?title=Human+papillomavirus+16/18+AS04‐adjuvanted+cervical+cancer+vaccine:+immunogenicity+and+safety+in+15‐25+years+old+healthy+Korean+women+&author=SC+Kim&author=YS+Song&author=YT+Kim&author=YT+Kim&author=KS+Ryu&author=B+Gunapalaiah&publication_year=2011&hl=en']",21860731,https://doi.org/10.3802/jgo.2011.22.2.67, Kim 2011 ,additional,CD009069-bbs2-0211,
CD009069-bib-0243,"Konno R, Tamura S, Dobbelaere K, Yoshikawa H. ","Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial", International Journal of Gynecological Cancer ,2010,20,    ,['citation-journal']," Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double‐blind, randomized, controlled trial.  International Journal of Gynecological Cancer 2010;20(3):404‐10.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/IGC.0b013e3181d373a5', 'https://www.ncbi.nlm.nih.gov/pubmed/20375805', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+human+papillomavirus+16/18+AS04‐adjuvanted+vaccine+in+Japanese+women+aged+20+to+25+years:+interim+analysis+of+a+phase+2+double‐blind,+randomized,+controlled+trial+&author=R+Konno&author=S+Tamura&author=K+Dobbelaere&author=H+Yoshikawa&publication_year=2010&hl=en']",20375805,https://doi.org/10.1111/IGC.0b013e3181d373a5, Konno 2010 ,additional,CD009069-bbs2-0212,
CD009069-bib-0244,"Konno R, Tamura S, Dobbelaere K, Yoshikawa H. ","Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial", International Journal of Gynecological Cancer ,2010,20,    ,['citation-journal']," Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus type 16/18 AS04‐adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double‐blind, randomized controlled trial.  International Journal of Gynecological Cancer 2010;20(5):847‐55.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/IGC.0b013e3181da2128', 'https://www.ncbi.nlm.nih.gov/pubmed/20606533', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+human+papillomavirus+type+16/18+AS04‐adjuvanted+vaccine+in+Japanese+women+aged+20+to+25+years:+final+analysis+of+a+phase+2+double‐blind,+randomized+controlled+trial+&author=R+Konno&author=S+Tamura&author=K+Dobbelaere&author=H+Yoshikawa&publication_year=2010&hl=en']",20606533,https://doi.org/10.1111/IGC.0b013e3181da2128, Konno 2010a ,additional,CD009069-bbs2-0213,
CD009069-bib-0245,"Konno R, Yoshikawa H, Okutani M, Quint W, Suryakiran V, Lin L, et al. ",Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women, Human Vaccines & Immunotherapeutics ,2014,10,    ,['citation-journal']," Konno R, Yoshikawa H, Okutani M, Quint W, Suryakiran V, Lin L, et al. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.  Human Vaccines & Immunotherapeutics 2014;10(7):1781‐94.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.4161/hv.28712', 'https://www.ncbi.nlm.nih.gov/pubmed/25424783', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+the+human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+vaccine+against+cervical+intraepithelial+neoplasia+and+cervical+infection+in+young+Japanese+women+&author=R+Konno&author=H+Yoshikawa&author=M+Okutani&author=W+Quint&author=V+Suryakiran&author=L+Lin&publication_year=2014&hl=en']",25424783,https://doi.org/10.4161/hv.28712, Konno 2014 ,additional,CD009069-bbs2-0214,
CD009069-bib-0246,"Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB. ",A controlled trial of a human papillomavirus type 16 vaccine, New England Journal of Medicine ,2002,347,    ,['citation-journal']," Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB. A controlled trial of a human papillomavirus type 16 vaccine.  New England Journal of Medicine 2002;347:1645‐51.    Link to article     Google Scholar     ","['https://doi.org/10.1056/NEJMoa020586', 'https://scholar.google.com/scholar_lookup?title=A+controlled+trial+of+a+human+papillomavirus+type+16+vaccine&author=LA+Koutsky&author=KA+Ault&author=CM+Wheeler&author=DR+Brown&author=E+Barr&author=FB+Alvarez&publication_year=2002&hl=en']",,https://doi.org/10.1056/NEJMoa020586, Koutsky 2002 ,additional,CD009069-bbs2-0215,
CD009069-bib-0247,"Koutsky LA, Harper DM. ",Chapter 13: Current findings from prophylactic HPV vaccine trials, Vaccine ,2006,24,    ,['citation-journal']," Koutsky LA, Harper DM. Chapter 13: Current findings from prophylactic HPV vaccine trials.  Vaccine 2006;24(Suppl 3):114‐21.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2006.06.014', 'https://scholar.google.com/scholar_lookup?title=Chapter+13:+Current+findings+from+prophylactic+HPV+vaccine+trials&author=LA+Koutsky&author=DM+Harper&publication_year=2006&hl=en']",,https://doi.org/10.1016/j.vaccine.2006.06.014, Koutsky 2006 ,additional,CD009069-bbs2-0216,
CD009069-bib-0248,"Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. ",Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine, Journal of the National Cancer Institute ,2011,103,    ,['citation-journal']," Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof‐of‐principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.  Journal of the National Cancer Institute 2011;103(19):1444‐51.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/jnci/djr319', 'https://www.ncbi.nlm.nih.gov/pubmed/21908768', 'https://scholar.google.com/scholar_lookup?title=Proof‐of‐principle+evaluation+of+the+efficacy+of+fewer+than+three+doses+of+a+bivalent+HPV16/18+vaccine+&author=AR+Kreimer&author=AC+Rodriguez&author=A+Hildesheim&author=R+Herrero&author=C+Porras&author=M+Schiffman&publication_year=2011&hl=en']",21908768,https://doi.org/10.1093/jnci/djr319, Kreimer 2011 ,additional,CD009069-bbs2-0217,
CD009069-bib-0249,"Kreimer AR, Sherman ME, Sahasrabuddhe VV, Safaeian M. ",The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents, Journal of the National Cancer Institute ,2015,107,    ,['citation-journal']," Kreimer AR, Sherman ME, Sahasrabuddhe VV, Safaeian M. The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents.  Journal of the National Cancer Institute 2015;107(3):dju436.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/jnci/dju436', 'https://www.ncbi.nlm.nih.gov/pubmed/25650316', 'https://scholar.google.com/scholar_lookup?title=The+case+for+conducting+a+randomized+clinical+trial+to+assess+the+efficacy+of+a+single+dose+of+prophylactic+HPV+vaccines+among+adolescents+&author=AR+Kreimer&author=ME+Sherman&author=VV+Sahasrabuddhe&author=M+Safaeian&publication_year=2015&hl=en']",25650316,https://doi.org/10.1093/jnci/dju436, Kreimer 2015b ,additional,CD009069-bbs2-0218,
CD009069-bib-0250,"Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P. ",Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates, American Journal of Epidemiology ,2014,180,    ,['citation-journal']," Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P. Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.  American Journal of Epidemiology 2014;180(6):599‐607.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/aje/kwu168', 'https://www.ncbi.nlm.nih.gov/pubmed/25139208', 'https://scholar.google.com/scholar_lookup?title=Effect+of+different+human+papillomavirus+serological+and+DNA+criteria+on+vaccine+efficacy+estimates+&author=KA+Kuhs&author=C+Porras&author=JT+Schiller&author=AC+Rodriguez&author=M+Schiffman&author=P+Gonzalez&publication_year=2014&hl=en']",25139208,https://doi.org/10.1093/aje/kwu168, Kuhs 2014 ,additional,CD009069-bbs2-0219,
CD009069-bib-0251,"Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin‐Hirsch PPL, et al. ",Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease, Cochrane Database of Systematic Reviews ,2017,,    ,['citation-journal']," Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin‐Hirsch PPL, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease.  Cochrane Database of Systematic Reviews 2017, Issue 11. [DOI: 10.1002/14651858.CD012847]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD012847', 'https://scholar.google.com/scholar_lookup?title=Obstetric+outcomes+after+conservative+treatment+for+cervical+intraepithelial+lesions+and+early+invasive+disease+&author=M+Kyrgiou&author=A+Athanasiou&author=IEJ+Kalliala&author=M+Paraskevaidi&author=A+Mitra&author=PPL+Martin‐Hirsch&publication_year=2017&hl=en']",,https://doi.org/10.1002/14651858.CD012847, Kyrgiou 2017 ,additional,CD009069-bbs2-0220,
CD009069-bib-0252,"Lacey CJ, Lowndes CM, Shah KV. ",Chapter 4: Burden and management of non‐cancerous HPV‐related conditions: HPV‐6/11 disease, Vaccine ,2006,24,    ,['citation-journal']," Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non‐cancerous HPV‐related conditions: HPV‐6/11 disease.  Vaccine 2006;24(0264‐410X (Print), Suppl 3):35‐41.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2006.06.015', 'https://scholar.google.com/scholar_lookup?title=Chapter+4:+Burden+and+management+of+non‐cancerous+HPV‐related+conditions:+HPV‐6/11+disease+&author=CJ+Lacey&author=CM+Lowndes&author=KV+Shah&publication_year=2006&hl=en']",,https://doi.org/10.1016/j.vaccine.2006.06.015, Lacey 2006 ,additional,CD009069-bbs2-0221,
CD009069-bib-0253,"Larson HJ, Cooper LZ, Eskola J, Katz SL, Ratzan S. ",Addressing the vaccine confidence gap, Lancet ,2011,378,    ,['citation-journal']," Larson HJ, Cooper LZ, Eskola J, Katz SL, Ratzan S. Addressing the vaccine confidence gap.  Lancet 2011;378(9790):526‐35.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(11)60678-8', 'https://www.ncbi.nlm.nih.gov/pubmed/21664679', 'https://scholar.google.com/scholar_lookup?title=Addressing+the+vaccine+confidence+gap&author=HJ+Larson&author=LZ+Cooper&author=J+Eskola&author=SL+Katz&author=S+Ratzan&publication_year=2011&hl=en']",21664679,https://doi.org/10.1016/S0140-6736(11)60678-8, Larson 2011 ,additional,CD009069-bbs2-0222,
CD009069-bib-0254,"Lehtinen M, Apter D, Dubin G, Kosunen E, Isaksson R, Korpivaara EL. ","Enrolment of 22,000 adolescent women to cancer registry follow‐up for long‐term human papillomavirus vaccine efficacy: guarding against guessing", International Journal of STD & AIDS ,2006,17,    ,['citation-journal']," Lehtinen M, Apter D, Dubin G, Kosunen E, Isaksson R, Korpivaara EL. Enrolment of 22,000 adolescent women to cancer registry follow‐up for long‐term human papillomavirus vaccine efficacy: guarding against guessing.  International Journal of STD & AIDS 2006;17(0956‐4624 (Print), 8):517‐21.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1258/095646206778145550', 'https://www.ncbi.nlm.nih.gov/pubmed/16925896', 'https://scholar.google.com/scholar_lookup?title=Enrolment+of+22,000+adolescent+women+to+cancer+registry+follow‐up+for+long‐term+human+papillomavirus+vaccine+efficacy:+guarding+against+guessing+&author=M+Lehtinen&author=D+Apter&author=G+Dubin&author=E+Kosunen&author=R+Isaksson&author=EL+Korpivaara&publication_year=2006&hl=en']",16925896,https://doi.org/10.1258/095646206778145550, Lehtinen 2006 ,additional,CD009069-bbs2-0223,
CD009069-bib-0255,"Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland S, Castellsagué X. ","Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial", Lancet Oncology ,2012,13,    ,['citation-journal']," Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland S, Castellsagué X. Overall efficacy of HPV‐16/18 ASO4‐adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‐year end‐of‐study analysis of the randomised, double‐blind PATRICIA trial.  Lancet Oncology 2012;13(1):89‐99.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1470-2045(11)70286-8', 'https://www.ncbi.nlm.nih.gov/pubmed/22075171', 'https://scholar.google.com/scholar_lookup?title=Overall+efficacy+of+HPV‐16/18+ASO4‐adjuvanted+vaccine+against+grade+3+or+greater+cervical+intraepithelial+neoplasia:+4‐year+end‐of‐study+analysis+of+the+randomised,+double‐blind+PATRICIA+trial+&author=M+Lehtinen&author=J+Paavonen&author=CM+Wheeler&author=U+Jaisamrarn&author=S+Garland&author=X+Castellsagué&publication_year=2012&hl=en']",22075171,https://doi.org/10.1016/S1470-2045(11)70286-8, Lehtinen 2012 ,additional,CD009069-bbs2-0224,
CD009069-bib-0256,"Lehtinen M, Dillner J. ",Clinical trials of human papillomavirus vaccines and beyond, Nature Reviews Clinical Oncology ,2013,10,    ,['citation-journal']," Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond.  Nature Reviews Clinical Oncology 2013;10(7):400‐10.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/nrclinonc.2013.84', 'https://www.ncbi.nlm.nih.gov/pubmed/23736648', 'https://scholar.google.com/scholar_lookup?title=Clinical+trials+of+human+papillomavirus+vaccines+and+beyond&author=M+Lehtinen&author=J+Dillner&publication_year=2013&hl=en']",23736648,https://doi.org/10.1038/nrclinonc.2013.84, Lehtinen 2013 ,additional,CD009069-bbs2-0225,
CD009069-bib-0257,"Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, et al. ",Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study, Journal of the National Cancer Institute ,2013,105,    ,['citation-journal']," Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.  Journal of the National Cancer Institute 2013;105(7):469‐74.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/jnci/djt032', 'https://www.ncbi.nlm.nih.gov/pubmed/23486550', 'https://scholar.google.com/scholar_lookup?title=Quadrivalent+human+papillomavirus+vaccine+effectiveness:+a+Swedish+national+cohort+study+&author=A+Leval&author=E+Herweijer&author=A+Ploner&author=S+Eloranta&author=J+FridmanSimard&author=J+Dillner&publication_year=2013&hl=en']",23486550,https://doi.org/10.1093/jnci/djt032, Leval 2013 ,additional,CD009069-bbs2-0226,
CD009069-bib-0258,"Lim BK, Ng KY, Omar J, Omar SZ, Gunapalaiah B, Teoh YL, et al. ",Immunogenicity and safety of the AS04‐adjuvanted human papillomavirus‐16/18 cervical cancer vaccine in Malaysian women aged 18‐35 years: a randomized controlled trial, Medical Journal of Malaysia ,2014,69,    ,['citation-journal']," Lim BK, Ng KY, Omar J, Omar SZ, Gunapalaiah B, Teoh YL, et al. Immunogenicity and safety of the AS04‐adjuvanted human papillomavirus‐16/18 cervical cancer vaccine in Malaysian women aged 18‐35 years: a randomized controlled trial.  Medical Journal of Malaysia 2014;69(0300‐5283 (Print), 0300‐5283 (Linking), 1):2‐8.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+the+AS04‐adjuvanted+human+papillomavirus‐16/18+cervical+cancer+vaccine+in+Malaysian+women+aged+18‐35+years:+a+randomized+controlled+trial+&author=BK+Lim&author=KY+Ng&author=J+Omar&author=SZ+Omar&author=B+Gunapalaiah&author=YL+Teoh&publication_year=2014&hl=en'],,, Lim 2014 ,additional,CD009069-bbs2-0227,
CD009069-bib-0259,"Lipkind HS, Vazquez‐Benitez G, Nordin JD, Romitti PA, Naleway AL, Klein NP, et al. ",Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy, Obstetrics and Gynecology ,2017,130,    ,['citation-journal']," Lipkind HS, Vazquez‐Benitez G, Nordin JD, Romitti PA, Naleway AL, Klein NP, et al. Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy.  Obstetrics and Gynecology 2017;130(3):599‐608.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/AOG.0000000000002191', 'https://www.ncbi.nlm.nih.gov/pubmed/28796684', 'https://scholar.google.com/scholar_lookup?title=Maternal+and+infant+outcomes+after+human+papillomavirus+vaccination+in+the+periconceptional+period+or+during+pregnancy+&author=HS+Lipkind&author=G+Vazquez‐Benitez&author=JD+Nordin&author=PA+Romitti&author=AL+Naleway&author=NP+Klein&publication_year=2017&hl=en']",28796684,https://doi.org/10.1097/AOG.0000000000002191, Lipkind 2017 ,additional,CD009069-bbs2-0228,
CD009069-bib-0260,"Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, Joura EA, et al. ",Phase II studies to select the formulation of a multivalent HPV L1 virus‐like particle (VLP) vaccine, Human Vaccines & Immunotherapeutics ,2015,11,    ,['citation-journal']," Luxembourg A, Brown D, Bouchard C, Giuliano AR, Iversen OE, Joura EA, et al. Phase II studies to select the formulation of a multivalent HPV L1 virus‐like particle (VLP) vaccine.  Human Vaccines & Immunotherapeutics 2015;11(6):1313‐22.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1080/21645515.2015.1012010', 'https://www.ncbi.nlm.nih.gov/pubmed/25912208', 'https://scholar.google.com/scholar_lookup?title=Phase+II+studies+to+select+the+formulation+of+a+multivalent+HPV+L1+virus‐like+particle+(VLP)+vaccine+&author=A+Luxembourg&author=D+Brown&author=C+Bouchard&author=AR+Giuliano&author=OE+Iversen&author=EA+Joura&publication_year=2015&hl=en']",25912208,https://doi.org/10.1080/21645515.2015.1012010, Luxembourg 2015 ,additional,CD009069-bbs2-0229,
CD009069-bib-0261,"Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ. ",Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial, Obstetrics and Gynecology ,2006,107,    ,['citation-journal']," Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ. Efficacy of human papillomavirus‐16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.  Obstetrics and Gynecology 2006;107(1):18‐27.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/01.AOG.0000192397.41191.fb', 'https://www.ncbi.nlm.nih.gov/pubmed/16394035', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+human+papillomavirus‐16+vaccine+to+prevent+cervical+intraepithelial+neoplasia:+a+randomized+controlled+trial+&author=C+Mao&author=LA+Koutsky&author=KA+Ault&author=CM+Wheeler&author=DR+Brown&author=DJ+Wiley&publication_year=2006&hl=en']",16394035,https://doi.org/10.1097/01.AOG.0000192397.41191.fb, Mao 2006 ,additional,CD009069-bbs2-0230,
CD009069-bib-0262,"Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. ","Reduction in in human papillomavirus (HPV) prevalence among young women following HPVvaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003‐2010", Journal of Infectious Diseases ,2013,208,    ,['citation-journal']," Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in in human papillomavirus (HPV) prevalence among young women following HPVvaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003‐2010.  Journal of Infectious Diseases 2013;208(3):385‐93.    Link to article     Google Scholar     ","['https://doi.org/10.1093/infdis/jit192', 'https://scholar.google.com/scholar_lookup?title=Reduction+in+in+human+papillomavirus+(HPV)+prevalence+among+young+women+following+HPVvaccine+introduction+in+the+United+States,+National+Health+and+Nutrition+Examination+Surveys,+2003‐2010+&author=LE+Markowitz&author=S+Hariri&author=C+Lin&author=EF+Dunne&author=M+Steinau&author=G+McQuillan&publication_year=2013&hl=en']",,https://doi.org/10.1093/infdis/jit192, Markowitz 2013 ,additional,CD009069-bbs2-0231,
CD009069-bib-0263,"Martin‐Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO. ",Surgery for cervical intraepithelial neoplasia, Cochrane Database of Systematic Reviews ,2013,,    ,['citation-journal']," Martin‐Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO. Surgery for cervical intraepithelial neoplasia.  Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD001318.pub3]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD001318.pub3', 'https://scholar.google.com/scholar_lookup?title=Surgery+for+cervical+intraepithelial+neoplasia&author=PP+Martin‐Hirsch&author=E+Paraskevaidis&author=A+Bryant&author=HO+Dickinson&publication_year=2013&hl=en']",,https://doi.org/10.1002/14651858.CD001318.pub3, Martin‐Hirsch 2013 ,additional,CD009069-bbs2-0232,
CD009069-bib-0264,"McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW. ",Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study, Lancet Oncology ,2008,9,    ,['citation-journal']," McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.  Lancet Oncology 2008;9(5):425‐34.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1470-2045(08)70103-7', 'https://www.ncbi.nlm.nih.gov/pubmed/18407790', 'https://scholar.google.com/scholar_lookup?title=Natural+history+of+cervical+neoplasia+and+risk+of+invasive+cancer+in+women+with+cervical+intraepithelial+neoplasia+3:+a+retrospective+cohort+study+&author=MR+McCredie&author=KJ+Sharples&author=C+Paul&author=J+Baranyai&author=G+Medley&author=RW+Jones&publication_year=2008&hl=en']",18407790,https://doi.org/10.1016/S1470-2045(08)70103-7, McCredie 2008 ,additional,CD009069-bbs2-0233,
CD009069-bib-0265,"Medeiros LR, Rosa DD, Da Rosa MI, Bozzetti MC, Zanini RR. ",Efficacy of human papillomavirus vaccines: a systematic quantitative review, International Journal of Gynecological Cancer ,2009,19,    ,['citation-journal']," Medeiros LR, Rosa DD, Da Rosa MI, Bozzetti MC, Zanini RR. Efficacy of human papillomavirus vaccines: a systematic quantitative review.  International Journal of Gynecological Cancer 2009;19(7):1166‐76.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/IGC.0b013e3181a3d100', 'https://www.ncbi.nlm.nih.gov/pubmed/19823051', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+human+papillomavirus+vaccines:+a+systematic+quantitative+review&author=LR+Medeiros&author=DD+Rosa&author=MI+Rosa&author=MC+Bozzetti&author=RR+Zanini&publication_year=2009&hl=en']",19823051,https://doi.org/10.1111/IGC.0b013e3181a3d100, Medeiros 2009 ,additional,CD009069-bbs2-0234,
CD009069-bib-0266,"Medina DM, Valencia A, de Velasquez A, Huang LM, Prymula R, Garcia‐Sicilia J. ","Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine: a randomized, controlled trial in adolescent girls", Journal of Adolescent Health ,2010,46,    ,['citation-journal']," Medina DM, Valencia A, de Velasquez A, Huang LM, Prymula R, Garcia‐Sicilia J. Safety and immunogenicity of the HPV‐16/18 AS04‐adjuvanted vaccine: a randomized, controlled trial in adolescent girls.  Journal of Adolescent Health 2010;46(1879‐1972 (Electronic), 1054‐139X (Linking), 5):414‐21.    Google Scholar     ","['https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine:+a+randomized,+controlled+trial+in+adolescent+girls+&author=DM+Medina&author=A+Valencia&author=A+Velasquez&author=LM+Huang&author=R+Prymula&author=J+Garcia‐Sicilia&publication_year=2010&hl=en']",,, Medina 2010 ,additional,CD009069-bbs2-0235,
CD009069-bib-0267,"Merckx M, Vanden Broeck D, Benoy I, Depuydt C, Weyers S, Arbyn M. ",Early effects of human papillomavirus vaccination in Belgium, European Journal of Cancer Prevention ,2015,24,    ,['citation-journal']," Merckx M, Vanden Broeck D, Benoy I, Depuydt C, Weyers S, Arbyn M. Early effects of human papillomavirus vaccination in Belgium.  European Journal of Cancer Prevention 2015;24(4):340‐2.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1097/CEJ.0000000000000067', 'https://www.ncbi.nlm.nih.gov/pubmed/25117724', 'https://scholar.google.com/scholar_lookup?title=Early+effects+of+human+papillomavirus+vaccination+in+Belgium&author=M+Merckx&author=D+VandenBroeck&author=I+Benoy&author=C+Depuydt&author=S+Weyers&author=M+Arbyn&publication_year=2015&hl=en']",25117724,https://doi.org/10.1097/CEJ.0000000000000067, Merckx 2015 ,additional,CD009069-bbs2-0236,
CD009069-bib-0268,"Molbak K, Hansen ND, Valentiner‐Branth P. ",Pre‐vaccination care‐seeking in females reporting severe adverse reactions to HPV vaccine. A registry based case‐control study, PLOS One ,2016,11,    ,['citation-journal']," Molbak K, Hansen ND, Valentiner‐Branth P. Pre‐vaccination care‐seeking in females reporting severe adverse reactions to HPV vaccine. A registry based case‐control study.  PLOS One 2016;11(9):e0162520.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1371/journal.pone.0162520', 'https://www.ncbi.nlm.nih.gov/pubmed/27611088', 'https://scholar.google.com/scholar_lookup?title=Pre‐vaccination+care‐seeking+in+females+reporting+severe+adverse+reactions+to+HPV+vaccine.+A+registry+based+case‐control+study+&author=K+Molbak&author=ND+Hansen&author=P+Valentiner‐Branth&publication_year=2016&hl=en']",27611088,https://doi.org/10.1371/journal.pone.0162520, Molbak 2016 ,additional,CD009069-bbs2-0237,
CD009069-bib-0269,"Mugo N, Ansah NA, Marino D, Saah A, Garner EIO. ",Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub‐Saharan Africa, Human Vaccines & Immunotherapeutics ,2015,11,    ,['citation-journal']," Mugo N, Ansah NA, Marino D, Saah A, Garner EIO. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub‐Saharan Africa.  Human Vaccines & Immunotherapeutics 2015;11(6):1323‐30.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1080/21645515.2015.1008877', 'https://www.ncbi.nlm.nih.gov/pubmed/25912475', 'https://scholar.google.com/scholar_lookup?title=Evaluation+of+safety+and+immunogenicity+of+a+quadrivalent+human+papillomavirus+vaccine+in+healthy+females+between+9+and+26+years+of+age+in+Sub‐Saharan+Africa+&author=N+Mugo&author=NA+Ansah&author=D+Marino&author=A+Saah&author=EIO+Garner&publication_year=2015&hl=en']",25912475,https://doi.org/10.1080/21645515.2015.1008877, Mugo 2015 ,additional,CD009069-bbs2-0238,
CD009069-bib-0270,"Munoz N, Bosch FX, Castellsague X, Diaz M, De Sanjose S, Hammouda D. ",Against which human papillomavirus types shall we vaccinate and screen? The international perspective, International Journal of Cancer ,2004,111,    ,['citation-journal']," Munoz N, Bosch FX, Castellsague X, Diaz M, De Sanjose S, Hammouda D. Against which human papillomavirus types shall we vaccinate and screen? The international perspective.  International Journal of Cancer 2004;111:278‐85.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/ijc.20244', 'https://www.ncbi.nlm.nih.gov/pubmed/15197783', 'https://scholar.google.com/scholar_lookup?title=Against+which+human+papillomavirus+types+shall+we+vaccinate+and+screen?+The+international+perspective+&author=N+Munoz&author=FX+Bosch&author=X+Castellsague&author=M+Diaz&author=S+Sanjose&author=D+Hammouda&publication_year=2004&hl=en']",15197783,https://doi.org/10.1002/ijc.20244, Munoz 2004 ,additional,CD009069-bbs2-0239,
CD009069-bib-0271,"Munoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K. ","Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial", Lancet ,2009,373,    ,['citation-journal']," Munoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24‐45 years: a randomised, double‐blind trial.  Lancet 2009;373(9679):1949‐57.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(09)60691-7', 'https://www.ncbi.nlm.nih.gov/pubmed/19493565', 'https://scholar.google.com/scholar_lookup?title=Safety,+immunogenicity,+and+efficacy+of+quadrivalent+human+papillomavirus+(types+6,+11,+16,+18)+recombinant+vaccine+in+women+aged+24‐45+years:+a+randomised,+double‐blind+trial+&author=N+Munoz&author=R+Manalastas&author=P+Pitisuttithum&author=D+Tresukosol&author=J+Monsonego&author=K+Ault&publication_year=2009&hl=en']",19493565,https://doi.org/10.1016/S0140-6736(09)60691-7, Munoz 2009 ,additional,CD009069-bbs2-0240,
CD009069-bib-0272,"Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM. ",Impact of human papillomavirus (HPV)‐6/11/16/18 vaccine on all HPV‐associated genital diseases in young women, Journal of the National Cancer Institute ,2010,102,    ,['citation-journal']," Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez‐Avila M, Wheeler CM. Impact of human papillomavirus (HPV)‐6/11/16/18 vaccine on all HPV‐associated genital diseases in young women.  Journal of the National Cancer Institute 2010;102(5):325‐39.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1093/jnci/djp534', 'https://www.ncbi.nlm.nih.gov/pubmed/20139221', 'https://scholar.google.com/scholar_lookup?title=Impact+of+human+papillomavirus+(HPV)‐6/11/16/18+vaccine+on+all+HPV‐associated+genital+diseases+in+young+women+&author=N+Munoz&author=SK+Kjaer&author=K+Sigurdsson&author=OE+Iversen&author=M+Hernandez‐Avila&author=CM+Wheeler&publication_year=2010&hl=en']",20139221,https://doi.org/10.1093/jnci/djp534, Munoz 2010 ,additional,CD009069-bbs2-0241,
CD009069-bib-0273,"Naleway AL, Crane B, Smith N, Daley MF, Donahue J, Gee J, et al. ","Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008‐2011", Vaccine ,2016,34,    ,['citation-journal']," Naleway AL, Crane B, Smith N, Daley MF, Donahue J, Gee J, et al. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008‐2011.  Vaccine 2016;34(1):167‐71.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2015.10.006', 'https://www.ncbi.nlm.nih.gov/pubmed/26549361', 'https://scholar.google.com/scholar_lookup?title=Absence+of+venous+thromboembolism+risk+following+quadrivalent+human+papillomavirus+vaccination,+Vaccine+Safety+Datalink,+2008‐2011+&author=AL+Naleway&author=B+Crane&author=N+Smith&author=MF+Daley&author=J+Donahue&author=J+Gee&publication_year=2016&hl=en']",26549361,https://doi.org/10.1016/j.vaccine.2015.10.006, Naleway 2016 ,additional,CD009069-bbs2-0242,
CD009069-bib-0274,"Naud PS, Roteli‐Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. ","Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination", Human Vaccines & Immunotherapeutics ,2014,10,    ,['citation-journal']," Naud PS, Roteli‐Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV‐16/18 AS04‐adjuvanted vaccine: Final analysis of a long‐term follow‐up study up to 9.4 years post‐vaccination.  Human Vaccines & Immunotherapeutics 2014;10(8):2147‐62.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.4161/hv.29532', 'https://www.ncbi.nlm.nih.gov/pubmed/25424918', 'https://scholar.google.com/scholar_lookup?title=Sustained+efficacy,+immunogenicity,+and+safety+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine:+Final+analysis+of+a+long‐term+follow‐up+study+up+to+9.4+years+post‐vaccination+&author=PS+Naud&author=CM+Roteli‐Martins&author=NS+Carvalho&author=JC+Teixeira&author=PC+Borba&author=N+Sanchez&publication_year=2014&hl=en']",25424918,https://doi.org/10.4161/hv.29532, Naud 2014 ,additional,CD009069-bbs2-0243,
CD009069-bib-0275,"Ngan HY, Cheung AN, Tam KF, Chan KK, Tang HW, Bi D, et al. ",Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong, Hong Kong Medical Journal ,2010,16,    ,['citation-journal']," Ngan HY, Cheung AN, Tam KF, Chan KK, Tang HW, Bi D, et al. Human papillomavirus‐16/18 AS04‐adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong.  Hong Kong Medical Journal 2010;16(1024‐2708 (Print), 1024‐2708 (Linking), 3):171‐9.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/20519752', 'https://scholar.google.com/scholar_lookup?title=Human+papillomavirus‐16/18+AS04‐adjuvanted+cervical+cancer+vaccine:+immunogenicity+and+safety+in+healthy+Chinese+women+from+Hong+Kong+&author=HY+Ngan&author=AN+Cheung&author=KF+Tam&author=KK+Chan&author=HW+Tang&author=D+Bi&publication_year=2010&hl=en']",20519752,, Ngan 2010 ,additional,CD009069-bbs2-0244,
CD009069-bib-0276,"Noronha AS, Markowitz LE, Dunne EF. ",Systematic review of human papillomavirus vaccine coadministration, Vaccine ,2014,32,    ,['citation-journal']," Noronha AS, Markowitz LE, Dunne EF. Systematic review of human papillomavirus vaccine coadministration.  Vaccine 2014;32(23):2670‐4.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2013.12.037', 'https://www.ncbi.nlm.nih.gov/pubmed/24412351', 'https://scholar.google.com/scholar_lookup?title=Systematic+review+of+human+papillomavirus+vaccine+coadministration&author=AS+Noronha&author=LE+Markowitz&author=EF+Dunne&publication_year=2014&hl=en']",24412351,https://doi.org/10.1016/j.vaccine.2013.12.037, Noronha 2014 ,additional,CD009069-bbs2-0245,
CD009069-bib-0277,"Ojha RP, Jackson BE, Tota JE, Offutt‐Powell TN, Singh KP, Bae S. ",Guillain‐Barré syndrome following quadrivalent human papillomavirus vaccination among vaccine‐eligible individuals in the United States, Human Vaccines & Immunotherapeutics ,2014,10,    ,['citation-journal']," Ojha RP, Jackson BE, Tota JE, Offutt‐Powell TN, Singh KP, Bae S. Guillain‐Barré syndrome following quadrivalent human papillomavirus vaccination among vaccine‐eligible individuals in the United States.  Human Vaccines & Immunotherapeutics 2014;10(1):232‐7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.4161/hv.26292', 'https://www.ncbi.nlm.nih.gov/pubmed/24013368', 'https://scholar.google.com/scholar_lookup?title=Guillain‐Barré+syndrome+following+quadrivalent+human+papillomavirus+vaccination+among+vaccine‐eligible+individuals+in+the+United+States+&author=RP+Ojha&author=BE+Jackson&author=JE+Tota&author=TN+Offutt‐Powell&author=KP+Singh&author=S+Bae&publication_year=2014&hl=en']",24013368,https://doi.org/10.4161/hv.26292, Ojha 2014 ,additional,CD009069-bbs2-0246,
CD009069-bib-0278,Ostor AG. ,Natural history of cervical intraepithelial neoplasia: a critical review, International Journal of Gynegological Pathology ,1993,12,    ,['citation-journal'], Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review.  International Journal of Gynegological Pathology 1993;12(2):186‐92.    Link to article     Google Scholar     ,"['https://doi.org/10.1097/00004347-199304000-00018', 'https://scholar.google.com/scholar_lookup?title=Natural+history+of+cervical+intraepithelial+neoplasia:+a+critical+review&author=AG+Ostor&publication_year=1993&hl=en']",,https://doi.org/10.1097/00004347-199304000-00018, Ostor 1993 ,additional,CD009069-bbs2-0247,
CD009069-bib-0279,"Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM. ","Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial", Lancet ,2007,369,    ,['citation-journal']," Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM. Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial.  Lancet 2007;369(9580):2161‐70.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(07)60946-5', 'https://www.ncbi.nlm.nih.gov/pubmed/17602732', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+a+prophylactic+adjuvanted+bivalent+L1+virus‐like‐particle+vaccine+against+infection+with+human+papillomavirus+types+16+and+18+in+young+women:+an+interim+analysis+of+a+phase+III+double‐blind,+randomised+controlled+trial+&author=J+Paavonen&author=D+Jenkins&author=FX+Bosch&author=P+Naud&author=J+Salmeron&author=CM+Wheeler&publication_year=2007&hl=en']",17602732,https://doi.org/10.1016/S0140-6736(07)60946-5, Paavonen 2007 ,additional,CD009069-bbs2-0248,
CD009069-bib-0280,"Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S‐N, Apter D. ","Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women", Lancet ,2009,374,    ,['citation-journal']," Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S‐N, Apter D. Efficacy of human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double‐blind, randomised study in young women.  Lancet 2009;374:301‐14.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(09)61248-4', 'https://www.ncbi.nlm.nih.gov/pubmed/19586656', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+human+papillomavirus+(HPV)‐16/18+ASO4‐adjuvanted+vaccine+against+cervical+infection+and+precancer+caused+by+oncogenic+HPV+types+(PATRICIA):+final+analysis+of+a+double‐blind,+randomised+study+in+young+women+&author=J+Paavonen&author=P+Naud&author=J+Salmeron&author=CM+Wheeler&author=S‐N+Chow&author=D+Apter&publication_year=2009&hl=en']",19586656,https://doi.org/10.1016/S0140-6736(09)61248-4, Paavonen 2009 ,additional,CD009069-bbs2-0249,
CD009069-bib-0281,"Pagliusi SR, Teresa Aguado M. ",Efficacy and other milestones for human papillomavirus vaccine introduction, Vaccine ,2004,23,    ,['citation-journal']," Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction.  Vaccine 2004;23(0264‐410X, 5):569‐78.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2004.07.046', 'https://www.ncbi.nlm.nih.gov/pubmed/15630792', 'https://scholar.google.com/scholar_lookup?title=Efficacy+and+other+milestones+for+human+papillomavirus+vaccine+introduction&author=SR+Pagliusi&author=M+TeresaAguado&publication_year=2004&hl=en']",15630792,https://doi.org/10.1016/j.vaccine.2004.07.046, Pagliusi 2004 ,additional,CD009069-bbs2-0250,
CD009069-bib-0282,"Panagiotou OA, Befano BL, Gonzalez P, Rodriguez AC, Herrero R, Schiller JT, et al. ",Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow‐up in the Costa Rica HPV Vaccine Trial, BMJ ,2015,351,    ,['citation-journal']," Panagiotou OA, Befano BL, Gonzalez P, Rodriguez AC, Herrero R, Schiller JT, et al. Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow‐up in the Costa Rica HPV Vaccine Trial.  BMJ 2015;351:h4358.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.h4358', 'https://www.ncbi.nlm.nih.gov/pubmed/26346155', 'https://scholar.google.com/scholar_lookup?title=Effect+of+bivalent+human+papillomavirus+vaccination+on+pregnancy+outcomes:+long+term+observational+follow‐up+in+the+Costa+Rica+HPV+Vaccine+Trial+&author=OA+Panagiotou&author=BL+Befano&author=P+Gonzalez&author=AC+Rodriguez&author=R+Herrero&author=JT+Schiller&publication_year=2015&hl=en']",26346155,https://doi.org/10.1136/bmj.h4358, Panagiotou 2015 ,additional,CD009069-bbs2-0251,
CD009069-bib-0283,"Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlan G, Silfverdal SA. ",Randomized trial: immunogenicity and safety of coadministered human papillomavirus‐16/18AS04‐adjuvanted vaccine and combined hepatitis A and B vaccine in girls, Journal of Adolescent Health ,2012,50,    ,['citation-journal']," Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlan G, Silfverdal SA. Randomized trial: immunogenicity and safety of coadministered human papillomavirus‐16/18AS04‐adjuvanted vaccine and combined hepatitis A and B vaccine in girls.  Journal of Adolescent Health 2012;50(1):38‐46.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.jadohealth.2011.10.009', 'https://scholar.google.com/scholar_lookup?title=Randomized+trial:+immunogenicity+and+safety+of+coadministered+human+papillomavirus‐16/18AS04‐adjuvanted+vaccine+and+combined+hepatitis+A+and+B+vaccine+in+girls+&author=C+Pedersen&author=M+Breindahl&author=N+Aggarwal&author=J+Berglund&author=G+Oroszlan&author=SA+Silfverdal&publication_year=2012&hl=en']",,https://doi.org/10.1016/j.jadohealth.2011.10.009, Pedersen 2012 ,additional,CD009069-bbs2-0252,
CD009069-bib-0284,"Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. ",Reduction of low‐ and high‐grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland, British Journal of Cancer ,2014,111,    ,['citation-journal']," Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low‐ and high‐grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.  British Journal of Cancer 2014;111(9):1261‐4.    Link to article     Google Scholar     ","['https://doi.org/10.1038/bjc.2014.479', 'https://scholar.google.com/scholar_lookup?title=Reduction+of+low‐+and+high‐grade+cervical+abnormalities+associated+with+high+uptake+of+the+HPV+bivalent+vaccine+in+Scotland+&author=KG+Pollock&author=K+Kavanagh&author=A+Potts&author=J+Love&author=K+Cuschieri&author=H+Cubie&publication_year=2014&hl=en']",,https://doi.org/10.1038/bjc.2014.479, Pollock 2014 ,additional,CD009069-bbs2-0253,
CD009069-bib-0285,"Rambout L, Hopkins L, Hutton B, Fergusson D. ",Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials, Canadian Medical Association Journal ,2007,177,    ,['citation-journal']," Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.  Canadian Medical Association Journal 2007;177(5):469‐79.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1503/cmaj.070948', 'https://www.ncbi.nlm.nih.gov/pubmed/17671238', 'https://scholar.google.com/scholar_lookup?title=Prophylactic+vaccination+against+human+papillomavirus+infection+and+disease+in+women:+a+systematic+review+of+randomized+controlled+trials+&author=L+Rambout&author=L+Hopkins&author=B+Hutton&author=D+Fergusson&publication_year=2007&hl=en']",17671238,https://doi.org/10.1503/cmaj.070948, Rambout 2007 ,additional,CD009069-bbs2-0254,
CD009069-bib-0286,"Nordic Cochrane Centre, The Cochrane Collaboration. ",Review Manager 5 (RevMan 5),,2014,,.   ,['citation-other']," Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.    ",[],,, Review Manager 2014 [Computer program] ,additional,CD009069-bbs2-0255,
CD009069-bib-0287,Richart RM. ,Cervical intraepithelial neoplasia, Pathology Annual ,1973,8,    ,['citation-journal'], Richart RM. Cervical intraepithelial neoplasia.  Pathology Annual 1973;8:301‐23.    PubMed     Google Scholar     ,"['https://www.ncbi.nlm.nih.gov/pubmed/4583016', 'https://scholar.google.com/scholar_lookup?title=Cervical+intraepithelial+neoplasia&author=RM+Richart&publication_year=1973&hl=en']",4583016,, Richart 1973 ,additional,CD009069-bbs2-0256,
CD009069-bib-0288,"Romanowski B, de Borba PC, Naud PS, Roteli‐Martins CM, De Carvalho NS, Teixeira JC, et al The GlaxoSmithKline Vaccine HPV‐007 Study Group. ",Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years, Lancet ,2009,374,    ,['citation-journal']," Romanowski B, de Borba PC, Naud PS, Roteli‐Martins CM, De Carvalho NS, Teixeira JC, et al The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years.  Lancet 2009;374(9706):1975‐85.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/19962185', 'https://scholar.google.com/scholar_lookup?title=Sustained+efficacy+and+immunogenicity+of+the+human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+vaccine:+analysis+of+a+randomised+placebo‐controlled+trial+up+to+6.4+years+&author=B+Romanowski&author=PC+Borba&author=PS+Naud&author=CM+Roteli‐Martins&author=NS+Carvalho&author=JC+Teixeira&publication_year=2009&hl=en']",19962185,, Romanowski 2009 ,additional,CD009069-bbs2-0257,
CD009069-bib-0289,Romanowski B. ,Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines, Human Vaccines ,2011,7,    ,['citation-journal'], Romanowski B. Long term protection against cervical infection with the human papillomavirus: Review of currently available vaccines.  Human Vaccines 2011;7(2):161‐9.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.4161/hv.7.2.13690', 'https://www.ncbi.nlm.nih.gov/pubmed/21307652', 'https://scholar.google.com/scholar_lookup?title=Long+term+protection+against+cervical+infection+with+the+human+papillomavirus:+Review+of+currently+available+vaccines+&author=B+Romanowski&publication_year=2011&hl=en']",21307652,https://doi.org/10.4161/hv.7.2.13690, Romanowski 2011 ,additional,CD009069-bbs2-0258,
CD009069-bib-0290,"Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. ",Efficacy of HPV‐based screening for prevention of invasive cervical cancer: follow‐up of four European randomised controlled trials, Lancet ,2014,383,    ,['citation-journal']," Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV‐based screening for prevention of invasive cervical cancer: follow‐up of four European randomised controlled trials.  Lancet 2014;383(9916):524‐32.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(13)62218-7', 'https://www.ncbi.nlm.nih.gov/pubmed/24192252', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+HPV‐based+screening+for+prevention+of+invasive+cervical+cancer:+follow‐up+of+four+European+randomised+controlled+trials+&author=G+Ronco&author=J+Dillner&author=KM+Elfstrom&author=S+Tunesi&author=PJ+Snijders&author=M+Arbyn&publication_year=2014&hl=en']",24192252,https://doi.org/10.1016/S0140-6736(13)62218-7, Ronco 2014 ,additional,CD009069-bbs2-0259,
CD009069-bib-0291,"Rowhani‐Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE. ",Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine, Vaccine ,2009,27,    ,['citation-journal']," Rowhani‐Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine.  Vaccine 2009;27(41):5612‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2009.07.027', 'https://www.ncbi.nlm.nih.gov/pubmed/19647066', 'https://scholar.google.com/scholar_lookup?title=Longer+term+efficacy+of+a+prophylactic+monovalent+human+papillomavirus+type+16+vaccine&author=A+Rowhani‐Rahbar&author=C+Mao&author=JP+Hughes&author=FB+Alvarez&author=JT+Bryan&author=SE+Hawes&publication_year=2009&hl=en']",19647066,https://doi.org/10.1016/j.vaccine.2009.07.027, Rowhani‐Rahbar 2009 ,additional,CD009069-bbs2-0260,
CD009069-bib-0292,"Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, et al. ",Durability of protection afforded by fewer doses of the HPV16/18 vaccine: The CVT Trial, Journal of the National Cancer Institute ,2018,110,    ,['citation-journal']," Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: The CVT Trial.  Journal of the National Cancer Institute 2018;110(2):djx158.    Link to article     Google Scholar     ","['https://doi.org/10.1093/jnci/djx158', 'https://scholar.google.com/scholar_lookup?title=Durability+of+protection+afforded+by+fewer+doses+of+the+HPV16/18+vaccine:+The+CVT+Trial+&author=M+Safaeian&author=JN+Sampson&author=Y+Pan&author=C+Porras&author=TJ+Kemp&author=R+Herrero&publication_year=2018&hl=en']",,https://doi.org/10.1093/jnci/djx158, Safaeian 2018 ,additional,CD009069-bbs2-0261,
CD009069-bib-0293,"Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al. ","Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study", Lancet Oncology ,2016,17,    ,['citation-journal']," Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.  Lancet Oncology 2016;17(1):67‐77.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1470-2045(15)00414-3', 'https://www.ncbi.nlm.nih.gov/pubmed/26652797', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+HPV+infection+after+one,+two,+and+three+doses+of+quadrivalent+HPV+vaccine+in+girls+in+India:+a+multicentre+prospective+cohort+study+&author=R+Sankaranarayanan&author=PR+Prabhu&author=M+Pawlita&author=T+Gheit&author=N+Bhatla&author=R+Muwonge&publication_year=2016&hl=en']",26652797,https://doi.org/10.1016/S1470-2045(15)00414-3, Sankaranarayanan 2016 ,additional,CD009069-bbs2-0262,
CD009069-bib-0294,"Scheller NM, Pasternak B, Svanstrom H, Hviid A. ",Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism, JAMA ,2014,312,    ,['citation-journal']," Scheller NM, Pasternak B, Svanstrom H, Hviid A. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism.  JAMA 2014;312(2):187‐8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jama.2014.2198', 'https://www.ncbi.nlm.nih.gov/pubmed/25005658', 'https://scholar.google.com/scholar_lookup?title=Quadrivalent+human+papillomavirus+vaccine+and+the+risk+of+venous+thromboembolism&author=NM+Scheller&author=B+Pasternak&author=H+Svanstrom&author=A+Hviid&publication_year=2014&hl=en']",25005658,https://doi.org/10.1001/jama.2014.2198, Scheller 2014 ,additional,CD009069-bbs2-0263,
CD009069-bib-0295,"Scheller NM, Svanstrom H, Pasternak B, Arnheim‐Dahlstrom L, Sundstrom K, Fink K, et al. ",Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system, JAMA ,2015,313,    ,['citation-journal']," Scheller NM, Svanstrom H, Pasternak B, Arnheim‐Dahlstrom L, Sundstrom K, Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.  JAMA 2015;313:54‐61.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jama.2014.16946', 'https://www.ncbi.nlm.nih.gov/pubmed/25562266', 'https://scholar.google.com/scholar_lookup?title=Quadrivalent+HPV+vaccination+and+risk+of+multiple+sclerosis+and+other+demyelinating+diseases+of+the+central+nervous+system+&author=NM+Scheller&author=H+Svanstrom&author=B+Pasternak&author=L+Arnheim‐Dahlstrom&author=K+Sundstrom&author=K+Fink&publication_year=2015&hl=en']",25562266,https://doi.org/10.1001/jama.2014.16946, Scheller 2015 ,additional,CD009069-bbs2-0264,
CD009069-bib-0296,"Schiffman MA, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. ",The carcinogenicity of human papillomavirus types reflects viral evolution, Virology ,2005,337,    ,['citation-journal']," Schiffman MA, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papillomavirus types reflects viral evolution.  Virology 2005;337(1):76‐84.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.virol.2005.04.002', 'https://www.ncbi.nlm.nih.gov/pubmed/15914222', 'https://scholar.google.com/scholar_lookup?title=The+carcinogenicity+of+human+papillomavirus+types+reflects+viral+evolution&author=MA+Schiffman&author=R+Herrero&author=R+Desalle&author=A+Hildesheim&author=S+Wacholder&author=AC+Rodriguez&publication_year=2005&hl=en']",15914222,https://doi.org/10.1016/j.virol.2005.04.002, Schiffman 2005 ,additional,CD009069-bbs2-0265,
CD009069-bib-0297,"Schiffman M, Clifford G, Buonaguro FM. ",Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline,,2009,,    ,['citation-other']," Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infectious Agents and Cancer2009; Vol. 4, issue 1:1‐8.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Classification+of+weakly+carcinogenic+human+papillomavirus+types:+addressing+the+limits+of+epidemiology+at+the+borderline+&author=M+Schiffman&author=G+Clifford&author=FM+Buonaguro&publication_year=2009&hl=en'],,, Schiffman 2009 ,additional,CD009069-bbs2-0266,
CD009069-bib-0298,"Schiller JT, Lowy DR. ",Immunogenicity testing in human papillomavirus virus‐like‐particle vaccine trials, Journal of Infectious Diseases ,2009,200,    ,['citation-journal']," Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus‐like‐particle vaccine trials.  Journal of Infectious Diseases 2009;200(2):166‐71.    Link to article     Google Scholar     ","['https://doi.org/10.1086/599988', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+testing+in+human+papillomavirus+virus‐like‐particle+vaccine+trials&author=JT+Schiller&author=DR+Lowy&publication_year=2009&hl=en']",,https://doi.org/10.1086/599988, Schiller 2009 ,additional,CD009069-bbs2-0267,
CD009069-bib-0299,"Schiller JT, Castellsague X, Garland SM. ",A review of clinical trials of human papillomavirus prophylactic vaccines, Vaccine ,2012,30 Suppl 5,    ,['citation-journal']," Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines.  Vaccine 2012;30 Suppl 5:F123‐38.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2012.04.108', 'https://www.ncbi.nlm.nih.gov/pubmed/23199956', 'https://scholar.google.com/scholar_lookup?title=A+review+of+clinical+trials+of+human+papillomavirus+prophylactic+vaccines&author=JT+Schiller&author=X+Castellsague&author=SM+Garland&publication_year=2012&hl=en']",23199956,https://doi.org/10.1016/j.vaccine.2012.04.108, Schiller 2012 ,additional,CD009069-bbs2-0268,
CD009069-bib-0300,"Schmeink CE, Bekkers RL, Josefsson A, Richardus JH, Berndtsson Blom K, David MP, et al. ",Co‐administration of human papillomavirus‐16/18 AS04‐adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls, Vaccine ,2011,29,    ,['citation-journal']," Schmeink CE, Bekkers RL, Josefsson A, Richardus JH, Berndtsson Blom K, David MP, et al. Co‐administration of human papillomavirus‐16/18 AS04‐adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.  Vaccine 2011;29(1873‐2518):9276‐83.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2011.08.037', 'https://www.ncbi.nlm.nih.gov/pubmed/21856349', 'https://scholar.google.com/scholar_lookup?title=Co‐administration+of+human+papillomavirus‐16/18+AS04‐adjuvanted+vaccine+with+hepatitis+B+vaccine:+randomized+study+in+healthy+girls+&author=CE+Schmeink&author=RL+Bekkers&author=A+Josefsson&author=JH+Richardus&author=K+BerndtssonBlom&author=MP+David&publication_year=2011&hl=en']",21856349,https://doi.org/10.1016/j.vaccine.2011.08.037, Schmeink 2011 ,additional,CD009069-bbs2-0269,
CD009069-bib-0301,"Schneider A, Gissmann L. ",Cervical cancer. The potential role of human papillomavirus (HPV)‐specific vaccines in prevention and treatment, American Journal of Cancer ,2003,2,    ,['citation-journal']," Schneider A, Gissmann L. Cervical cancer. The potential role of human papillomavirus (HPV)‐specific vaccines in prevention and treatment.  American Journal of Cancer 2003;2:1‐253.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Cervical+cancer.+The+potential+role+of+human+papillomavirus+(HPV)‐specific+vaccines+in+prevention+and+treatment+&author=A+Schneider&author=L+Gissmann&publication_year=2003&hl=en'],,, Schneider 2003 ,additional,CD009069-bbs2-0270,
CD009069-bib-0302,"Schwarz TF, Huang LM, Medina DM, Valencia A, Lin TY, Behre U, et al. ",Four‐year follow‐up of the immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine when administered to adolescent girls aged 10‐14 years, Journal of Adolescent Health ,2012,50,    ,['citation-journal']," Schwarz TF, Huang LM, Medina DM, Valencia A, Lin TY, Behre U, et al. Four‐year follow‐up of the immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine when administered to adolescent girls aged 10‐14 years.  Journal of Adolescent Health 2012;50(2):187‐94.    Link to article     Google Scholar     ","['https://doi.org/10.1016/j.jadohealth.2011.11.004', 'https://scholar.google.com/scholar_lookup?title=Four‐year+follow‐up+of+the+immunogenicity+and+safety+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+when+administered+to+adolescent+girls+aged+10‐14+years+&author=TF+Schwarz&author=LM+Huang&author=DM+Medina&author=A+Valencia&author=TY+Lin&author=U+Behre&publication_year=2012&hl=en']",,https://doi.org/10.1016/j.jadohealth.2011.11.004, Schwarz 2012 ,additional,CD009069-bbs2-0271,
CD009069-bib-0303,Sharp S. ,Meta‐analysis regression, Statistics Technical Bulletin ,1998,7,    ,['citation-journal'], Sharp S. Meta‐analysis regression.  Statistics Technical Bulletin 1998;7(42):148‐55. [MEDLINE: 11989]    Google Scholar     ,['https://scholar.google.com/scholar_lookup?title=Meta‐analysis+regression&author=S+Sharp&publication_year=1998&hl=en'],,, Sharp 1998 ,additional,CD009069-bbs2-0272,
CD009069-bib-0304,"Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano‐Ponce E, Salmeron J. ","Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study", Lancet ,2014,384,    ,['citation-journal']," Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano‐Ponce E, Salmeron J. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 4‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study.  Lancet 2014;384(9961):2213‐27.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S0140-6736(14)60920-X', 'https://www.ncbi.nlm.nih.gov/pubmed/25189358', 'https://scholar.google.com/scholar_lookup?title=Efficacy,+safety,+and+immunogenicity+of+the+human+papillomavirus+16/18+AS04‐adjuvanted+vaccine+in+women+older+than+25+years:+4‐year+interim+follow‐up+of+the+phase+3,+double‐blind,+randomised+controlled+VIVIANE+study+&author=SR+Skinner&author=A+Szarewski&author=B+Romanowski&author=SM+Garland&author=E+Lazcano‐Ponce&author=J+Salmeron&publication_year=2014&hl=en']",25189358,https://doi.org/10.1016/S0140-6736(14)60920-X, Skinner 2014 ,additional,CD009069-bbs2-0273,
CD009069-bib-0305,"Skufca J, Ollgren J, Ruokokoski E, Lyytikäinen O, Nohynek H. ","Incidence rates of Guillain‐Barré‚ (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002‐2012", Papillomavirus Research ,2017,3,    ,['citation-journal']," Skufca J, Ollgren J, Ruokokoski E, Lyytikäinen O, Nohynek H. Incidence rates of Guillain‐Barré‚ (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002‐2012.  Papillomavirus Research 2017;3:91‐6.    PubMed     Google Scholar     ","['https://www.ncbi.nlm.nih.gov/pubmed/28720463', 'https://scholar.google.com/scholar_lookup?title=Incidence+rates+of+Guillain‐Barré‚+(GBS),+chronic+fatigue/systemic+exertion+intolerance+disease+(CFS/SEID)+and+postural+orthostatic+tachycardia+syndrome+(POTS)+prior+to+introduction+of+human+papilloma+virus+(HPV)+vaccination+among+adolescent+girls+in+Finland,+2002‐2012+&author=J+Skufca&author=J+Ollgren&author=E+Ruokokoski&author=O+Lyytikäinen&author=H+Nohynek&publication_year=2017&hl=en']",28720463,, Skufca 2017 ,additional,CD009069-bbs2-0274,
CD009069-bib-0306,"Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. ",Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine, JAMA ,2009,302,    ,['citation-journal']," Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.  JAMA 2009;302(7):750‐7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jama.2009.1201', 'https://www.ncbi.nlm.nih.gov/pubmed/19690307', 'https://scholar.google.com/scholar_lookup?title=Postlicensure+safety+surveillance+for+quadrivalent+human+papillomavirus+recombinant+vaccine+&author=BA+Slade&author=L+Leidel&author=C+Vellozzi&author=EJ+Woo&author=W+Hua&author=A+Sutherland&publication_year=2009&hl=en']",19690307,https://doi.org/10.1001/jama.2009.1201, Slade 2009 ,additional,CD009069-bbs2-0275,
CD009069-bib-0307,"Smith HO, Tiffany MF, Qualls CR, Key CR. ",The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States‐a 24‐year population‐based study,,2000,,    ,['citation-other']," Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States‐a 24‐year population‐based study. Gynecologic Oncology2000; Vol. 78, issue 2:97‐105.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=The+rising+incidence+of+adenocarcinoma+relative+to+squamous+cell+carcinoma+of+the+uterine+cervix+in+the+United+States‐a+24‐year+population‐based+study+&author=HO+Smith&author=MF+Tiffany&author=CR+Qualls&author=CR+Key&publication_year=2000&hl=en'],,, Smith 2000 ,additional,CD009069-bbs2-0276,
CD009069-bib-0308,"Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M. ",The 2001 Bethesda System: terminology for reporting results of cervical cytology, JAMA ,2002,287,    ,['citation-journal']," Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M. The 2001 Bethesda System: terminology for reporting results of cervical cytology.  JAMA 2002;287:2114‐9.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1001/jama.287.16.2114', 'https://www.ncbi.nlm.nih.gov/pubmed/11966386', ""https://scholar.google.com/scholar_lookup?title=The+2001+Bethesda+System:+terminology+for+reporting+results+of+cervical+cytology&author=D+Solomon&author=D+Davey&author=R+Kurman&author=A+Moriarty&author=D+O'Connor&author=M+Prey&publication_year=2002&hl=en""]",11966386,https://doi.org/10.1001/jama.287.16.2114, Solomon 2002 ,additional,CD009069-bbs2-0277,
CD009069-bib-0309,"Sow PS, Watson‐Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J. ",Safety and immunogenicity of human papillomavirus‐16/18 AS04‐adjuvanted vaccine: a randomized trial in 10‐25‐year‐old HIV‐seronegative African girls and young women, Journal of Infectious Diseases ,2013,207,    ,['citation-journal']," Sow PS, Watson‐Jones D, Kiviat N, Changalucha J, Mbaye KD, Brown J. Safety and immunogenicity of human papillomavirus‐16/18 AS04‐adjuvanted vaccine: a randomized trial in 10‐25‐year‐old HIV‐seronegative African girls and young women.  Journal of Infectious Diseases 2013;207(11):1753‐63.    Link to article     Google Scholar     ","['https://doi.org/10.1093/infdis/jis619', 'https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+human+papillomavirus‐16/18+AS04‐adjuvanted+vaccine:+a+randomized+trial+in+10‐25‐year‐old+HIV‐seronegative+African+girls+and+young+women+&author=PS+Sow&author=D+Watson‐Jones&author=N+Kiviat&author=J+Changalucha&author=KD+Mbaye&author=J+Brown&publication_year=2013&hl=en']",,https://doi.org/10.1093/infdis/jis619, Sow 2013 ,additional,CD009069-bbs2-0278,
CD009069-bib-0310,Stanley MA. ,Human papillomavirus vaccines, Reviews in Medical Virology ,2006,16,    ,['citation-journal']," Stanley MA. Human papillomavirus vaccines.  Reviews in Medical Virology 2006;16(1052‐9276 (Print), 3):139‐49.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/rmv.498', 'https://www.ncbi.nlm.nih.gov/pubmed/16710836', 'https://scholar.google.com/scholar_lookup?title=Human+papillomavirus+vaccines&author=MA+Stanley&publication_year=2006&hl=en']",16710836,https://doi.org/10.1002/rmv.498, Stanley 2006 ,additional,CD009069-bbs2-0279,
CD009069-bib-0311,"Stanley M, Pinto LA, Trimble C. ",Human papillomavirus vaccines ‐ immune responses, Vaccine ,2012,30 (Suppl 5),    ,['citation-journal']," Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines ‐ immune responses.  Vaccine 2012;30 (Suppl 5):F83‐7.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2012.04.106', 'https://www.ncbi.nlm.nih.gov/pubmed/23199968', 'https://scholar.google.com/scholar_lookup?title=Human+papillomavirus+vaccines+‐+immune+responses&author=M+Stanley&author=LA+Pinto&author=C+Trimble&publication_year=2012&hl=en']",23199968,https://doi.org/10.1016/j.vaccine.2012.04.106, Stanley 2012 ,additional,CD009069-bbs2-0280,
CD009069-bib-0312,"Stanley MA, Sudenga SL, Giuliano AR. ",Alternative dosage schedules with HPV virus‐like particle vaccines, Expert Review of Vaccines ,2014,13,    ,['citation-journal']," Stanley MA, Sudenga SL, Giuliano AR. Alternative dosage schedules with HPV virus‐like particle vaccines.  Expert Review of Vaccines 2014;13(8):1027‐38.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1586/14760584.2014.935767', 'https://www.ncbi.nlm.nih.gov/pubmed/25001893', 'https://scholar.google.com/scholar_lookup?title=Alternative+dosage+schedules+with+HPV+virus‐like+particle+vaccines&author=MA+Stanley&author=SL+Sudenga&author=AR+Giuliano&publication_year=2014&hl=en']",25001893,https://doi.org/10.1586/14760584.2014.935767, Stanley 2014 ,additional,CD009069-bbs2-0281,
CD009069-bib-0313,"Starkie Camejo H, Li X, Van Kriekinge G, Ryser M. ",Response letter regarding the letter to the editors by Butt et al. Does it matter Discounting and its role in the cost‐effectiveness of preventative interventions. The case of HPV vaccination, Public Health ,2016,132,    ,['citation-journal']," Starkie Camejo H, Li X, Van Kriekinge G, Ryser M. Response letter regarding the letter to the editors by Butt et al. Does it matter Discounting and its role in the cost‐effectiveness of preventative interventions. The case of HPV vaccination.  Public Health 2016;132:110‐2.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.puhe.2015.11.020', 'https://www.ncbi.nlm.nih.gov/pubmed/26804476', 'https://scholar.google.com/scholar_lookup?title=Response+letter+regarding+the+letter+to+the+editors+by+Butt+et+al.+Does+it+matter+Discounting+and+its+role+in+the+cost‐effectiveness+of+preventative+interventions.+The+case+of+HPV+vaccination+&author=H+StarkieCamejo&author=X+Li&author=G+Kriekinge&author=M+Ryser&publication_year=2016&hl=en']",26804476,https://doi.org/10.1016/j.puhe.2015.11.020, Starkie Camejo 2016 ,additional,CD009069-bbs2-0282,
CD009069-bib-0314,Szarewski A. ,HPV vaccine: Cervarix, Expert Opinion on Biological Therapy ,2010,10,    ,['citation-journal'], Szarewski A. HPV vaccine: Cervarix.  Expert Opinion on Biological Therapy 2010;10(3):477‐87.    Link to article     PubMed     Google Scholar     ,"['https://doi.org/10.1517/14712591003601944', 'https://www.ncbi.nlm.nih.gov/pubmed/20132062', 'https://scholar.google.com/scholar_lookup?title=HPV+vaccine:+Cervarix&author=A+Szarewski&publication_year=2010&hl=en']",20132062,https://doi.org/10.1517/14712591003601944, Szarewski 2010 ,additional,CD009069-bbs2-0283,
CD009069-bib-0315,"Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P. ",Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15‐25 years with and without serological evidence of previous exposure to HPV‐16/18, Internaitonal Journal of Cancer ,2011,131,    ,['citation-journal']," Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P. Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15‐25 years with and without serological evidence of previous exposure to HPV‐16/18.  Internaitonal Journal of Cancer 2011;131(1):106‐16.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Efficacy+of+the+human+papillomavirus+(HPV)‐16/18+AS04‐adjuvanted+vaccine+in+women+aged+15‐25+years+with+and+without+serological+evidence+of+previous+exposure+to+HPV‐16/18+&author=A+Szarewski&author=WA+Poppe&author=SR+Skinner&author=CM+Wheeler&author=J+Paavonen&author=P+Naud&publication_year=2011&hl=en'],,, Szarewski 2011 ,additional,CD009069-bbs2-0284,
CD009069-bib-0316,"Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. ",Fall in human papillomavirus prevalence following a national vaccination program, Journal of Infectious Diseases ,2012,206,    ,['citation-journal']," Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program.  Journal of Infectious Diseases 2012;206(11):1645‐51.    Link to article     Google Scholar     ","['https://doi.org/10.1093/infdis/jis590', 'https://scholar.google.com/scholar_lookup?title=Fall+in+human+papillomavirus+prevalence+following+a+national+vaccination+program&author=SN+Tabrizi&author=JM+Brotherton&author=JM+Kaldor&author=SR+Skinner&author=E+Cummins&author=B+Liu&publication_year=2012&hl=en']",,https://doi.org/10.1093/infdis/jis590, Tabrizi 2012 ,additional,CD009069-bbs2-0285,
CD009069-bib-0317,"Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. ",Assessment of herd immunity and cross‐protection after a human papillomavirus vaccination programme in Australia: a repeat cross‐sectional study, Lancet Infectious Diseases ,2014,14,    ,['citation-journal']," Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross‐protection after a human papillomavirus vaccination programme in Australia: a repeat cross‐sectional study.  Lancet Infectious Diseases 2014;14(10):958‐66.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1473-3099(14)70841-2', 'https://www.ncbi.nlm.nih.gov/pubmed/25107680', 'https://scholar.google.com/scholar_lookup?title=Assessment+of+herd+immunity+and+cross‐protection+after+a+human+papillomavirus+vaccination+programme+in+Australia:+a+repeat+cross‐sectional+study+&author=SN+Tabrizi&author=JM+Brotherton&author=JM+Kaldor&author=SR+Skinner&author=B+Liu&author=D+Bateson&publication_year=2014&hl=en']",25107680,https://doi.org/10.1016/S1473-3099(14)70841-2, Tabrizi 2014 ,additional,CD009069-bbs2-0286,
CD009069-bib-0318,"Taylor S, Ryser M, Mihalyi A, van Effelterre T. ",Response letter regarding the letter to the editors by Brown et al,,2016,,    ,['citation-other']," Taylor S, Ryser M, Mihalyi A, van Effelterre T. Response letter regarding the letter to the editors by Brown et al. Human Vaccinnes and Immunotherapeutics2016; Vol. 7:1943‐6.    Google Scholar     ",['https://scholar.google.com/scholar_lookup?title=Response+letter+regarding+the+letter+to+the+editors+by+Brown+et+al&author=S+Taylor&author=M+Ryser&author=A+Mihalyi&author=T+Effelterre&publication_year=2016&hl=en'],,, Taylor 2016 ,additional,CD009069-bbs2-0287,
CD009069-bib-0319,The GlaxoSmithKline Vaccine HPV‐007 Study Group. ,Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years, Lancet ,2009,374,    ,['citation-journal'], The GlaxoSmithKline Vaccine HPV‐007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)‐16/18 ASO4‐adjuvanted vaccine: analysis of a randomised placebo‐controlled trial up to 6.4 years.  Lancet 2009;374:1975‐85.    Link to article     PubMed     ,"['https://doi.org/10.1016/S0140-6736(09)61567-1', 'https://www.ncbi.nlm.nih.gov/pubmed/19962185']",19962185,https://doi.org/10.1016/S0140-6736(09)61567-1, The GSK Study Group 2009 ,additional,CD009069-bbs2-0288,
CD009069-bib-0320,"Thompson SG, Sharp SJ. ",Explaining heterogeneity in meta‐analysis: a comparison of methods, Statistics in Medicine ,1999,18,    ,['citation-journal']," Thompson SG, Sharp SJ. Explaining heterogeneity in meta‐analysis: a comparison of methods.  Statistics in Medicine 1999;18(20):2693‐708. [MEDLINE: 11967]    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V', 'https://www.ncbi.nlm.nih.gov/pubmed/10521860', 'https://scholar.google.com/scholar_lookup?title=Explaining+heterogeneity+in+meta‐analysis:+a+comparison+of+methods&author=SG+Thompson&author=SJ+Sharp&publication_year=1999&hl=en']",10521860,https://doi.org/10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V, Thompson 1999 ,additional,CD009069-bbs2-0289,
CD009069-bib-0321,"Unger E, Dillner J. ",,Human Papillomavirus Laboratory Manual,2010,,.   ,['citation-book']," Unger E, Dillner J. Human Papillomavirus Laboratory Manual. 1st Edition. Geneva: WHO (Quality, Safety and Standards (QSS) team of the Department of Immunization, Vaccines and Biologicals), 2010.    ",[],,, Unger 2010 ,additional,CD009069-bbs2-0290,
CD009069-bib-0322,"van Damme P, Leroux‐Roels G, Simon P, Foidart JM, Donders G, Hoppenbrouwers K, et al. ",Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials, Vaccine ,2014,32,    ,['citation-journal']," van Damme P, Leroux‐Roels G, Simon P, Foidart JM, Donders G, Hoppenbrouwers K, et al. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.  Vaccine 2014;32(29):3694‐705.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2014.03.040', 'https://www.ncbi.nlm.nih.gov/pubmed/24674663', 'https://scholar.google.com/scholar_lookup?title=Effects+of+varying+antigens+and+adjuvant+systems+on+the+immunogenicity+and+safety+of+investigational+tetravalent+human+oncogenic+papillomavirus+vaccines:+results+from+two+randomized+trials+&author=P+Damme&author=G+Leroux‐Roels&author=P+Simon&author=JM+Foidart&author=G+Donders&author=K+Hoppenbrouwers&publication_year=2014&hl=en']",24674663,https://doi.org/10.1016/j.vaccine.2014.03.040, Van Damme 2014 ,additional,CD009069-bbs2-0291,
CD009069-bib-0323,"Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, et al. ",Immunogenicity and Safety of a 9‐Valent HPV Vaccine, Pediatrics ,2015,136,    ,['citation-journal']," Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, et al. Immunogenicity and Safety of a 9‐Valent HPV Vaccine.  Pediatrics 2015;136(1):e28‐e39.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1542/peds.2014-3745', 'https://www.ncbi.nlm.nih.gov/pubmed/26101366', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+Safety+of+a+9‐Valent+HPV+Vaccine&author=P+Damme&author=SE+Olsson&author=S+Block&author=X+Castellsague&author=GE+Gray&author=T+Herrera&publication_year=2015&hl=en']",26101366,https://doi.org/10.1542/peds.2014-3745, Van Damme 2015 ,additional,CD009069-bbs2-0292,
CD009069-bib-0324,"Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, et al. ",Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines, Vaccine ,2008,26,    ,['citation-journal']," Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines.  Vaccine 2008;26(0264‐410X (Print), 0264‐410X (Linking), 51):6630‐8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2008.09.049', 'https://www.ncbi.nlm.nih.gov/pubmed/18845199', 'https://scholar.google.com/scholar_lookup?title=Analysis+of+adverse+events+of+potential+autoimmune+aetiology+in+a+large+integrated+safety+database+of+AS04+adjuvanted+vaccines+&author=T+Verstraeten&author=D+Descamps&author=MP+David&author=T+Zahaf&author=K+Hardt&author=P+Izurieta&publication_year=2008&hl=en']",18845199,https://doi.org/10.1016/j.vaccine.2008.09.049, Verstraeten 2008 ,additional,CD009069-bbs2-0293,
CD009069-bib-0325,"Vesikari T, Brodszki N, Van Damme P, Diez‐Domingo J, Icardi G, Kjeld PL, et al. ","A randomized, double‐blind, phase III study of the immunogenicity and safety of a 9‐valent human papillomavirus L1 virus‐like particle vaccine (V503) versus Gardasil(R) in 9‐15‐year‐old girls", Pediatric Infectious Disease Journal ,2015,34,    ,['citation-journal']," Vesikari T, Brodszki N, Van Damme P, Diez‐Domingo J, Icardi G, Kjeld PL, et al. A randomized, double‐blind, phase III study of the immunogenicity and safety of a 9‐valent human papillomavirus L1 virus‐like particle vaccine (V503) versus Gardasil(R) in 9‐15‐year‐old girls.  Pediatric Infectious Disease Journal 2015;34(9):992‐8.    Link to article     Google Scholar     ","['https://doi.org/10.1097/INF.0000000000000773', 'https://scholar.google.com/scholar_lookup?title=A+randomized,+double‐blind,+phase+III+study+of+the+immunogenicity+and+safety+of+a+9‐valent+human+papillomavirus+L1+virus‐like+particle+vaccine+(V503)+versus+Gardasil(R)+in+9‐15‐year‐old+girls+&author=T+Vesikari&author=N+Brodszki&author=P+Damme&author=J+Diez‐Domingo&author=G+Icardi&author=PL+Kjeld&publication_year=2015&hl=en']",,https://doi.org/10.1097/INF.0000000000000773, Vesikari 2015 ,additional,CD009069-bbs2-0294,
CD009069-bib-0326,"Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, et al. ",An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015, Pediatric Infectious Disease Journal ,2015,34,    ,['citation-journal']," Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015.  Pediatric Infectious Disease Journal 2015;34(9):983‐1.    Link to article     Google Scholar     ","['https://doi.org/10.1097/INF.0000000000000793', 'https://scholar.google.com/scholar_lookup?title=An+overview+of+quadrivalent+human+papillomavirus+vaccine+safety:+2006+to+2015&author=M+Vichnin&author=P+Bonanni&author=NP+Klein&author=SM+Garland&author=SL+Block&author=SK+Kjaer&publication_year=2015&hl=en']",,https://doi.org/10.1097/INF.0000000000000793, Vichnin 2015 ,additional,CD009069-bbs2-0295,
CD009069-bib-0327,"Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR. ","Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial", Lancet Oncology ,2005,6,    ,['citation-journal']," Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like particle vaccine in young women: a randomised double‐blind placebo‐controlled multicentre phase II efficacy trial.  Lancet Oncology 2005;6(5):271‐8.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/S1470-2045(05)70101-7', 'https://www.ncbi.nlm.nih.gov/pubmed/15863374', 'https://scholar.google.com/scholar_lookup?title=Prophylactic+quadrivalent+human+papillomavirus+(types+6,+11,+16,+and+18)+L1+virus‐like+particle+vaccine+in+young+women:+a+randomised+double‐blind+placebo‐controlled+multicentre+phase+II+efficacy+trial+&author=LL+Villa&author=RL+Costa&author=CA+Petta&author=RP+Andrade&author=KA+Ault&author=AR+Giuliano&publication_year=2005&hl=en']",15863374,https://doi.org/10.1016/S1470-2045(05)70101-7, Villa 2005 ,additional,CD009069-bbs2-0296,
CD009069-bib-0328,"Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP. ","Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18", Vaccine ,2006,24,    ,['citation-journal']," Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.  Vaccine 2006;24(27):5571‐83.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1016/j.vaccine.2006.04.068', 'https://www.ncbi.nlm.nih.gov/pubmed/16753240', 'https://scholar.google.com/scholar_lookup?title=Immunologic+responses+following+administration+of+a+vaccine+targeting+human+papillomavirus+Types+6,+11,+16,+and+18+&author=LL+Villa&author=KA+Ault&author=AR+Giuliano&author=RL+Costa&author=CA+Petta&author=RP+Andrade&publication_year=2006&hl=en']",16753240,https://doi.org/10.1016/j.vaccine.2006.04.068, Villa 2006 ,additional,CD009069-bbs2-0297,
CD009069-bib-0329,"Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE. ",High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up, British Journal of Cancer ,2006,95,    ,['citation-journal']," Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus‐like particle vaccine through 5 years of follow‐up.  British Journal of Cancer 2006;95(11):1459‐66.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1038/sj.bjc.6603469', 'https://www.ncbi.nlm.nih.gov/pubmed/17117182', 'https://scholar.google.com/scholar_lookup?title=High+sustained+efficacy+of+a+prophylactic+quadrivalent+human+papillomavirus+types+6/11/16/18+L1+virus‐like+particle+vaccine+through+5+years+of+follow‐up+&author=LL+Villa&author=RL+Costa&author=CA+Petta&author=RP+Andrade&author=J+Paavonen&author=OE+Iversen&publication_year=2006&hl=en']",17117182,https://doi.org/10.1038/sj.bjc.6603469, Villa 2006a ,additional,CD009069-bbs2-0298,
CD009069-bib-0330,"Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B. ",Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials, BMJ ,2010,340,    ,['citation-journal']," Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials.  BMJ 2010;340:c712.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1136/bmj.c712', 'https://www.ncbi.nlm.nih.gov/pubmed/20197322', 'https://scholar.google.com/scholar_lookup?title=Risk+of+miscarriage+with+bivalent+vaccine+against+human+papillomavirus+(HPV)+types+16+and+18:+pooled+analysis+of+two+randomised+controlled+trials+&author=S+Wacholder&author=BE+Chen&author=A+Wilcox&author=G+Macones&author=P+Gonzalez&author=B+Befano&publication_year=2010&hl=en']",20197322,https://doi.org/10.1136/bmj.c712, Wacholder 2010 ,additional,CD009069-bbs2-0299,
CD009069-bib-0331,"Wheeler CM, Skinner SR, Del Rosario‐Raymundo MR, Garland SM, Chatterjee A, Lazcano‐Ponce E, et al. ","Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study", Lancet Infectious Diseases ,2016,16 (10),    ,['citation-journal']," Wheeler CM, Skinner SR, Del Rosario‐Raymundo MR, Garland SM, Chatterjee A, Lazcano‐Ponce E, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04‐adjuvanted vaccine in women older than 25 years: 7‐year interim follow‐up of the phase 3, double‐blind, randomised controlled VIVIANE study.  Lancet Infectious Diseases 2016;16 (10):1154‐68.    Link to article     Google Scholar     ","['https://doi.org/10.1016/S1473-3099(16)30120-7', 'https://scholar.google.com/scholar_lookup?title=Efficacy,+safety,+and+immunogenicity+of+the+human+papillomavirus+16/18+AS04‐adjuvanted+vaccine+in+women+older+than+25+years:+7‐year+interim+follow‐up+of+the+phase+3,+double‐blind,+randomised+controlled+VIVIANE+study+&author=CM+Wheeler&author=SR+Skinner&author=MR+Rosario‐Raymundo&author=SM+Garland&author=A+Chatterjee&author=E+Lazcano‐Ponce&publication_year=2016&hl=en']",,https://doi.org/10.1016/S1473-3099(16)30120-7, Wheeler 2016 ,additional,CD009069-bbs2-0300,
CD009069-bib-0332,Initiative for Vaccine Research of the Department of Immunization Vaccines and Biologicals (WHO). ,Human Papillomavirus (HPV) Vaccine Background Paper,,2009,,:1‐249.   ,['citation-other'], Initiative for Vaccine Research of the Department of Immunization Vaccines and Biologicals (WHO). Human Papillomavirus (HPV) Vaccine Background Paper. World Health Organization (WHO)2009:1‐249.    ,[],,, WHO 2009 ,additional,CD009069-bbs2-0301,
CD009069-bib-0333,WHO. ,Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination,,2014,,    ,['citation-other'], WHO. Global Advisory Committee on Vaccine Safety Statement on the continued safety of HPV vaccination. http://www.who.int/vaccine_safety/committee/topics/hpv/GACVS_Statement_HPV_12_Mar_2014.pdf2014.    Google Scholar     ,['https://scholar.google.com/scholar_lookup?title=Global+Advisory+Committee+on+Vaccine+Safety+Statement+on+the+continued+safety+of+HPV+vaccination+&author=+WHO&publication_year=2014&hl=en'],,, WHO 2014 ,additional,CD009069-bbs2-0302,
CD009069-bib-0334,WHO. ,"Safety of HPV vaccines (from meeting of 2‐3 December, 2015)", Weekly Epidemiological Record ,2016,91,    ,['citation-journal']," WHO. Safety of HPV vaccines (from meeting of 2‐3 December, 2015).  Weekly Epidemiological Record 2016;91(3):26‐8.    Google Scholar     ","['https://scholar.google.com/scholar_lookup?title=Safety+of+HPV+vaccines+(from+meeting+of+2‐3+December,+2015)&author=+WHO&publication_year=2016&hl=en']",,, WHO 2016 ,additional,CD009069-bbs2-0303,
CD009069-bib-0335,"Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. ",Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students, Journal of Epidemiology ,2003,157,    ,['citation-journal']," Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students.  Journal of Epidemiology 2003;157:218‐26.    Link to article     Google Scholar     ","['https://doi.org/10.1093/aje/kwf180', 'https://scholar.google.com/scholar_lookup?title=Genital+human+papillomavirus+infection:+incidence+and+risk+factors+in+a+cohort+of+female+university+students+&author=RL+Winer&author=SK+Lee&author=JP+Hughes&author=DE+Adam&author=NB+Kiviat&author=LA+Koutsky&publication_year=2003&hl=en']",,https://doi.org/10.1093/aje/kwf180, Winer 2003 ,additional,CD009069-bbs2-0304,
CD009069-bib-0336,"Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. ",Risk of female human papillomavirus acquisition associated with first male sex partner, Journal of Infectious Diseases ,2008,197,    ,['citation-journal']," Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner.  Journal of Infectious Diseases 2008;197(0022‐1899 (Print), 2):279‐82.    Link to article     Google Scholar     ","['https://doi.org/10.1086/524875', ""https://scholar.google.com/scholar_lookup?title=Risk+of+female+human+papillomavirus+acquisition+associated+with+first+male+sex+partner&author=RL+Winer&author=Q+Feng&author=JP+Hughes&author=S+O'Reilly&author=NB+Kiviat&author=LA+Koutsky&publication_year=2008&hl=en""]",,https://doi.org/10.1086/524875, Winer 2008 ,additional,CD009069-bbs2-0305,
CD009069-bib-0337,"Yoshikawa H, Ebihara K, Tanaka Y, Noda K. ","Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18‐26 years", Cancer Science ,2013,104,    ,['citation-journal']," Yoshikawa H, Ebihara K, Tanaka Y, Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18‐26 years.  Cancer Science 2013;104(4):465‐72.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1111/cas.12106', 'https://www.ncbi.nlm.nih.gov/pubmed/23331518', 'https://scholar.google.com/scholar_lookup?title=Efficacy+of+quadrivalent+human+papillomavirus+(types+6,+11,+16+and+18)+vaccine+(GARDASIL)+in+Japanese+women+aged+18‐26+years+&author=H+Yoshikawa&author=K+Ebihara&author=Y+Tanaka&author=K+Noda&publication_year=2013&hl=en']",23331518,https://doi.org/10.1111/cas.12106, Yoshikawa 2013 ,additional,CD009069-bbs2-0306,
CD009069-bib-0338,"Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X. ","Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial", International Journal of Cancer ,2014,135,    ,['citation-journal']," Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X. Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18‐25 years: results from a randomized controlled trial.  International Journal of Cancer 2014;135(1097‐0215 (Electronic), 0020‐7136 (Linking), 11):2612‐22.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.1002/ijc.28897', 'https://www.ncbi.nlm.nih.gov/pubmed/24740596', 'https://scholar.google.com/scholar_lookup?title=Efficacy,+immunogenicity+and+safety+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+in+healthy+Chinese+women+aged+18‐25+years:+results+from+a+randomized+controlled+trial+&author=FC+Zhu&author=W+Chen&author=YM+Hu&author=Y+Hong&author=J+Li&author=X+Zhang&publication_year=2014&hl=en']",24740596,https://doi.org/10.1002/ijc.28897, Zhu 2014 ,additional,CD009069-bbs2-0307,
CD009069-bib-0339,"Zhu F, Li J, Hu Y, Zhang X, Yang X, Zhao H, et al. ",Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years, Human Vaccines & Immunotherapeutics ,2014,10,    ,['citation-journal']," Zhu F, Li J, Hu Y, Zhang X, Yang X, Zhao H, et al. Immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.  Human Vaccines & Immunotherapeutics 2014;10(7):1795‐806.    Link to article     PubMed     Google Scholar     ","['https://doi.org/10.4161/hv.28702', 'https://www.ncbi.nlm.nih.gov/pubmed/25424785', 'https://scholar.google.com/scholar_lookup?title=Immunogenicity+and+safety+of+the+HPV‐16/18+AS04‐adjuvanted+vaccine+in+healthy+Chinese+girls+and+women+aged+9+to+45+years+&author=F+Zhu&author=J+Li&author=Y+Hu&author=X+Zhang&author=X+Yang&author=H+Zhao&publication_year=2014&hl=en']",25424785,https://doi.org/10.4161/hv.28702, Zhu 2014a ,additional,CD009069-bbs2-0308,
CD009069-bib-0340,"Arbyn M, Bryant A, Beutels P, Martin‐Hirsch PL, Paraskevaidis E, Van Hoof E, et al. ",Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors, Cochrane Database of Systematic Reviews ,2011,,    ,['citation-journal']," Arbyn M, Bryant A, Beutels P, Martin‐Hirsch PL, Paraskevaidis E, Van Hoof E, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.  Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD009069]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD009069', 'https://scholar.google.com/scholar_lookup?title=Prophylactic+vaccination+against+human+papillomaviruses+to+prevent+cervical+cancer+and+its+precursors+&author=M+Arbyn&author=A+Bryant&author=P+Beutels&author=PL+Martin‐Hirsch&author=E+Paraskevaidis&author=E+Hoof&publication_year=2011&hl=en']",,https://doi.org/10.1002/14651858.CD009069, Arbyn 2011b ,other_versions,CD009069-bbs2-0309,
CD009069-bib-0341,"Arbyn M, Bryant A, Martin‐Hirsch PL, Xu L, Simoens C, Markowitz L. ",Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors, Cochrane Database of Systematic Reviews ,2013,,    ,['citation-journal']," Arbyn M, Bryant A, Martin‐Hirsch PL, Xu L, Simoens C, Markowitz L. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.  Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD009069.pub2]    Link to article     Google Scholar     ","['https://doi.org/10.1002/14651858.CD009069.pub2', 'https://scholar.google.com/scholar_lookup?title=Prophylactic+vaccination+against+human+papillomaviruses+to+prevent+cervical+cancer+and+its+precursors+&author=M+Arbyn&author=A+Bryant&author=PL+Martin‐Hirsch&author=L+Xu&author=C+Simoens&author=L+Markowitz&publication_year=2013&hl=en']",,https://doi.org/10.1002/14651858.CD009069.pub2, Arbyn 2013 ,other_versions,CD009069-bbs2-0310,
